EP4028401B1 - 4,4a,5,7,8,8a-hexapyrido[4,3-b][1,4]oxazin-3-one compounds as magl inhibitors - Google Patents
4,4a,5,7,8,8a-hexapyrido[4,3-b][1,4]oxazin-3-one compounds as magl inhibitors Download PDFInfo
- Publication number
- EP4028401B1 EP4028401B1 EP20772007.9A EP20772007A EP4028401B1 EP 4028401 B1 EP4028401 B1 EP 4028401B1 EP 20772007 A EP20772007 A EP 20772007A EP 4028401 B1 EP4028401 B1 EP 4028401B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- oxazin
- hexahydropyrido
- carbonyl
- azabicyclo
- fluoro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- XEKAWZARUWARND-UHFFFAOYSA-N 6h-oxazin-3-one Chemical class O=C1NOCC=C1 XEKAWZARUWARND-UHFFFAOYSA-N 0.000 title claims description 16
- 239000003112 inhibitor Substances 0.000 title description 7
- 150000001875 compounds Chemical class 0.000 claims description 144
- -1 8-azabicyclo[3.2.1]octan-8-yl Chemical group 0.000 claims description 88
- 150000003839 salts Chemical class 0.000 claims description 77
- 229910052739 hydrogen Inorganic materials 0.000 claims description 54
- 239000001257 hydrogen Substances 0.000 claims description 54
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 45
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 44
- 229910052736 halogen Inorganic materials 0.000 claims description 38
- 150000002367 halogens Chemical class 0.000 claims description 34
- 208000002193 Pain Diseases 0.000 claims description 25
- 241000124008 Mammalia Species 0.000 claims description 23
- 125000005915 C6-C14 aryl group Chemical group 0.000 claims description 22
- 238000011282 treatment Methods 0.000 claims description 20
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 19
- 230000036407 pain Effects 0.000 claims description 18
- 125000001153 fluoro group Chemical group F* 0.000 claims description 16
- 238000011321 prophylaxis Methods 0.000 claims description 16
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims description 14
- 230000004770 neurodegeneration Effects 0.000 claims description 14
- 230000003959 neuroinflammation Effects 0.000 claims description 14
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 13
- 229910052757 nitrogen Inorganic materials 0.000 claims description 13
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 11
- 125000005843 halogen group Chemical group 0.000 claims description 11
- 125000005842 heteroatom Chemical group 0.000 claims description 11
- 208000020016 psychiatric disease Diseases 0.000 claims description 11
- 208000004998 Abdominal Pain Diseases 0.000 claims description 10
- 208000024827 Alzheimer disease Diseases 0.000 claims description 10
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 10
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 10
- 201000006417 multiple sclerosis Diseases 0.000 claims description 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 10
- 208000018737 Parkinson disease Diseases 0.000 claims description 9
- 201000011510 cancer Diseases 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 230000009529 traumatic brain injury Effects 0.000 claims description 9
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims description 8
- 125000006708 (C5-C14) heteroaryl group Chemical group 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 206010029350 Neurotoxicity Diseases 0.000 claims description 8
- 206010044221 Toxic encephalopathy Diseases 0.000 claims description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
- 231100000228 neurotoxicity Toxicity 0.000 claims description 8
- 230000007135 neurotoxicity Effects 0.000 claims description 8
- 125000004289 pyrazol-3-yl group Chemical group [H]N1N=C(*)C([H])=C1[H] 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 7
- 125000001424 substituent group Chemical group 0.000 claims description 7
- 208000019901 Anxiety disease Diseases 0.000 claims description 6
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 6
- 230000036506 anxiety Effects 0.000 claims description 6
- 238000002512 chemotherapy Methods 0.000 claims description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 6
- 208000004296 neuralgia Diseases 0.000 claims description 6
- 208000021722 neuropathic pain Diseases 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 6
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 5
- ZNBIKIFZULVUQS-UHFFFAOYSA-N 4a,5,6,7,8,8a-hexahydro-4H-pyrido[2,3-e]oxazin-3-one Chemical group O1NC(CC2C1CCCN2)=O ZNBIKIFZULVUQS-UHFFFAOYSA-N 0.000 claims description 5
- VPBPBNPGVADQOO-TTYWBHEPSA-N FC1=C(C=CC(=C1)C(F)(F)F)CO[C@@H]1[C@H]2CN([C@@H](C1)C2)C(=O)N1C[C@@H]2[C@@H](OCC(N2)=O)CC1 Chemical compound FC1=C(C=CC(=C1)C(F)(F)F)CO[C@@H]1[C@H]2CN([C@@H](C1)C2)C(=O)N1C[C@@H]2[C@@H](OCC(N2)=O)CC1 VPBPBNPGVADQOO-TTYWBHEPSA-N 0.000 claims description 5
- 208000019695 Migraine disease Diseases 0.000 claims description 5
- 208000006011 Stroke Diseases 0.000 claims description 5
- 206010015037 epilepsy Diseases 0.000 claims description 5
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 5
- 206010027599 migraine Diseases 0.000 claims description 5
- 201000001119 neuropathy Diseases 0.000 claims description 5
- 230000007823 neuropathy Effects 0.000 claims description 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 5
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 5
- CWHUPWVANBGRKR-IWTFSIHTSA-N C1=NC(=CC=2CCCCC1=2)CO[C@@H]1[C@H]2CN([C@@H](C1)C2)C(=O)N1C[C@@H]2[C@@H](OCC(N2)=O)CC1 Chemical compound C1=NC(=CC=2CCCCC1=2)CO[C@@H]1[C@H]2CN([C@@H](C1)C2)C(=O)N1C[C@@H]2[C@@H](OCC(N2)=O)CC1 CWHUPWVANBGRKR-IWTFSIHTSA-N 0.000 claims description 4
- 208000000094 Chronic Pain Diseases 0.000 claims description 4
- YPVGQNJXGABVJJ-PZUZUOETSA-N ClC=1C(=CC(=NC=1)CO[C@@H]1[C@H]2CN([C@@H](C1)C2)C(=O)N1C[C@@H]2[C@@H](OCC(N2)=O)CC1)C1CC1 Chemical compound ClC=1C(=CC(=NC=1)CO[C@@H]1[C@H]2CN([C@@H](C1)C2)C(=O)N1C[C@@H]2[C@@H](OCC(N2)=O)CC1)C1CC1 YPVGQNJXGABVJJ-PZUZUOETSA-N 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 230000004736 colon carcinogenesis Effects 0.000 claims description 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 4
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 4
- 208000009935 visceral pain Diseases 0.000 claims description 4
- BIUDHHGROGJSHN-UHFFFAOYSA-N 4-fluoro-3-(trifluoromethyl)benzaldehyde Chemical group FC1=CC=C(C=O)C=C1C(F)(F)F BIUDHHGROGJSHN-UHFFFAOYSA-N 0.000 claims description 3
- AANBGDMVCZSSML-CMRLANAISA-N ClC1=C(OC2CC3C(CN(C3)C(=O)N3C[C@@H]4[C@@H](OCC(N4)=O)CC3)C2)C=CC(=C1)F Chemical compound ClC1=C(OC2CC3C(CN(C3)C(=O)N3C[C@@H]4[C@@H](OCC(N4)=O)CC3)C2)C=CC(=C1)F AANBGDMVCZSSML-CMRLANAISA-N 0.000 claims description 3
- CLEMEGHIJBVDNE-VTJZIFNJSA-N ClC1=C(OC2CC3C(CN(C3)C(=O)N3C[C@@H]4[C@@H](OCC(N4)=O)CC3)C2)C=CC=C1 Chemical compound ClC1=C(OC2CC3C(CN(C3)C(=O)N3C[C@@H]4[C@@H](OCC(N4)=O)CC3)C2)C=CC=C1 CLEMEGHIJBVDNE-VTJZIFNJSA-N 0.000 claims description 3
- ZRJWZFGVDPEQMG-UMAFKHPFSA-N FC1=C(C=CC(=C1)C(F)(F)F)COC1C[C@@H]2CC[C@H](C1)N2C(=O)N1C[C@@H]2[C@@H](OCC(N2)=O)CC1 Chemical compound FC1=C(C=CC(=C1)C(F)(F)F)COC1C[C@@H]2CC[C@H](C1)N2C(=O)N1C[C@@H]2[C@@H](OCC(N2)=O)CC1 ZRJWZFGVDPEQMG-UMAFKHPFSA-N 0.000 claims description 3
- 208000008238 Muscle Spasticity Diseases 0.000 claims description 3
- 239000013543 active substance Substances 0.000 claims description 3
- 208000005298 acute pain Diseases 0.000 claims description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 3
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 3
- 208000018198 spasticity Diseases 0.000 claims description 3
- HCMJWOGOISXSDL-UHFFFAOYSA-N (2-isothiocyanato-1-phenylethyl)benzene Chemical compound C=1C=CC=CC=1C(CN=C=S)C1=CC=CC=C1 HCMJWOGOISXSDL-UHFFFAOYSA-N 0.000 claims description 2
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims description 2
- IPOQIUOTDLGORQ-UQVLAFNGSA-N C1(=CC=CC=C1)S(=O)(=O)N1CC2C(C1)CN(C2)C(=O)N1C[C@@H]2[C@@H](OCC(N2)=O)CC1 Chemical compound C1(=CC=CC=C1)S(=O)(=O)N1CC2C(C1)CN(C2)C(=O)N1C[C@@H]2[C@@H](OCC(N2)=O)CC1 IPOQIUOTDLGORQ-UQVLAFNGSA-N 0.000 claims description 2
- CWAKPGDYHQOJIB-BSBOYSKGSA-N CC1=C(OC2CC3C(CN(C3)C(=O)N3C[C@@H]4[C@@H](OCC(N4)=O)CC3)C2)C=CC=C1 Chemical compound CC1=C(OC2CC3C(CN(C3)C(=O)N3C[C@@H]4[C@@H](OCC(N4)=O)CC3)C2)C=CC=C1 CWAKPGDYHQOJIB-BSBOYSKGSA-N 0.000 claims description 2
- OYJCSQCGYZWKIV-BMAZIBOLSA-N ClC1=C(C=CC(=C1)F)COC1CC2C(CN(C2)C(=O)N2C[C@@H]3[C@@H](OCC(N3)=O)CC2)C1 Chemical compound ClC1=C(C=CC(=C1)F)COC1CC2C(CN(C2)C(=O)N2C[C@@H]3[C@@H](OCC(N3)=O)CC2)C1 OYJCSQCGYZWKIV-BMAZIBOLSA-N 0.000 claims description 2
- OGPAQUSIHIOXNB-WQEUCSPDSA-N ClC1=C(OCC2C3CN(CC2CC3)C(=O)N2C[C@@H]3[C@@H](OCC(N3)=O)CC2)C=CC(=C1)F Chemical compound ClC1=C(OCC2C3CN(CC2CC3)C(=O)N2C[C@@H]3[C@@H](OCC(N3)=O)CC2)C=CC(=C1)F OGPAQUSIHIOXNB-WQEUCSPDSA-N 0.000 claims description 2
- OGPAQUSIHIOXNB-WYRITBPASA-N ClC1=C(OCC2C3CN(CC2CC3)C(=O)N2C[C@H]3[C@H](OCC(N3)=O)CC2)C=CC(=C1)F Chemical compound ClC1=C(OCC2C3CN(CC2CC3)C(=O)N2C[C@H]3[C@H](OCC(N3)=O)CC2)C=CC(=C1)F OGPAQUSIHIOXNB-WYRITBPASA-N 0.000 claims description 2
- MKDSLQQIRKUBAV-GGEUNZLYSA-N ClC1=C(OCC2CC3CCC(C2)N3C(=O)N2C[C@@H]3[C@@H](OCC(N3)=O)CC2)C=CC(=C1)F Chemical compound ClC1=C(OCC2CC3CCC(C2)N3C(=O)N2C[C@@H]3[C@@H](OCC(N3)=O)CC2)C=CC(=C1)F MKDSLQQIRKUBAV-GGEUNZLYSA-N 0.000 claims description 2
- KCHLBZONAJIMJN-PCHAPFSGSA-N FC(C1=CC=C(C=C1)S(=O)(=O)N1CC2C(C1)CN(C2)C(=O)N1C[C@@H]2[C@@H](OCC(N2)=O)CC1)(F)F Chemical compound FC(C1=CC=C(C=C1)S(=O)(=O)N1CC2C(C1)CN(C2)C(=O)N1C[C@@H]2[C@@H](OCC(N2)=O)CC1)(F)F KCHLBZONAJIMJN-PCHAPFSGSA-N 0.000 claims description 2
- AJLIBDHMIVUHHV-DYVMVFLESA-N FC1=C(C=CC(=C1)C(F)(F)F)COC1C2CN(CC1C2)C(=O)N1C[C@@H]2[C@@H](OCC(N2)=O)CC1 Chemical compound FC1=C(C=CC(=C1)C(F)(F)F)COC1C2CN(CC1C2)C(=O)N1C[C@@H]2[C@@H](OCC(N2)=O)CC1 AJLIBDHMIVUHHV-DYVMVFLESA-N 0.000 claims description 2
- VEAQUXDUPUKPGH-DQDQBAQVSA-N FC1=C(C=CC(=C1)C(F)(F)F)CO[C@@H]1C[C@H]2CN([C@@H]1C2)C(=O)N1C[C@@H]2[C@@H](OCC(N2)=O)CC1 Chemical compound FC1=C(C=CC(=C1)C(F)(F)F)CO[C@@H]1C[C@H]2CN([C@@H]1C2)C(=O)N1C[C@@H]2[C@@H](OCC(N2)=O)CC1 VEAQUXDUPUKPGH-DQDQBAQVSA-N 0.000 claims description 2
- VEAQUXDUPUKPGH-RNEPCJONSA-N FC1=C(C=CC(=C1)C(F)(F)F)CO[C@H]1C[C@H]2CN([C@@H]1C2)C(=O)N1C[C@@H]2[C@@H](OCC(N2)=O)CC1 Chemical compound FC1=C(C=CC(=C1)C(F)(F)F)CO[C@H]1C[C@H]2CN([C@@H]1C2)C(=O)N1C[C@@H]2[C@@H](OCC(N2)=O)CC1 VEAQUXDUPUKPGH-RNEPCJONSA-N 0.000 claims description 2
- 150000002431 hydrogen Chemical group 0.000 claims 6
- XISPDFMAOWZEQG-UHFFFAOYSA-N 4h-1,4-oxazin-3-one Chemical compound O=C1COC=CN1 XISPDFMAOWZEQG-UHFFFAOYSA-N 0.000 claims 1
- KRKJIQQQWKUDHN-UMAFKHPFSA-N FC1=C(C=CC(=C1)C(F)(F)F)COC1C[C@@H]2COC[C@H](C1)N2C(=O)N1C[C@@H]2[C@@H](OCC(N2)=O)CC1 Chemical compound FC1=C(C=CC(=C1)C(F)(F)F)COC1C[C@@H]2COC[C@H](C1)N2C(=O)N1C[C@@H]2[C@@H](OCC(N2)=O)CC1 KRKJIQQQWKUDHN-UMAFKHPFSA-N 0.000 claims 1
- UNFCHVVFXUEVBO-CMRLANAISA-N FC1=C(OC2CC3C(CN(C3)C(=O)N3C[C@@H]4[C@@H](OCC(N4)=O)CC3)C2)C=CC(=C1)C(F)(F)F Chemical compound FC1=C(OC2CC3C(CN(C3)C(=O)N3C[C@@H]4[C@@H](OCC(N4)=O)CC3)C2)C=CC(=C1)C(F)(F)F UNFCHVVFXUEVBO-CMRLANAISA-N 0.000 claims 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 74
- 238000000034 method Methods 0.000 description 58
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 54
- 102000005398 Monoacylglycerol Lipase Human genes 0.000 description 45
- 108020002334 Monoacylglycerol lipase Proteins 0.000 description 45
- 239000000543 intermediate Substances 0.000 description 40
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 36
- 238000006243 chemical reaction Methods 0.000 description 35
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 32
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 28
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 28
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 28
- 239000000047 product Substances 0.000 description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 26
- RCRCTBLIHCHWDZ-UHFFFAOYSA-N 2-Arachidonoyl Glycerol Chemical compound CCCCCC=CCC=CCC=CCC=CCCCC(=O)OC(CO)CO RCRCTBLIHCHWDZ-UHFFFAOYSA-N 0.000 description 25
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 25
- 125000006239 protecting group Chemical group 0.000 description 24
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 23
- 235000019439 ethyl acetate Nutrition 0.000 description 21
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 20
- 239000000203 mixture Substances 0.000 description 20
- 239000000243 solution Substances 0.000 description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- 239000002904 solvent Substances 0.000 description 19
- 239000003153 chemical reaction reagent Substances 0.000 description 16
- 230000000670 limiting effect Effects 0.000 description 16
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 14
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 14
- 229940114079 arachidonic acid Drugs 0.000 description 14
- 235000021342 arachidonic acid Nutrition 0.000 description 14
- 210000004556 brain Anatomy 0.000 description 14
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 13
- 238000003818 flash chromatography Methods 0.000 description 13
- 239000003921 oil Substances 0.000 description 13
- 235000019198 oils Nutrition 0.000 description 13
- 239000011541 reaction mixture Substances 0.000 description 13
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 12
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- 238000003786 synthesis reaction Methods 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 11
- 125000004432 carbon atom Chemical group C* 0.000 description 11
- 229910052681 coesite Inorganic materials 0.000 description 11
- 229910052906 cristobalite Inorganic materials 0.000 description 11
- 229940093499 ethyl acetate Drugs 0.000 description 11
- 238000004128 high performance liquid chromatography Methods 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 11
- 239000000377 silicon dioxide Substances 0.000 description 11
- 229910052682 stishovite Inorganic materials 0.000 description 11
- 229910052905 tridymite Inorganic materials 0.000 description 11
- 125000003545 alkoxy group Chemical group 0.000 description 10
- 125000000217 alkyl group Chemical group 0.000 description 10
- 239000004202 carbamide Substances 0.000 description 10
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 10
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 239000000460 chlorine Substances 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 9
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 8
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 8
- 230000004913 activation Effects 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 8
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 8
- 239000012074 organic phase Substances 0.000 description 8
- 125000006413 ring segment Chemical group 0.000 description 8
- 229910052938 sodium sulfate Inorganic materials 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- PSSWASGEGXCINO-RFZPGFLSSA-N (3R,4R)-3-aminopiperidin-4-ol Chemical class N[C@@H]1CNCC[C@H]1O PSSWASGEGXCINO-RFZPGFLSSA-N 0.000 description 7
- MQUCRCQNRDHRPL-UHFFFAOYSA-N 1-(bromomethyl)-2-fluoro-4-(trifluoromethyl)benzene Chemical compound FC1=CC(C(F)(F)F)=CC=C1CBr MQUCRCQNRDHRPL-UHFFFAOYSA-N 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 7
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 7
- 150000001412 amines Chemical class 0.000 description 7
- 229910052786 argon Inorganic materials 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 235000019253 formic acid Nutrition 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 7
- 239000007858 starting material Substances 0.000 description 7
- 238000004808 supercritical fluid chromatography Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 102100036214 Cannabinoid receptor 2 Human genes 0.000 description 6
- 101710187022 Cannabinoid receptor 2 Proteins 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 6
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 6
- 150000001200 N-acyl ethanolamides Chemical class 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 6
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 6
- 150000001805 chlorine compounds Chemical class 0.000 description 6
- 125000000753 cycloalkyl group Chemical group 0.000 description 6
- 239000002621 endocannabinoid Substances 0.000 description 6
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 6
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 6
- 210000004248 oligodendroglia Anatomy 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- 235000011152 sodium sulphate Nutrition 0.000 description 6
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 6
- CPDAYCDBCSPKNF-RITPCOANSA-N (4aR,8aS)-4a,5,6,7,8,8a-hexahydro-4H-pyrido[4,3-b][1,4]oxazin-3-one Chemical compound O=C1CO[C@H]2CCNC[C@H]2N1 CPDAYCDBCSPKNF-RITPCOANSA-N 0.000 description 5
- IGYXYGDEYHNFFT-UHFFFAOYSA-N 2-chloro-4-fluorophenol Chemical compound OC1=CC=C(F)C=C1Cl IGYXYGDEYHNFFT-UHFFFAOYSA-N 0.000 description 5
- 102100033868 Cannabinoid receptor 1 Human genes 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
- 125000003118 aryl group Chemical group 0.000 description 5
- 210000003169 central nervous system Anatomy 0.000 description 5
- 229910052801 chlorine Inorganic materials 0.000 description 5
- 239000013058 crude material Substances 0.000 description 5
- 238000010511 deprotection reaction Methods 0.000 description 5
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 239000002158 endotoxin Substances 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 125000001072 heteroaryl group Chemical group 0.000 description 5
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 5
- 229920006008 lipopolysaccharide Polymers 0.000 description 5
- 125000002950 monocyclic group Chemical group 0.000 description 5
- 210000000653 nervous system Anatomy 0.000 description 5
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 150000003180 prostaglandins Chemical class 0.000 description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 description 5
- 229910000104 sodium hydride Inorganic materials 0.000 description 5
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 4
- PAQZWJGSJMLPMG-UHFFFAOYSA-N 2,4,6-tripropyl-1,3,5,2$l^{5},4$l^{5},6$l^{5}-trioxatriphosphinane 2,4,6-trioxide Chemical compound CCCP1(=O)OP(=O)(CCC)OP(=O)(CCC)O1 PAQZWJGSJMLPMG-UHFFFAOYSA-N 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- 102000018208 Cannabinoid Receptor Human genes 0.000 description 4
- 108050007331 Cannabinoid receptor Proteins 0.000 description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- 101000650817 Homo sapiens Semaphorin-4D Proteins 0.000 description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 4
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 4
- 102100027744 Semaphorin-4D Human genes 0.000 description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 125000002619 bicyclic group Chemical group 0.000 description 4
- 229910052794 bromium Inorganic materials 0.000 description 4
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 4
- 150000002066 eicosanoids Chemical class 0.000 description 4
- 239000007903 gelatin capsule Substances 0.000 description 4
- 125000000623 heterocyclic group Chemical group 0.000 description 4
- 150000002430 hydrocarbons Chemical group 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 229920005862 polyol Polymers 0.000 description 4
- 150000003077 polyols Chemical class 0.000 description 4
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Substances [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 description 4
- 239000012312 sodium hydride Substances 0.000 description 4
- 235000011121 sodium hydroxide Nutrition 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- DIDQRACXWWEPDZ-UHFFFAOYSA-N tert-butyl 5-hydroxy-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrole-2-carboxylate Chemical compound C1C(O)CC2CN(C(=O)OC(C)(C)C)CC21 DIDQRACXWWEPDZ-UHFFFAOYSA-N 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- LOVPHSMOAVXQIH-UHFFFAOYSA-M (4-nitrophenyl) carbonate Chemical compound [O-]C(=O)OC1=CC=C([N+]([O-])=O)C=C1 LOVPHSMOAVXQIH-UHFFFAOYSA-M 0.000 description 3
- YZXBAPSDXZZRGB-PNXWREOESA-N (5z,8z,11z,14z)-2,2,3,3,4,4,5,6-octadeuterioicosa-5,8,11,14-tetraenoic acid Chemical compound OC(=O)C([2H])([2H])C([2H])([2H])C([2H])([2H])C(/[2H])=C(/[2H])C\C=C/C\C=C/C\C=C/CCCCC YZXBAPSDXZZRGB-PNXWREOESA-N 0.000 description 3
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 3
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 3
- CPDAYCDBCSPKNF-UHFFFAOYSA-N 4a,5,6,7,8,8a-hexahydro-4h-pyrido[4,3-b][1,4]oxazin-3-one Chemical class C1CNCC2NC(=O)COC21 CPDAYCDBCSPKNF-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 238000006751 Mitsunobu reaction Methods 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 3
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 229910000024 caesium carbonate Inorganic materials 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000012230 colorless oil Substances 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- HCUYBXPSSCRKRF-UHFFFAOYSA-N diphosgene Chemical compound ClC(=O)OC(Cl)(Cl)Cl HCUYBXPSSCRKRF-UHFFFAOYSA-N 0.000 description 3
- 239000008298 dragée Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 125000004438 haloalkoxy group Chemical group 0.000 description 3
- 125000001188 haloalkyl group Chemical group 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 150000002617 leukotrienes Chemical class 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- IUYHWZFSGMZEOG-UHFFFAOYSA-M magnesium;propane;chloride Chemical compound [Mg+2].[Cl-].C[CH-]C IUYHWZFSGMZEOG-UHFFFAOYSA-M 0.000 description 3
- 210000000274 microglia Anatomy 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- XSXHWVKGUXMUQE-UHFFFAOYSA-N osmium dioxide Inorganic materials O=[Os]=O XSXHWVKGUXMUQE-UHFFFAOYSA-N 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 230000000770 proinflammatory effect Effects 0.000 description 3
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 3
- 230000004224 protection Effects 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- HDPGSWMTDGGUEB-HLTSFMKQSA-N tert-butyl (1r,4r,5s)-5-hydroxy-2-azabicyclo[2.2.1]heptane-2-carboxylate Chemical compound C1[C@H]2N(C(=O)OC(C)(C)C)C[C@@H]1[C@@H](O)C2 HDPGSWMTDGGUEB-HLTSFMKQSA-N 0.000 description 3
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 3
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 3
- 150000003672 ureas Chemical class 0.000 description 3
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 3
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 2
- BARRCLLWVNPCJS-NEPJUHHUSA-N (4-nitrophenyl) (4aR,8aS)-3-oxo-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazine-6-carboxylate Chemical compound [O-][N+](=O)C1=CC=C(OC(=O)N2CC[C@@H]3OCC(=O)N[C@@H]3C2)C=C1 BARRCLLWVNPCJS-NEPJUHHUSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- SVLXXPTVOWLLEY-UHFFFAOYSA-N 4a,5,6,7,8,8a-hexahydro-4H-pyrido[4,3-b][1,4]oxazin-3-one dihydrochloride Chemical compound Cl.Cl.O=C1COC2CCNCC2N1 SVLXXPTVOWLLEY-UHFFFAOYSA-N 0.000 description 2
- 238000006677 Appel reaction Methods 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- ZKCWQFLLRLAFCM-UHFFFAOYSA-N BrCC1=NC=C(C(=C1)C1CC1)Cl Chemical compound BrCC1=NC=C(C(=C1)C1CC1)Cl ZKCWQFLLRLAFCM-UHFFFAOYSA-N 0.000 description 2
- DZMFNQMWFOPABT-UHFFFAOYSA-N BrCC=1N=CC=2CCCCC=2C=1 Chemical compound BrCC=1N=CC=2CCCCC=2C=1 DZMFNQMWFOPABT-UHFFFAOYSA-N 0.000 description 2
- RBNVBHXZOFGEHX-QRQLOZEOSA-N C1=NC(=CC=2CCCCC1=2)CO[C@@H]1[C@H]2CN([C@@H](C1)C2)C(=O)OC(C)(C)C Chemical compound C1=NC(=CC=2CCCCC1=2)CO[C@@H]1[C@H]2CN([C@@H](C1)C2)C(=O)OC(C)(C)C RBNVBHXZOFGEHX-QRQLOZEOSA-N 0.000 description 2
- FOGPQCMZBGONBC-UHFFFAOYSA-N C1C2CC(C1NC2)OCC3=C(C=C(C=C3)C(F)(F)F)F.C(=O)(C(F)(F)F)O Chemical compound C1C2CC(C1NC2)OCC3=C(C=C(C=C3)C(F)(F)F)F.C(=O)(C(F)(F)F)O FOGPQCMZBGONBC-UHFFFAOYSA-N 0.000 description 2
- HDPGSWMTDGGUEB-XHNCKOQMSA-N C1[C@@H]2N(C(=O)OC(C)(C)C)C[C@H]1[C@H](O)C2 Chemical compound C1[C@@H]2N(C(=O)OC(C)(C)C)C[C@H]1[C@H](O)C2 HDPGSWMTDGGUEB-XHNCKOQMSA-N 0.000 description 2
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 description 2
- 102000009132 CB1 Cannabinoid Receptor Human genes 0.000 description 2
- 108010073366 CB1 Cannabinoid Receptor Proteins 0.000 description 2
- 102000009135 CB2 Cannabinoid Receptor Human genes 0.000 description 2
- 108010073376 CB2 Cannabinoid Receptor Proteins 0.000 description 2
- DOPQJNDSPNYMDW-UHFFFAOYSA-N ClC1=C(OCC2C3CN(CC2CC3)C(=O)OC(C)(C)C)C=CC(=C1)F Chemical compound ClC1=C(OCC2C3CN(CC2CC3)C(=O)OC(C)(C)C)C=CC(=C1)F DOPQJNDSPNYMDW-UHFFFAOYSA-N 0.000 description 2
- HRQFLKQTRVKHHW-SIIHOXLZSA-N ClC=1C(=CC(=NC=1)CO[C@@H]1[C@H]2CN([C@@H](C1)C2)C(=O)OC(C)(C)C)C1CC1 Chemical compound ClC=1C(=CC(=NC=1)CO[C@@H]1[C@H]2CN([C@@H](C1)C2)C(=O)OC(C)(C)C)C1CC1 HRQFLKQTRVKHHW-SIIHOXLZSA-N 0.000 description 2
- 229910021591 Copper(I) chloride Inorganic materials 0.000 description 2
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- CNOLPIWCIPTYTR-UHFFFAOYSA-N FC1=C(OC2CC3C(CN(C3)C(=O)OC(C)(C)C)C2)C=CC(=C1)C(F)(F)F Chemical compound FC1=C(OC2CC3C(CN(C3)C(=O)OC(C)(C)C)C2)C=CC(=C1)C(F)(F)F CNOLPIWCIPTYTR-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 2
- 239000007832 Na2SO4 Substances 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 2
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- XNRNNGPBEPRNAR-UHFFFAOYSA-N Thromboxane B2 Natural products CCCCCC(O)C=CC1OC(O)CC(O)C1CC=CCCCC(O)=O XNRNNGPBEPRNAR-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- LGEQQWMQCRIYKG-DOFZRALJSA-N anandamide Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO LGEQQWMQCRIYKG-DOFZRALJSA-N 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- 210000001130 astrocyte Anatomy 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004296 chiral HPLC Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 210000004953 colonic tissue Anatomy 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 2
- DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 2
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 2
- 238000003821 enantio-separation Methods 0.000 description 2
- 210000000105 enteric nervous system Anatomy 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 150000003840 hydrochlorides Chemical class 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- KVKFRMCSXWQSNT-UHFFFAOYSA-N n,n'-dimethylethane-1,2-diamine Chemical compound CNCCNC KVKFRMCSXWQSNT-UHFFFAOYSA-N 0.000 description 2
- 239000006225 natural substrate Substances 0.000 description 2
- 210000004498 neuroglial cell Anatomy 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 2
- 210000001428 peripheral nervous system Anatomy 0.000 description 2
- 230000009038 pharmacological inhibition Effects 0.000 description 2
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 2
- 238000012877 positron emission topography Methods 0.000 description 2
- 239000011736 potassium bicarbonate Substances 0.000 description 2
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 2
- 235000011181 potassium carbonates Nutrition 0.000 description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 150000003335 secondary amines Chemical class 0.000 description 2
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- ZWCSPNASTQNGJH-ULKQDVFKSA-N tert-butyl (1r,5s)-6-acetyl-3-azabicyclo[3.1.0]hexane-3-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)C[C@H]2C(C(=O)C)[C@H]21 ZWCSPNASTQNGJH-ULKQDVFKSA-N 0.000 description 2
- PABFVGKPNHVSCG-YIZRAAEISA-N tert-butyl (1s,4r,5s)-5-hydroxy-3-azabicyclo[2.2.1]heptane-3-carboxylate Chemical compound C1[C@H](O)[C@@H]2N(C(=O)OC(C)(C)C)C[C@H]1C2 PABFVGKPNHVSCG-YIZRAAEISA-N 0.000 description 2
- SEGZJJSZYOEABC-ULKQDVFKSA-N tert-butyl (1s,5r)-3-hydroxy-8-azabicyclo[3.2.1]octane-8-carboxylate Chemical compound C1C(O)C[C@H]2CC[C@@H]1N2C(=O)OC(C)(C)C SEGZJJSZYOEABC-ULKQDVFKSA-N 0.000 description 2
- WKBWNRUVSJJEAM-ULKQDVFKSA-N tert-butyl (1s,5r)-7-hydroxy-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylate Chemical compound C1OC[C@@H]2CC(O)C[C@H]1N2C(=O)OC(C)(C)C WKBWNRUVSJJEAM-ULKQDVFKSA-N 0.000 description 2
- FIPZGKLMWFRNLL-UHFFFAOYSA-N tert-butyl 6-hydroxy-3-azabicyclo[3.1.1]heptane-3-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CC2C(O)C1C2 FIPZGKLMWFRNLL-UHFFFAOYSA-N 0.000 description 2
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- XNRNNGPBEPRNAR-JQBLCGNGSA-N thromboxane B2 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1OC(O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O XNRNNGPBEPRNAR-JQBLCGNGSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 239000011592 zinc chloride Substances 0.000 description 2
- XOFNMNLYGPKKOV-UHFFFAOYSA-N (2-chloro-4-fluorophenyl)boronic acid Chemical compound OB(O)C1=CC=C(F)C=C1Cl XOFNMNLYGPKKOV-UHFFFAOYSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- OVBMVFFZXDNHPT-NJJJQDLFSA-N (3aR,6aS)-5-(benzenesulfonyl)-2,3,3a,4,6,6a-hexahydro-1H-pyrrolo[3,4-c]pyrrole hydrochloride Chemical compound Cl.O=S(=O)(N1C[C@@H]2CNC[C@@H]2C1)c1ccccc1 OVBMVFFZXDNHPT-NJJJQDLFSA-N 0.000 description 1
- BARRCLLWVNPCJS-NWDGAFQWSA-N (4-nitrophenyl) (4aS,8aR)-3-oxo-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazine-6-carboxylate Chemical compound O=C1N[C@@H]2[C@H](OC1)CCN(C2)C(=O)OC1=CC=C(C=C1)[N+](=O)[O-] BARRCLLWVNPCJS-NWDGAFQWSA-N 0.000 description 1
- NXLNNXIXOYSCMB-UHFFFAOYSA-N (4-nitrophenyl) carbonochloridate Chemical compound [O-][N+](=O)C1=CC=C(OC(Cl)=O)C=C1 NXLNNXIXOYSCMB-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- GAUUDQVOPUKGJD-UHFFFAOYSA-N 1-(bromomethyl)-2-chloro-4-fluorobenzene Chemical compound FC1=CC=C(CBr)C(Cl)=C1 GAUUDQVOPUKGJD-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical group C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
- NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 1
- RCRCTBLIHCHWDZ-DOFZRALJSA-N 2-arachidonoylglycerol Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)OC(CO)CO RCRCTBLIHCHWDZ-DOFZRALJSA-N 0.000 description 1
- NRGGMCIBEHEAIL-UHFFFAOYSA-N 2-ethylpyridine Chemical compound CCC1=CC=CC=N1 NRGGMCIBEHEAIL-UHFFFAOYSA-N 0.000 description 1
- WEUIJSDNBZVSNY-UHFFFAOYSA-N 2-fluoro-4-(trifluoromethyl)phenol Chemical compound OC1=CC=C(C(F)(F)F)C=C1F WEUIJSDNBZVSNY-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- PSSWASGEGXCINO-UHFFFAOYSA-N 3-aminopiperidin-4-ol Chemical class NC1CNCCC1O PSSWASGEGXCINO-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- LBUNNMJLXWQQBY-UHFFFAOYSA-N 4-fluorophenylboronic acid Chemical compound OB(O)C1=CC=C(F)C=C1 LBUNNMJLXWQQBY-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- QRCGFTXRXYMJOS-UHFFFAOYSA-N 4h-1,4-benzoxazin-3-one Chemical class C1=CC=C2NC(=O)COC2=C1 QRCGFTXRXYMJOS-UHFFFAOYSA-N 0.000 description 1
- SZSMYQPIAAUBBY-UHFFFAOYSA-N 5,6,7,8-tetrahydroisoquinolin-3-ylmethanol Chemical compound C1CCCC2=C1C=C(CO)N=C2 SZSMYQPIAAUBBY-UHFFFAOYSA-N 0.000 description 1
- KVDMSFCCPOLCAF-UHFFFAOYSA-N 5-(2-chlorophenoxy)-1,2,3,3a,4,5,6,6a-octahydrocyclopenta[c]pyrrole Chemical compound Clc1ccccc1OC1CC2CNCC2C1 KVDMSFCCPOLCAF-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 102000001381 Arachidonate 5-Lipoxygenase Human genes 0.000 description 1
- 108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- DWJFOGZSJYQKND-IBTYICNHSA-N C(C)(=O)O.O1[C@@H]2[C@H](NC(C1)=O)CNCC2 Chemical compound C(C)(=O)O.O1[C@@H]2[C@H](NC(C1)=O)CNCC2 DWJFOGZSJYQKND-IBTYICNHSA-N 0.000 description 1
- ZVSQDSKXACJPFJ-UHFFFAOYSA-N CS(=O)(=O)OCC1C2CN(CC1CC2)C(=O)OC(C)(C)C Chemical compound CS(=O)(=O)OCC1C2CN(CC1CC2)C(=O)OC(C)(C)C ZVSQDSKXACJPFJ-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- CKDWPUIZGOQOOM-UHFFFAOYSA-N Carbamyl chloride Chemical class NC(Cl)=O CKDWPUIZGOQOOM-UHFFFAOYSA-N 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- YDLDAGREOCOAQA-UHFFFAOYSA-N Cl.ClC1=C(OCC2CC3CCC(C2)N3)C=CC(=C1)F Chemical compound Cl.ClC1=C(OCC2CC3CCC(C2)N3)C=CC(=C1)F YDLDAGREOCOAQA-UHFFFAOYSA-N 0.000 description 1
- GUUGQXCJQYONGD-YCUKKYJWSA-N ClC1=C(C=CC(=C1)F)S(=O)(=O)N1CC2C(C1)CN(C2)C(=O)N1C[C@@H]2[C@@H](OCC(N2)=O)CC1 Chemical compound ClC1=C(C=CC(=C1)F)S(=O)(=O)N1CC2C(C1)CN(C2)C(=O)N1C[C@@H]2[C@@H](OCC(N2)=O)CC1 GUUGQXCJQYONGD-YCUKKYJWSA-N 0.000 description 1
- YMIXGENTHNLHJF-UHFFFAOYSA-N ClC=1C(=CC(=NC=1)CO)C1CC1 Chemical compound ClC=1C(=CC(=NC=1)CO)C1CC1 YMIXGENTHNLHJF-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- KKJHRXUWCBGKRP-UHFFFAOYSA-N FC(C(=O)O)(F)F.ClC1=C(COC2CC3C(CNC3)C2)C=CC(=C1)F Chemical compound FC(C(=O)O)(F)F.ClC1=C(COC2CC3C(CNC3)C2)C=CC(=C1)F KKJHRXUWCBGKRP-UHFFFAOYSA-N 0.000 description 1
- QNYSCWJOGKZNJY-UHFFFAOYSA-N FC(C(=O)O)(F)F.ClC1=C(OC2CC3C(CNC3)C2)C=CC(=C1)F Chemical compound FC(C(=O)O)(F)F.ClC1=C(OC2CC3C(CNC3)C2)C=CC(=C1)F QNYSCWJOGKZNJY-UHFFFAOYSA-N 0.000 description 1
- OCKFOWXMWIMDNE-UHFFFAOYSA-N FC(C(=O)O)(F)F.ClC1=C(OCC2C3CNCC2CC3)C=CC(=C1)F Chemical compound FC(C(=O)O)(F)F.ClC1=C(OCC2C3CNCC2CC3)C=CC(=C1)F OCKFOWXMWIMDNE-UHFFFAOYSA-N 0.000 description 1
- BFESNPJVGYMUCU-UHFFFAOYSA-N FC(C(=O)O)(F)F.FC(C(=O)O)(F)F.ClC=1C(=CC(=NC1)COC1C2CNC(C1)C2)C2CC2 Chemical compound FC(C(=O)O)(F)F.FC(C(=O)O)(F)F.ClC=1C(=CC(=NC1)COC1C2CNC(C1)C2)C2CC2 BFESNPJVGYMUCU-UHFFFAOYSA-N 0.000 description 1
- OARGKGDBJQNEGS-WQSJENOOSA-N FC(C(=O)O)(F)F.FC(C(=O)O)(F)F.[C@H]12NC[C@H]([C@H](C1)OCC=1N=CC=3CCCCC3C1)C2 Chemical compound FC(C(=O)O)(F)F.FC(C(=O)O)(F)F.[C@H]12NC[C@H]([C@H](C1)OCC=1N=CC=3CCCCC3C1)C2 OARGKGDBJQNEGS-WQSJENOOSA-N 0.000 description 1
- UISAZRSTJLMXIK-UHFFFAOYSA-N FC(C(=O)O)(F)F.FC1=C(COC2CC3C(CNC3)C2)C=CC(=C1)C(F)(F)F Chemical compound FC(C(=O)O)(F)F.FC1=C(COC2CC3C(CNC3)C2)C=CC(=C1)C(F)(F)F UISAZRSTJLMXIK-UHFFFAOYSA-N 0.000 description 1
- HXOCHKJLHMTUHM-UHFFFAOYSA-N FC(C(=O)O)(F)F.FC1=C(OC2CC3C(CNC3)C2)C=CC(=C1)C(F)(F)F Chemical compound FC(C(=O)O)(F)F.FC1=C(OC2CC3C(CNC3)C2)C=CC(=C1)C(F)(F)F HXOCHKJLHMTUHM-UHFFFAOYSA-N 0.000 description 1
- BSGUBQOGJTZRIG-BMAZIBOLSA-N FC1=C(C=CC(=C1)C(F)(F)F)COC1CC2C(CN(C2)C(=O)N2C[C@@H]3[C@@H](OCC(N3)=O)CC2)C1 Chemical compound FC1=C(C=CC(=C1)C(F)(F)F)COC1CC2C(CN(C2)C(=O)N2C[C@@H]3[C@@H](OCC(N3)=O)CC2)C1 BSGUBQOGJTZRIG-BMAZIBOLSA-N 0.000 description 1
- PGMNNGJXVGAASQ-XZJROXQQSA-N FC1=C(CO[C@H]2C[C@H]3CN([C@@H]2C3)C(=O)OC(C)(C)C)C=CC(=C1)C(F)(F)F Chemical compound FC1=C(CO[C@H]2C[C@H]3CN([C@@H]2C3)C(=O)OC(C)(C)C)C=CC(=C1)C(F)(F)F PGMNNGJXVGAASQ-XZJROXQQSA-N 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 101000929834 Homo sapiens Monoacylglycerol lipase ABHD6 Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 229910010084 LiAlH4 Inorganic materials 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102100035912 Monoacylglycerol lipase ABHD6 Human genes 0.000 description 1
- 229940122357 Monoacylglycerol lipase inhibitor Drugs 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- 229910020889 NaBH3 Inorganic materials 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000001294 Nociceptive Pain Diseases 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 229910020667 PBr3 Inorganic materials 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229910002666 PdCl2 Inorganic materials 0.000 description 1
- 208000004983 Phantom Limb Diseases 0.000 description 1
- 206010056238 Phantom pain Diseases 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010053395 Progressive multiple sclerosis Diseases 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 229910006124 SOCl2 Inorganic materials 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 125000005227 alkyl sulfonate group Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000002001 anti-metastasis Effects 0.000 description 1
- 230000001168 anti-motility effect Effects 0.000 description 1
- 230000003502 anti-nociceptive effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000002622 anti-tumorigenesis Effects 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- LGEQQWMQCRIYKG-UHFFFAOYSA-N arachidonic acid ethanolamide Natural products CCCCCC=CCC=CCC=CCC=CCCCC(=O)NCCO LGEQQWMQCRIYKG-UHFFFAOYSA-N 0.000 description 1
- 125000002886 arachidonoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])/C([H])=C([H])\C([H])([H])/C([H])=C([H])\C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 125000005228 aryl sulfonate group Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 125000004273 azetidin-2-yl group Chemical group [H]N1C([H])([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004567 azetidin-3-yl group Chemical group N1CC(C1)* 0.000 description 1
- 125000005604 azodicarboxylate group Chemical group 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- YHNUDLCUIKMNSN-UHFFFAOYSA-N bis(1,2,4-triazol-1-yl)methanone Chemical compound C1=NC=NN1C(=O)N1C=NC=N1 YHNUDLCUIKMNSN-UHFFFAOYSA-N 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 229930003827 cannabinoid Natural products 0.000 description 1
- 239000003557 cannabinoid Substances 0.000 description 1
- 229940065144 cannabinoids Drugs 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 230000006720 chronic neuroinflammation Effects 0.000 description 1
- 230000037326 chronic stress Effects 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 231100000858 damage to nervous tissue Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 229960004132 diethyl ether Drugs 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000006274 endogenous ligand Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 1
- 231100000318 excitotoxic Toxicity 0.000 description 1
- 230000003492 excitotoxic effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000004136 fatty acid synthesis Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 1
- 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 description 1
- 125000002140 imidazol-4-yl group Chemical group [H]N1C([H])=NC([*])=C1[H] 0.000 description 1
- 125000000336 imidazol-5-yl group Chemical group [H]N1C([H])=NC([H])=C1[*] 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000000593 indol-1-yl group Chemical group [H]C1=C([H])C([H])=C2N([*])C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000002249 indol-2-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([*])=C([H])C2=C1[H] 0.000 description 1
- 125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 description 1
- 125000004531 indol-5-yl group Chemical group [H]N1C([H])=C([H])C2=C([H])C(*)=C([H])C([H])=C12 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003870 intestinal permeability Effects 0.000 description 1
- 229960004903 invert sugar Drugs 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000011418 maintenance treatment Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000002025 microglial effect Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 125000004572 morpholin-3-yl group Chemical group N1C(COCC1)* 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 239000002581 neurotoxin Substances 0.000 description 1
- 231100000618 neurotoxin Toxicity 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000002825 nitriles Chemical group 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000004287 oxazol-2-yl group Chemical group [H]C1=C([H])N=C(*)O1 0.000 description 1
- 125000003145 oxazol-4-yl group Chemical group O1C=NC(=C1)* 0.000 description 1
- 125000004304 oxazol-5-yl group Chemical group O1C=NC=C1* 0.000 description 1
- 125000004274 oxetan-2-yl group Chemical group [H]C1([H])OC([H])(*)C1([H])[H] 0.000 description 1
- 125000006299 oxetan-3-yl group Chemical group [H]C1([H])OC([H])([H])C1([H])* 0.000 description 1
- 230000004783 oxidative metabolism Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- IPNPIHIZVLFAFP-UHFFFAOYSA-N phosphorus tribromide Chemical compound BrP(Br)Br IPNPIHIZVLFAFP-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 125000004353 pyrazol-1-yl group Chemical group [H]C1=NN(*)C([H])=C1[H] 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- 230000003238 somatosensory effect Effects 0.000 description 1
- VNFWTIYUKDMAOP-UHFFFAOYSA-N sphos Chemical group COC1=CC=CC(OC)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 VNFWTIYUKDMAOP-UHFFFAOYSA-N 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- PABFVGKPNHVSCG-DJLDLDEBSA-N tert-butyl (1s,4r,5r)-5-hydroxy-3-azabicyclo[2.2.1]heptane-3-carboxylate Chemical compound C1[C@@H](O)[C@@H]2N(C(=O)OC(C)(C)C)C[C@H]1C2 PABFVGKPNHVSCG-DJLDLDEBSA-N 0.000 description 1
- PABFVGKPNHVSCG-UHFFFAOYSA-N tert-butyl 5-hydroxy-3-azabicyclo[2.2.1]heptane-3-carboxylate Chemical compound C1C(O)C2N(C(=O)OC(C)(C)C)CC1C2 PABFVGKPNHVSCG-UHFFFAOYSA-N 0.000 description 1
- RTLCPCOGXPWAQH-UHFFFAOYSA-N tert-butyl 8-(hydroxymethyl)-3-azabicyclo[3.2.1]octane-3-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CC2CCC1C2CO RTLCPCOGXPWAQH-UHFFFAOYSA-N 0.000 description 1
- VPQNIRLIMWSXGD-UHFFFAOYSA-N tert-butyl n-(2-chloroanilino)carbamate Chemical compound CC(C)(C)OC(=O)NNC1=CC=CC=C1Cl VPQNIRLIMWSXGD-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- NHGXDBSUJJNIRV-UHFFFAOYSA-M tetrabutylammonium chloride Chemical compound [Cl-].CCCC[N+](CCCC)(CCCC)CCCC NHGXDBSUJJNIRV-UHFFFAOYSA-M 0.000 description 1
- DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 235000019798 tripotassium phosphate Nutrition 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000004222 uncontrolled growth Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Definitions
- the present invention relates to organic compounds useful for therapy or prophylaxis in a mammal, and in particular to monoacylglycerol lipase (MAGL) inhibitors for use in the treatment or prophylaxis of neuroinflammation, neurodegenerative diseases, pain, cancer, mental disorders, multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, inflammatory bowel disease, abdominal pain, abdominal pain associated with irritable bowel syndrome and/or visceral pain in a mammal.
- MLM monoacylglycerol lipase
- Endocannabinoids are signaling lipids that exert their biological actions by interacting with cannabinoid receptors (CBRs), CB1 and CB2. They modulate multiple physiological processes including neuroinflammation, neurodegeneration and tissue regeneration ( Iannotti, F.A., et al., Progress in lipid research 2016, 62, 107-28 .).
- CBRs cannabinoid receptors
- CB1 and CB2 cannabinoid receptors
- DAGL diacyglycerol lipases
- MAGL monoacylglycerol lipase
- MAGL is expressed throughout the brain and in most brain cell types, including neurons, astrocytes, oligodendrocytes and microglia cells ( Chanda, P.K., et al., Molecular pharmacology 2010, 78, 996 ; Viader, A., et al., Cell reports 2015, 12, 798 .).
- 2-AG hydrolysis results in the formation of arachidonic acid (AA), the precursor of prostaglandins (PGs) and leukotrienes (LTs).
- Oxidative metabolism of AA is increased in inflamed tissues.
- the cyclo-oxygenase which produces PGs
- the 5-lipoxygenase which produces LTs.
- PGE2 is one of the most important. These products have been detected at sites of inflammation, e.g. in the cerebrospinal fluid of patients suffering from neurodegenerative disorders and are believed to contribute to inflammatory response and disease progression.
- mice lacking MAGL exhibit dramatically reduced 2-AG hydrolase activity and elevated 2-AG levels in the nervous system while other arachidonoyl-containing phospho- and neutral lipid species including anandamide (AEA), as well as other free fatty acids, are unaltered.
- levels of AA and AA-derived prostaglandins and other eicosanoids including prostaglandin E2 (PGE2), D2 (PGD2), F2 (PGF2), and thromboxane B2 (TXB2), are strongly decreased.
- Phospholipase A 2 (PLA 2 ) enzymes have been viewed as the principal source of AA, but cPLA 2 -deficient mice have unaltered AA levels in their brain, reinforcing the key role of MAGL in the brain for AA production and regulation of the brain inflammatory process.
- Neuroinflammation is a common pathological change characteristic of diseases of the brain including, but not restricted to, neurodegenerative diseases (e.g. multiple sclerosis, Alzheimer's disease, Parkinson disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy and mental disorders such as anxiety and migraine).
- neurodegenerative diseases e.g. multiple sclerosis, Alzheimer's disease, Parkinson disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy and mental disorders such as anxiety and migraine.
- LPS lipopolysaccharide
- LPS treatment also induces a widespread elevation in pro-inflammatory cytokines including interleukin-1-a (IL-1-a), IL-1b, IL-6, and tumor necrosis factor-a (TNF-a) that is prevented in Mgll-/- mice.
- IL-1-a interleukin-1-a
- IL-6 IL-6
- TNF-a tumor necrosis factor-a
- Neuroinflammation is characterized by the activation of the innate immune cells of the central nervous system, the microglia and the astrocytes. It has been reported that anti-inflammatory drugs can suppress in preclinical models the activation of glia cells and the progression of disease including Alzheimer's disease and mutiple sclerosis ( Lleo A., Cell Mol Life Sci. 2007, 64, 1403 .). Importantly, genetic and/or pharmacological disruption of MAGL activity also blocks LPS-induced activation of microglial cells in the brain ( Nomura, D.K., et al., Science 2011, 334, 809 .).
- MAGL activity was shown to be protective in several animal models of neurodegeneration including, but not restricted to, Alzheimer's disease, Parkinson's disease and multiple sclerosis.
- an irreversible MAGL inhibitor has been widely used in preclinical models of neuroinflammation and neurodegeneration ( Long, J.Z., et al., Nature chemical biology 2009, 5, 37 .).
- 2-AG has been reported to show beneficial effects on pain with, for example, anti-nociceptive effects in mice ( Ignatowska-Jankowska B. et al., J. Pharmacol. Exp. Ther. 2015, 353, 424 .) and on mental disorders, such as depression in chronic stress models ( Zhong P. et al., Neuropsychopharmacology 2014, 39, 1763 .).
- oligodendrocytes the myelinating cells of the central nervous system, and their precursors (OPCs) express the cannabinoid receptor 2 (CB2) on their membrane.
- CB2 cannabinoid receptor 2
- 2-AG is the endogenous ligand of CB1 and CB2 receptors. It has been reported that both cannabinoids and pharmacological inhibition of MAGL attenuate OLs's and OPCs's vulnerability to excitotoxic insults and therefore may be neuroprotective ( Bernal-Chico, A., et al., Glia 2015, 63, 163 .).
- MAGL inhibition increases the number of myelinating OLs in the brain of mice, suggesting that MAGL inhibition may promote differentiation of OPCs in myelinating OLs in vivo ( Alpar, A., et al., Nature communications 2014, 5, 4421 .). Inhibition of MAGL was also shown to promote remyelination and functional recovery in a mouse model of progressive multiple sclerosis ( Feliu A. et al., Journal of Neuroscience 2017, 37 (35), 8385 .).
- MAGL as an important decomposing enzyme for both lipid metabolism and the endocannabinoids system, additionally as a part of a gene expression signature, contributes to different aspects of tumourigenesis, including in glioblastoma ( Qin, H., et al., Cell Biochem. Biophys.
- CBRs cannabinoid receptors
- CB1 receptors are present throughout the GI tract of animals and healthy humans, especially in the enteric nervous system (ENS) and the epithelial lining, as well as smooth muscle cells of blood vessels in the colonic wall ( Wright K. et al., Gastroenterology 2005, 129(2), 437-453 ; Duncan, M. et al., Aliment Pharmacol Ther 2005, 22(8), 667-683 ).
- CB1 Activation of CB1 produces anti-emetic, anti-motility, and anti-inflammatory effect, and help to modulate pain ( Perisetti, A. et al., Ann Gastroenterol 2020, 33(2), 134-144 ).
- CB2 receptors are expressed in immune cells such as plasma cells and macrophages, in the lamina intestinal of the GI tract ( Wright K. et al., Gastroenterology 2005, 129(2), 437-453 ), and primarily on the epithelium of human colonic tissue associated with inflammatory bowel disease (IBD).
- IBD inflammatory bowel disease
- Activation of CB2 exerts anti-inflammatory effect by reducing pro-inflammatory cytokines.
- Expression of MAGL is increased in colonic tissue in UC patients ( Marquez L.
- MAGL inhibition prevents TNBS-induced mouse colitis and decreases local and circulating inflammatory markers via a CB1/CB2 MoA ( Marquez L. et al., PLoS One 2009, 4(9), e6893 ). Furthermore, MAGL inhibition improves gut wall integrity and intestinal permeability via a CB1 driven MoA ( Wang, J. et al., Biochem Biophys Res Commun 2020, 525(4), 962-967 ). WO2019/115660 discloses 4H-1,4-benzoxazin-3-one compounds as MAGL inhibitors.
- suppressing the action and/or the activation of MAGL is a promising new therapeutic strategy for the treatment or prevention of neuroinflammation, neurodegenerative diseases, pain, cancer, mental disorders, inflammatory bowel disease, abdominal pain and abdominal pain associated with irritable bowel syndrome. Furthermore, suppressing the action and/or the activation of MAGL is a promising new therapeutic strategy for providing neuroprotection and myelin regeneration. Accordingly, there is a high unmet medical need for new MAGL inhibitors.
- the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein A, B, L, X, and R 1 to R 4 are as described herein. Also disclosed herein but not part of the invention is a process of manufacturing the urea compounds of formula (I) described herein, and pharmaceutically acceptable salts thereof, comprising:
- the present invention provides a compound of formula (I) as described herein, for use as therapeutically active substance.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising a compound of formula (I) as described herein and a therapeutically inert carrier.
- the present invention provides a compound of formula (I) as described herein or of a pharmaceutical composition described herein for use in inhibiting monoacylglycerol lipase (MAGL) in a mammal.
- MAGL monoacylglycerol lipase
- the present invention provides a compound of formula (I) as described herein or of a pharmaceutical composition described herein for use in the treatment or prophylaxis of neuroinflammation, neurodegenerative diseases, pain, cancer, mental disorders and/or inflammatory bowel disease in a mammal.
- the present invention provides a compound of formula (I) as described herein or of a pharmaceutical composition described herein for use in the treatment or prophylaxis of multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colon carcinogenesis, ovarian cancer, neuropathic pain, chemotherapy induced neuropathy, acute pain, chronic pain, spasticity associated with pain, abdominal pain, abdominal pain associated with irritable bowel syndrome and/or visceral pain in a mammal.
- multiple sclerosis Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colon carcinogenesis, ovarian cancer, neuropathic pain, chemotherapy induced neuropathy, acute pain, chronic pain, spasticity associated with pain, abdominal pain, abdominal pain associated with irritable bowel syndrome
- alkyl refers to a mono- or multivalent, e.g., a mono- or bivalent, linear or branched saturated hydrocarbon group of 1 to 6 carbon atoms ("C 1 -C 6 -alkyl”), e.g., 1, 2, 3, 4, 5, or 6 carbon atoms. In some embodiments, the alkyl group contains 1 to 3 carbon atoms, e.g., 1, 2 or 3 carbon atoms.
- alkyl include methyl, ethyl, propyl, 2-propyl (isopropyl), n-butyl, iso-butyl, sec-butyl, tert-butyl, and 2,2-dimethylpropyl.
- a particularly preferred, yet non-limiting example of alkyl is methyl.
- alkoxy refers to an alkyl group, as previously defined, attached to the parent molecular moiety via an oxygen atom. Unless otherwise specified, the alkoxy group contains 1 to 6 carbon atoms ("C 1 -C 6 -alkoxy"). In some preferred embodiments, the alkoxy group contains contains 1 to 4 carbon atoms. In still other embodiments, the alkoxy group contains 1 to 3 carbon atoms. Some non-limiting examples of alkoxy groups include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy and tert-butoxy. A particularly preferred, yet non-limiting example of alkoxy is methoxy.
- halogen refers to fluoro (F), chloro (Cl), bromo (Br), or iodo (I).
- halogen refers to fluoro (F), chloro (Cl) or bromo (Br).
- Particularly preferred, yet non-limiting examples of "halogen” or “halo” are fluoro (F) and chloro (Cl).
- bridged bicyclic heterocycle refers to a chemical entity consisting of two heterocyclyl moieties as defined herein, or to a combination of one heterocyclyl and one cycloalkyl moiety, having two ring atoms in common, i.e., the bridge separating the two rings is either a single bond or a chain of one or two ring atoms.
- the bridged bicyclic heterocycle is a 6-14 membered bridged bicyclic heterocycle comprising 1-3 heteroatoms selected from N, S, and O.
- the bridged bicyclic heterocycle is a 6-9 membered bridged bicyclic heterocycle comprising 1-2 heteroatoms selected from N and O.
- the bridged bicyclic heterocycle is a 6-8 membered bridged bicyclic heterocycle comprising 1 nitrogen atom.
- Some preferred, yet non-limiting examples of bridged bicyclic heterocycles include 8-azabicyclo[3.2.1]octane-yl; 3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrolyl; 3-azabicyclo[3.1.0]hexanyl; 2-azabicyclo[2.2.1]heptane-yl; 3-azabicyclo[3.2.1]octane-yl; 2,3,3a,4,6,6a-hexahydro-1H-pyrrolo[3,4-c]pyrrolyl; 3-oxa-9-azabicyclo[3.3.1]nonane-yl; and 3-azabicyclo[3.1.1]heptane-yl.
- heterocyclyl refers to a saturated or partly unsaturated monocyclic ring system of 3 to 10 ring atoms, preferably 3 to 8 ring atoms, wherein 1, 2, or 3 of said ring atoms are heteroatoms selected from N, O and S, the remaining ring atoms being carbon.
- 1, 2, or 3 of said ring atoms are heteroatoms selected from N, O and S, the remaining ring atoms being carbon.
- 1 to 2 of said ring atoms are selected from N and O, the remaining ring atoms being carbon.
- heterocyclyl groups include azetidin-3-yl, azetidin-2-yl, oxetan-3-yl, oxetan-2-yl, 2-oxopyrrolidin-1-yl, 2-oxopyrrolidin-3-yl, 5-oxopyrrolidin-2-yl, 5-oxopyrrolidin-3-yl, 2-oxo-1-piperidyl, 2-oxo-3-piperidyl, 2-oxo-4-piperidyl, 6-oxo-2-piperidyl, 6-oxo-3-piperidyl, 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-piperidinyl, morpholino, morpholin-2-yl and morpholin-3-yl.
- cycloalkyl refers to a saturated or partly unsaturated monocyclic hydrocarbon group of 3 to 10 ring carbon atoms (“C 3 -C 10 -cycloalkyl”).
- the cycloalkyl group is a saturated monocyclic hydrocarbon group of 3 to 8 ring carbon atoms.
- the cycloalkyl group is a saturated monocyclic hydrocarbon group of 3 to 6 ring carbon atoms, e.g., of 3, 4, 5 or 6 carbon atoms.
- Some non-limiting examples of cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.
- a particularly preferred, yet non-limiting example of cycloalkyl is cyclopropyl.
- aryl refers to a monocyclic, bicyclic, or tricyclic carbocyclic ring system having a total of 6 to 14 ring members ("C 6 -C 14 -aryl”), preferably, 6 to 12 ring members, and more preferably 6 to 10 ring members, and wherein at least one ring in the system is aromatic.
- C 6 -C 14 -aryl 6 to 14 ring members
- a particularly preferred, yet non-limiting example of aryl is phenyl.
- heteroaryl refers to a mono- or multivalent, monocyclic or bicyclic, preferably bicyclic ring system having a total of 5 to 14 ring members, preferably, 5 to 12 ring members, and more preferably 5 to 10 ring members, wherein at least one ring in the system is aromatic, and at least one ring in the system contains one or more heteroatoms.
- heteroaryl refers to a 5-10 membered heteroaryl comprising 1, 2, 3 or 4 heteroatoms independently selected from O, S and N.
- heteroaryl refers to a 5-10 membered heteroaryl comprising 1 to 2 heteroatoms independently selected from O and N.
- heteroaryl examples include 2-pyridyl, 3-pyridyl, 4-pyridyl, indol-1-yl, 1H-indol-2-yl, 1H-indol-3-yl, 1H-indol-4-yl, 1H-indol-5-yl, 1H-indol-6-yl, 1H-indol-7-yl, 1,2-benzoxazol-3-yl, 1,2-benzoxazol-4-yl, 1,2-benzoxazol-5-yl, 1,2-benzoxazol-6-yl, 1,2-benzoxazol-7-yl, 1H-indazol-3-yl, 1H-indazol-4-yl, 1H-indazol-5-yl, 1H-indazol-6-yl, 1H-indazol-7-yl, pyrazol-1-yl, 1H-pyrazol-3-yl, 1H-o-yl
- hydroxy refers to an -OH group.
- cyano refers to a -CN (nitrile) group.
- alkylsulfonyl refers to an alkyl group attached to the parent molecular moiety via an SO 2 moiety.
- a particularly preferred, yet non-limiting example of alkylsulfonyl is methylsulfonyl.
- haloalkyl refers to an alkyl group, wherein at least one of the hydrogen atoms of the alkyl group has been replaced by a halogen atom, preferably fluoro.
- haloalkyl refers to an alkyl group wherein 1, 2 or 3 hydrogen atoms of the alkyl group have been replaced by a halogen atom, most preferably fluoro.
- a particularly preferred, yet non-limiting example of haloalkyl is trifluoromethyl (CF 3 ).
- haloalkoxy refers to an alkoxy group, wherein at least one of the hydrogen atoms of the alkoxy group has been replaced by a halogen atom, preferably fluoro.
- haloalkoxy refers to an alkoxy group wherein 1, 2 or 3 hydrogen atoms of the alkoxy group have been replaced by a halogen atom, most preferably fluoro.
- a particularly preferred, yet non-limiting example of haloalkoxy is trifluoromethoxy (-OCF 3 ).
- salts refers to those salts which retain the biological effectiveness and properties of the free bases or free acids, which are not biologically or otherwise undesirable.
- the salts are formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, in particular hydrochloric acid, and organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, N-acetylcystein and the like.
- salts derived from an inorganic base include, but are not limited to, the sodium, potassium, lithium, ammonium, calcium, magnesium salts and the like.
- Salts derived from organic bases include, but are not limited to salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, lysine, arginine, N-ethylpiperidine, piperidine, polyimine resins and the like.
- Particular pharmaceutically acceptable salts of compounds of formula (I) are hydrochloride salts.
- protective group denotes the group which selectively blocks a reactive site in a multifunctional compound such that a chemical reaction can be carried out selectively at another unprotected reactive site in the meaning conventionally associated with it in synthetic chemistry.
- Protective groups can be removed at the appropriate point.
- Exemplary protective groups are amino-protective groups, carboxy-protective groups or hydroxy-protective groups.
- Particular protective groups are the tert-butoxycarbonyl (Boc), benzyloxycarbonyl (Cbz), fluorenylmethoxycarbonyl (Fmoc) and benzyl (Bn).
- protective groups are the tert-butoxycarbonyl (Boc) and the fluorenylmethoxycarbonyl (Fmoc). More particular protective group is the tert-butoxycarbonyl (Boc).
- Exemplary protective groups and their application in organic synthesis are described, for example, in " Protective Groups in Organic Chemistry” by T. W. Greene and P. G. M. Wutts, 5th Ed., 2014, John Wiley & Sons, N.Y .
- urea forming reagent refers to a chemical compound that is able to render a first amine to a species that will react with a second amine, thereby forming an urea derivative.
- Non-limiting examples of urea forming reagents include bis(trichloromethyl) carbonate, phosgene, trichloromethyl chloroformate, (4-nitrophenyl)carbonate and 1,1'-carbonyldiimidazole.
- the urea forming reagents described in G. Sartori et al., Green Chemistry 2000, 2, 140 are incorporated herein by reference.
- the compounds of formula (I) can contain several asymmetric centers and can be present in the form of optically pure enantiomers, mixtures of enantiomers such as, for example, racemates, optically pure diastereioisomers, mixtures of diastereoisomers, diastereoisomeric racemates or mixtures of diastereoisomeric racemates.
- the compound of formula (I) according to the invention is a cis-enantiomer of formula (Ia) or (Ib), respectively, as described herein.
- the asymmetric carbon atom can be of the "R” or "S” configuration.
- MAGL refers to the enzyme monoacylglycerol lipase.
- the terms “MAGL” and “monoacylglycerol lipase” are used herein interchangeably.
- treatment includes: (1) inhibiting the state, disorder or condition (e.g. arresting, reducing or delaying the development of the disease, or a relapse thereof in case of maintenance treatment, of at least one clinical or subclinical symptom thereof); and/or (2) relieving the condition (i.e., causing regression of the state, disorder or condition or at least one of its clinical or subclinical symptoms).
- the benefit to a patient to be treated is either statistically significant or at least perceptible to the patient or to the physician.
- the outcome may not always be effective treatment.
- prophylaxis includes: preventing or delaying the appearance of clinical symptoms of the state, disorder or condition developing in a mammal and especially a human that may be afflicted with or predisposed to the state, disorder or condition but does not yet experience or display clinical or subclinical symptoms of the state, disorder or condition.
- neuroinflammation as used herein relates to acute and chronic inflammation of the nervous tissue, which is the main tissue component of the two parts of the nervous system; the brain and spinal cord of the central nervous system (CNS), and the branching peripheral nerves of the peripheral nervous system (PNS).
- Chronic neuroinflammation is associated with neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and multiple sclerosis.
- Acute neuroinflammation usually follows injury to the central nervous system immediately, e.g., as a result of traumatic brain injury (TBI).
- TBI traumatic brain injury
- TBI traumatic brain injury
- intracranial injury relates to damage to the brain resulting from external mechanical force, such as rapid acceleration or deceleration, impact, blast waves, or penetration by a projectile.
- neurodegenerative diseases relates to diseases that are related to the progressive loss of structure or function of neurons, including death of neurons.
- Examples of neurodegenerative diseases include, but are not limited to, multiple sclerosis, Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis.
- mental disorders also called mental illnesses or psychiatric disorders
- mental disorders relate to behavioral or mental patterns that may cause suffering or a poor ability to function in life. Such features may be persistent, relapsing and remitting, or occur as a single episode. Examples of mental disorders include, but are not limited to, anxiety and depression.
- pain relates to an unpleasant sensory and emotional experience associated with actual or potential tissue damage.
- pain include, but are not limited to, nociceptive pain, chronic pain (including idiopathic pain), neuropathic pain including chemotherapy induced neuropathy, phantom pain and phsychogenic pain.
- neuropathic pain which is caused by damage or disease affecting any part of the nervous system involved in bodily feelings (i.e., the somatosensory system).
- "pain” is neuropathic pain resulting from amputation or thoracotomy.
- "pain” is chemotherapy induced neuropathy.
- neurotoxicity relates to toxicity in the nervous system. It occurs when exposure to natural or artificial toxic substances (neurotoxins) alter the normal activity of the nervous system in such a way as to cause damage to nervous tissue.
- neurotoxicity include, but are not limited to, neurotoxicity resulting from exposure to substances used in chemotherapy, radiation treatment, drug therapies, drug abuse, and organ transplants, as well as exposure to heavy metals, certain foods and food additives, pesticides, industrial and/or cleaning solvents, cosmetics, and some naturally occurring substances.
- cancer refers to a disease characterized by the presence of a neoplasm or tumor resulting from abnormal uncontrolled growth of cells (such cells being “cancer cells”).
- cancer explicitly includes, but is not limited to, hepatocellular carcinoma, colon carcinogenesis and ovarian cancer.
- mammal as used herein includes both humans and non-humans and includes but is not limited to humans, non-human primates, canines, felines, murines, bovines, equines, and porcines. In a particularly preferred embodiment, the term “mammal” refers to humans.
- the present invention provides compounds of Formula (I) or pharmaceutically acceptable salts thereof, wherein:
- the present invention provides pharmaceutically acceptable salts of the compounds according to formula (I) as described herein, especially hydrochloride salts.
- the present invention provides compounds according to formula (I) as described herein as free bases.
- the compounds of formula (I) are isotopically-labeled by having one or more atoms therein replaced by an atom having a different atomic mass or mass number.
- isotopically-labeled (i.e., radiolabeled) compounds of formula (I) are considered to be within the scope of this disclosure.
- isotopes that can be incorporated into the compounds of formula (I) include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, sulfur, fluorine, chlorine, and iodine, such as, but not limited to, 2 H, 3 H, 11 C, 13 C, 14 C, 13 N, 15 N, 15 O, 17 O, 18 O, 31 P, 32 P, 35 S, 18 F, 36 Cl, 123 I, and 125 I, respectively.
- Certain isotopically-labeled compounds of formula (I) for example, those incorporating a radioactive isotope, are useful in drug and/or substrate tissue distribution studies.
- the radioactive isotopes tritium, i.e.
- a compound of formula (I) can be enriched with 1, 2, 5, 10, 25, 50, 75, 90, 95, or 99 percent of a given isotope.
- substitution with heavier isotopes such as deuterium, i.e. 2 H, may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements.
- Isotopically-labeled compounds of formula (I) can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the Examples as set out below using an appropriate isotopically-labeled reagent in place of the non-labeled reagent previously employed.
- one of the starting materials, intermediates or compounds of formula (I) contain one or more functional groups which are not stable or are reactive under the reaction conditions of one or more reaction steps
- appropriate protective groups as described e.g., in " Protective Groups in Organic Chemistry” by T. W. Greene and P. G. M. Wutts, 5th Ed., 2014, John Wiley & Sons, N.Y .
- Such protective groups can be removed at a later stage of the synthesis using standard methods described in the literature.
- compounds of formula (I) can be obtained as mixtures of diastereomers or enantiomers, which can be separated by methods well known in the art e.g., chiral HPLC, chiral SFC or chiral crystallization. Racemic compounds can e.g., be separated into their antipodes via diastereomeric salts by crystallization with optically pure acids or by separation of the antipodes by specific chromatographic methods using either a chiral adsorbent or a chiral eluent. It is equally possible to separate starting materials and intermediates containing stereogenic centers to afford diastereomerically/enantiomerically enriched starting materials and intermediates. Using such diastereomerically/enantiomerically enriched starting materials and intermediates in the synthesis of compounds of formula (I) will typically lead to the respective diastereomerically/enantiomerically enriched compounds of formula (I).
- the compounds of formula (I) can be manufactured by the methods given below, by the methods given in the examples or by analogous methods.
- Appropriate reaction conditions for the individual reaction steps are known to a person skilled in the art.
- reaction conditions described in literature affecting the described reactions see for example: Comprehensive Organic Transformations: A Guide to Functional Group Preparations, 2nd Edition, Richard C. Larock. John Wiley & Sons, New York, NY. 1999 ). It was found convenient to carry out the reactions in the presence or absence of a solvent. There is no particular restriction on the nature of the solvent to be employed, provided that it has no adverse effect on the reaction or the reagents involved and that it can dissolve the reagents, at least to some extent.
- the described reactions can take place over a wide range of temperatures, and the precise reaction temperature is not critical to the invention. It is convenient to carry out the described reactions in a temperature range between -78 °C to reflux.
- the time required for the reaction may also vary widely, depending on many factors, notably the reaction temperature and the nature of the reagents. However, a period of from 0.5 hours to several days will usually suffice to yield the described intermediates and compounds.
- the reaction sequence is not limited to the one displayed in the schemes, however, depending on the starting materials and their respective reactivity, the sequence of reaction steps can be freely altered.
- urea forming reagent such as bis(trichloromethyl) carbonate using a suitable base and solvent such as, e.g. sodium bicarbonate in DCM, to give compounds of formula I ( step a ).
- a urea forming reagent such as bis(trichloromethyl) carbonate using a suitable base and solvent such as, e.g. sodium bicarbonate in DCM
- a suitable base and solvent such as, e.g. sodium bicarbonate in DCM
- urea forming reagents include but are not limited to phosgene, trichloromethyl chloroformate, (4-nitrophenyl)carbonate, 1,1'-carbonyldiimidazole or 1,1'-carbonyl-di-(1,2,4-triazole).
- 3-aminopiperidin-4-ol derivatives 3 in which "PG” signifies a suitable protective group such as a Cbz or Boc protective group, and R 2 is as defined herein can be acylated for example with acyl chlorides 4 in which R 1 is as defined herein and "LG” signifies a suitable leaving group (e.g., Cl or Br), using a suitable base such as sodium or potassium carbonate, sodium hydroxide or sodium acetate in an appropriate solvent such as THF, water, acetone or mixtures thereof, to provide intermediates 5 ( step a ).
- Intermediates 5 can be cyclized to intermediates 6 using methods well known in the art, for example by treatment of 5 with sodium hydride in THF or potassium tert-butoxide in IPA and water (step b ). Reactions of that type are described in literature (e.g. Z. Rafinski et al., J. Org. Chem. 2015, 80, 7468 ; S. Dugar et al., Synthesis 2015, 47(5), 712 ; WO2005/066187 ).
- Intermediates 1 can be obtained as mixtures of diastereomers and enantiomers, respectively, or as single stereoisomers depending on whether racemic mixtures or enantiomerically pure forms of cis- or trans-3-aminopiperidin-4-ol derivatives 3 and acid chlorides 4 (when R 1 is not H) are employed in their syntheses.
- the resulting diastereoisomers may be separated by chromatography (e.g. HPLC, chiral HPLC) or other methods known in the art.
- Intermediates 3 are commercially available and their synthesis has also been described in literature (e.g.
- Optically pure cis-configured intermediates 1B and 1C can be obtained for example according to Scheme 3 by chiral separation of commercially available rac-(4aR,8aS)-4a,5,6,7,8,8a-hexahydro-4H-pyrido[4,3-b][1,4]oxazin-3-one ( 1A ) (optionally in form of a salt such as, e.g. a hydrochloride salt) using methods known in the art, e.g. by diastereomeric salt crystallization or by chiral chromatography ( step a ).
- a salt such as, e.g. a hydrochloride salt
- intermediates 2 are intermediates of type A.
- Intermediates of type A in which A, B, R 3 and R 4 are as described herein and R 5 is hydrogen, C 1-6 -alkyl or halo-C 1-6 -alkyl, can be prepared by methods well known by a person skilled in the art and as exemplified by the general synthetic procedure outlined in Scheme 4.
- PG signifies a suitable protective group such as a Boc, Cbz or Bn protecting group
- Intermediates 9 may alternatively be prepared by alkylation of compounds 8 with spirocyclic derivatives 10 (either commercially available or prepared by methods known in the art) in which LG signifies a suitable leaving group such as chlorine, bromine, iodine, OSO 2 alkyl (e.g. mesylate (methanesulfonate), OSO 2 fluoroalkyl (e.g. triflate (trifluoromethanesulfonate) or OSO 2 aryl (e.g. tosylate (p-toluenesulfonate) using a suitable base and an appropriate solvent (e.g. sodium hydride in DMF or potassium tert-butoxide in THF) at temperatures between 0°C and the boiling temperature of the solvent ( step c ).
- OSO 2 alkyl e.g. mesylate (methanesulfonate)
- OSO 2 fluoroalkyl e.g. triflate (trifluoromethan
- intermediates 2 are intermediates of type B.
- Intermediates of type B in which A, B, R 3 and R 4 are as described herein and R 5 is hydrogen; C 1-6 -alkyl or halo-C 1-6 -alkyl can be prepared by methods well known in the art and as exemplified by the general synthetic procedures outlined in Scheme 5.
- Bicyclic compounds 7 in which PG is a suitable protective group can be alkylated with compounds 13 in which LG is a suitable leaving group such as chlorine, bromine, iodine, methanesulfonate, trifluoromethanesulfonate or p-toluenesulfonate (prepared by literature methods for example from compounds 11 ) using using a suitable base and an appropriate solvent (e.g. sodium hydride in DMF or potassium tert-butoxide in THF) at temperatures between 0°C and the boiling temperature of the solvent ( step c ) to provide intermediates 12 ( step a ).
- an appropriate solvent e.g. sodium hydride in DMF or potassium tert-butoxide in THF
- step b furnishes intermediates B ( step b ).
- intermediates 12 may be prepared from intermediates 7 and compounds 11 via Mitsunobu reaction, applying for example the conditions described under Scheme 4 , step a ( step c).
- intermediates 12 may be also prepared by alkylation of compounds 7 with compounds 10 and using for example the conditions described under Scheme 4 , step c ( step d ).
- Intermediates 10 in turn may be synthesized from compounds 7 converting the hydroxy function into a suitable leaving group such as an alkyl halide (e.g. bromine by using of PBr 3 , chlorine through the use of SOCl 2 ) or alkyl- or aryl-sulfonate such as methanesulfonate (using mesyl chloride) or p-toluenesulfonate (using tosyl chloride). Reactions of that type are broadly described in literature and are well known in the art.
- alkyl halide e.g. bromine by using of PBr 3 , chlorine through the use of SOCl 2
- alkyl- or aryl-sulfonate such as methanesulfonate (using mesyl chloride) or p-toluene
- intermediates 2 are intermediates of type C.
- C 1-6 -alkyl or halo-C 1-6 -alkyl can be prepared by methods well known in the art and as exemplified by the general synthetic procedures outlined in Scheme 6 and described in more detail in J. Med. Chem. 2018, 61, 3008-3026 .
- urea forming reagent is selected from bis(trichloromethyl) carbonate, phosgene, trichloromethyl chloroformate, (4-nitrophenyl)carbonate and 1,1'-carbonyldiimidazole, preferably wherein said urea forming reagent is bis(trichloromethyl) carbonate.
- compositions of the present invention are MAGL inhibitors.
- the present invention provides the compounds of formula (I) as described herein for use in inhibiting
- the present invention provides compounds of formula (I) as described herein for use in a method of inhibiting MAGL in a mammal.
- the present invention provides the compounds of formula (I) as described herein for use in a method for inhibiting MAGL in a mammal, which method comprises administering an effective amount of a compound of formula (I) as described herein to the mammal.
- the 2-AG assay was carried out in 384 well assay plates (PP, Greiner Cat# 784201) in a total volume of 20 ⁇ L.
- Compound dilutions were made in 100% DMSO (VWR Chemicals 23500.297) in a polypropylene plate in 3-fold dilution steps to give a final concentration range in the assay from 12.5 ⁇ M to 0.8 pM.
- 0.25 ⁇ L compound dilutions (100% DMSO) were added to 9 ⁇ L MAGL in assay buffer (50 mM TRIS (GIBCO, 15567-027), 1 mM EDTA (Fluka, 03690-100ml), 0.01% (v/v) Tween.
- a C18 SPE cartridge (G9205A) was used in an acetonitrile/water liquid setup.
- the mass spectrometer was operated in negative electrospray mode following the mass transitions 303.1 ⁇ 259.1 for arachidonic acid and 311.1 ⁇ 267.0 for d8-arachidonic acid.
- the activity of the compounds was calculated based on the ratio of intensities [arachidonic acid / d8-arachidonic acid]. Table 1 Ex.
- the present invention provides compounds of formula (I) and their pharmaceutically acceptable salts or esters as described herein, wherein said compounds of formula (I) and their pharmaceutically acceptable salts or esters have IC 50 's for MAGL inhibition below 25 ⁇ M, preferably below 10 ⁇ M, more preferably below 5 ⁇ M as measured in the MAGL assays described herein.
- compounds of formula (I) and their pharmaceutically acceptable salts or esters as described herein have IC 50 (MAGL inhibition) values between 0.000001 ⁇ M and 25 ⁇ M, particular compounds have IC 50 values between 0.000005 ⁇ M and 10 ⁇ M, further particular compounds have IC 50 values between 0.00005 ⁇ M and 5 ⁇ M, as measured in the MAGL assays described herein.
- IC 50 MAGL inhibition
- the present invention provides compounds of formula (I) as described herein for use as therapeutically active substance.
- the present invention provides compounds of formula (I) as described herein for use in the treatment or prophylaxis of neuroinflammation, neurodegenerative diseases, pain, cancer, mental disorders and/or inflammatory bowel disease in a mammal.
- the present invention provides compounds of formula (I) as described herein for use in the treatment or prophylaxis of neuroinflammation and/or neurodegenerative diseases in a mammal.
- the present invention provides compounds of formula (I) as described herein for use in the treatment or prophylaxis of cancer in a mammal.
- the present invention provides compounds of formula (I) as described herein for use in the treatment or prophylaxis of neurodegenerative diseases in a mammal.
- the present invention provides compounds of formula (I) as described herein for use in the treatment or prophylaxis of inflammatory bowel disease in a mammal.
- the present invention provides compounds of formula (I) as described herein for use in the treatment or prophylaxis of pain in a mammal.
- the present invention provides compounds of formula (I) as described herein for use in the treatment or prophylaxis of multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colon carcinogenesis, ovarian cancer, neuropathic pain, chemotherapy induced neuropathy, acute pain, chronic pain, spasticity associated with pain, abdominal pain, abdominal pain associated with irritable bowel syndrome and/or visceral pain in a mammal.
- multiple sclerosis Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colon carcinogenesis, ovarian cancer, neuropathic pain, chemotherapy induced neuropathy, acute pain, chronic pain, spasticity associated with pain, abdominal pain, abdominal pain associated with irritable bowel syndrome and/or visceral pain in a ma
- the present invention provides compounds of formula (I) as described herein for use in the treatment or prophylaxis of multiple sclerosis, Alzheimer's disease and/or Parkinson's disease in a mammal.
- the present invention provides compounds of formula (I) as described herein for use in the treatment or prophylaxis of multiple sclerosis in a mammal.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising a compound of formula (I) as described herein and a therapeutically inert carrier.
- the compounds of formula (I) and their pharmaceutically acceptable salts and esters can be used as medicaments (e.g. in the form of pharmaceutical preparations).
- the pharmaceutical preparations can be administered internally, such as orally (e.g. in the form of tablets, coated tablets, dragées, hard and soft gelatin capsules, solutions, emulsions or suspensions), nasally (e.g. in the form of nasal sprays) or rectally (e.g. in the form of suppositories).
- the administration can also be effected parentally, such as intramuscularly or intravenously (e.g. in the form of injection solutions).
- the compounds of formula (I) and their pharmaceutically acceptable salts and esters can be processed with pharmaceutically inert, inorganic or organic adjuvants for the production of tablets, coated tablets, dragées and hard gelatin capsules.
- Lactose, corn starch or derivatives thereof, talc, stearic acid or its salts etc. can be used, for example, as such adjuvants for tablets, dragées and hard gelatin capsules.
- Suitable adjuvants for soft gelatin capsules are, for example, vegetable oils, waxes, fats, semisolid substances and liquid polyols, etc.
- Suitable adjuvants for the production of solutions and syrups are, for example, water, polyols, saccharose, invert sugar, glucose, etc.
- Suitable adjuvants for injection solutions are, for example, water, alcohols, polyols, glycerol, vegetable oils, etc.
- Suitable adjuvants for suppositories are, for example, natural or hardened oils, waxes, fats, semisolid or liquid polyols, etc.
- the pharmaceutical preparations can contain preservatives, solubilizers, viscosity-increasing substances, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents or antioxidants. They can also contain still other therapeutically valuable substances.
- the dosage can vary in wide limits and will, of course, be fitted to the individual requirements in each particular case.
- the pure enantiomers can be separated by methods described herein or by methods known to the man skilled in the art, such as e.g., chiral chromatography (e.g., chiral SFC) or crystallization.
- A2 (illustrated for example 1)
- A3 (illustrated for example 12)
- a microwave vial was heat gun-dried and charged with bis(trichloromethyl) carbonate (26.6 mg, 89.6 ⁇ mol) and sodium bicarbonate (32.3 mg, 384 ⁇ mol).
- the flask was placed under argon and DCM (1 ml) was added to give a suspension.
- the suspension was cooled by an ice-bath and (1R,5S,6r)-6-((2-chloro-4-fluorophenoxy)methyl)-3-azabicyclo[3.1.0]hexane hydrochloride (BB13, 35.6 mg, 128 ⁇ mol) was added to the reaction.
- the mixture was stirred at 0 °C for 15 min and at room temperature overnight.
- the suspension turned into a clear solution overnight.
- reaction mixture was then cooled down in an-ice bath and DCM (500 ⁇ l) and DIPEA (49.7 mg, 67.1 ⁇ l, 384 ⁇ mol) followed by (4aR,8aS)-hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one ( BB1 , 20 mg, 128 ⁇ mol) were added.
- DCM 500 ⁇ l
- DIPEA 49.7 mg, 67.1 ⁇ l, 384 ⁇ mol
- (4aR,8aS)-hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one BB1 , 20 mg, 128 ⁇ mol
- tert-butyl (1R,5S,6r)-6-acetyl-3-azabicyclo[3.1.0]hexane-3-carboxylate ( CAS 2075712-96-6 , 990 mg, 4.39 mmol) was combined with N,N-dimethylformamide dimethyl acetal (3.24 g, 3.64 ml, 26.4 mmol) and heated at 100°C over night for 15 hrs. The mixture was cooled to room temperature and directly evaporated in vacuo.
- tert-butyl (1R,5S,6r)-6-((E)-3-(dimethylamino)acryloyl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (1.21 g, 4.32 mmol) was dissolved in ethanol (6 ml) and hydrazine hydrate (302 mg, 293 ⁇ l, 6.04 mmol) was added. The reaction was stirred 1 hr at 80°C.
- BB10 was prepared similarly as described for BB9, using tert-butyl (1R,5S,6r)-6-(1H-pyrazol-3-yl)-3-azabicyclo[3.1.0]hexane-3-carboxylate and (2-chloro-4-fluorophenyl)boronic acid in step c).
- BB16 was prepared similarly as described for BB11 (step b and Boc-deprotection), using tert-butyl 5-hydroxyhexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate and 1-(bromomethyl)-2-chloro-4-fluorobenzene.
- BB17 was prepared similarly as described for BB11 (step b and Boc-deprotection), using tert-butyl 5-hydroxyhexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate and 1-(bromomethyl)-2-fluoro-4-(trifluoromethyl)benzene.
- tert-butyl 5-hydroxyhexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate (0.250 g, 1.1 mmol) was dissolved in THF (5 ml), and 2-fluoro-4-(trifluoromethyl)phenol (198 mg, 138 ⁇ l, 1.1 mmol) and triphenylphosphine (317 mg, 1.21 mmol) were added.
- BB20 was prepared similarly as described for BB19, using rac-tert-butyl (1R,4S,6R)-6-hydroxy-2-azabicyclo[2.2.1]heptane-2-carboxylate (Combi-Blocks QE-8592, CAS : 207405-59-2 ) and 1-(bromomethyl)-2-fluoro-4-(trifluoromethyl)benzene.
- BB21 was prepared similarly as described for BB19, using rac-tert-butyl (1R,4R,5S)-5-hydroxy-2-azabicyclo[2.2.1]heptane-2-carboxylate (AbovChem, CAS : 198835-03-9 ) and 1-(bromomethyl)-2-fluoro-4-(trifluoromethyl)benzene.
- BB22 was prepared similarly as described for BB19, using tert-butyl 6-hydroxy-3-azabicyclo[3.1.1]heptane-3-carboxylate (Spirochem, CAS: 1357353-36-6 ) and 1-(bromomethyl)-2-fluoro-4-(trifluoromethyl)benzene.
- BB23 was prepared similarly as described for BB19, using tert-butyl (1R,5S,7s)-7-hydroxy-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylate (endo, Spirochem, CAS: 1148006-31-8 ) and 1-(bromomethyl)-2-fluoro-4-(trifluoromethyl)benzene.
- BB24 was prepared similarly as described for BB19, using tert-butyl (1R,3r,5S)-3-hydroxy-8-azabicyclo[3.2.1]octane-8-carboxylate (endo, Spirochem, CAS: 143557-91-9 ) and 1-(bromomethyl)-2-fluoro-4-(trifluoromethyl)benzene.
- BB25 was prepared similarly as described for BB18, using tert-butyl (1R,SS,6r)-6-(hydroxymethyl)-3-azabicyclo[3.1.0]hexane-3-carboxylate and 2-chloro-4-fluorophenol
- BB26 was prepared similarly as described for BB13, using tert-butyl 8-(methylsulfonyloxymethyl)-3-azabicyclo[3.2.1]octane-3-carboxylate and 2-chloro-4-fluorophenol
- a compound of formula (I) can be used in a manner known per se as the active ingredient for the production of tablets of the following composition: Per tablet Active ingredient 200 mg Microcrystalline cellulose 155 mg Corn starch 25 mg Talc 25 mg Hydroxypropylmethylcellulose 20 mg 425 mg
- a compound of formula (I) can be used in a manner known per se as the active ingredient for the production of capsules of the following composition: Per capsule Active ingredient 100.0 mg Corn starch 20.0 mg Lactose 95.0 mg Talc 4.5 mg Magnesium stearate 0.5 mg 220.0 mg
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Description
- The present invention relates to organic compounds useful for therapy or prophylaxis in a mammal, and in particular to monoacylglycerol lipase (MAGL) inhibitors for use in the treatment or prophylaxis of neuroinflammation, neurodegenerative diseases, pain, cancer, mental disorders, multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, inflammatory bowel disease, abdominal pain, abdominal pain associated with irritable bowel syndrome and/or visceral pain in a mammal.
- Endocannabinoids (ECs) are signaling lipids that exert their biological actions by interacting with cannabinoid receptors (CBRs), CB1 and CB2. They modulate multiple physiological processes including neuroinflammation, neurodegeneration and tissue regeneration (Iannotti, F.A., et al., Progress in lipid research 2016, 62, 107-28.). In the brain, the main endocannabinoid, 2-arachidonoylglycerol (2-AG), is produced by diacyglycerol lipases (DAGL) and hydrolyzed by the monoacylglycerol lipase, MAGL. MAGL hydrolyses 85% of 2-AG; the remaining 15% being hydrolysed by ABHD6 and ABDH12 (Nomura, D.K., et al., Science 2011, 334, 809.). MAGL is expressed throughout the brain and in most brain cell types, including neurons, astrocytes, oligodendrocytes and microglia cells (Chanda, P.K., et al., Molecular pharmacology 2010, 78, 996; Viader, A., et al., Cell reports 2015, 12, 798.). 2-AG hydrolysis results in the formation of arachidonic acid (AA), the precursor of prostaglandins (PGs) and leukotrienes (LTs). Oxidative metabolism of AA is increased in inflamed tissues. There are two principal enzyme pathways of arachidonic acid oxygenation involved in inflammatory processes, the cyclo-oxygenase which produces PGs and the 5-lipoxygenase which produces LTs. Of the various cyclooxygenase products formed during inflammation, PGE2 is one of the most important. These products have been detected at sites of inflammation, e.g. in the cerebrospinal fluid of patients suffering from neurodegenerative disorders and are believed to contribute to inflammatory response and disease progression. Mice lacking MAGL (Mgll-/-) exhibit dramatically reduced 2-AG hydrolase activity and elevated 2-AG levels in the nervous system while other arachidonoyl-containing phospho- and neutral lipid species including anandamide (AEA), as well as other free fatty acids, are unaltered. Conversely, levels of AA and AA-derived prostaglandins and other eicosanoids, including prostaglandin E2 (PGE2), D2 (PGD2), F2 (PGF2), and thromboxane B2 (TXB2), are strongly decreased. Phospholipase A2 (PLA2) enzymes have been viewed as the principal source of AA, but cPLA2-deficient mice have unaltered AA levels in their brain, reinforcing the key role of MAGL in the brain for AA production and regulation of the brain inflammatory process.
- Neuroinflammation is a common pathological change characteristic of diseases of the brain including, but not restricted to, neurodegenerative diseases (e.g. multiple sclerosis, Alzheimer's disease, Parkinson disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy and mental disorders such as anxiety and migraine). In the brain, production of eicosanoids and prostaglandins controls the neuroinflammation process. The pro-inflammatory agent lipopolysaccharide (LPS) produces a robust, time-dependent increase in brain eicosanoids that is markedly blunted in Mgll-/- mice. LPS treatment also induces a widespread elevation in pro-inflammatory cytokines including interleukin-1-a (IL-1-a), IL-1b, IL-6, and tumor necrosis factor-a (TNF-a) that is prevented in Mgll-/- mice.
- Neuroinflammation is characterized by the activation of the innate immune cells of the central nervous system, the microglia and the astrocytes. It has been reported that anti-inflammatory drugs can suppress in preclinical models the activation of glia cells and the progression of disease including Alzheimer's disease and mutiple sclerosis (Lleo A., Cell Mol Life Sci. 2007, 64, 1403.). Importantly, genetic and/or pharmacological disruption of MAGL activity also blocks LPS-induced activation of microglial cells in the brain (Nomura, D.K., et al., Science 2011, 334, 809.).
- In addition, genetic and/or pharmacological disruption of MAGL activity was shown to be protective in several animal models of neurodegeneration including, but not restricted to, Alzheimer's disease, Parkinson's disease and multiple sclerosis. For example, an irreversible MAGL inhibitor has been widely used in preclinical models of neuroinflammation and neurodegeneration (Long, J.Z., et al., Nature chemical biology 2009, 5, 37.). Systemic injection of such inhibitor recapitulates the Mgll-/- mice phenotype in the brain, including an increase in 2-AG levels, a reduction in AA levels and related eicosanoids production, as well as the prevention of cytokines production and microglia activation following LPS-induced neuroinflammation (Nomura, D.K., et al., Science 2011, 334, 809.), altogether confirming that MAGL is a druggable target.
- Consecutive to the genetic and/or pharmacological disruption of MAGL activity, the endogenous levels of the MAGL natural substrate in the brain, 2-AG, are increased. 2-AG has been reported to show beneficial effects on pain with, for example, anti-nociceptive effects in mice (Ignatowska-Jankowska B. et al., J. Pharmacol. Exp. Ther. 2015, 353, 424.) and on mental disorders, such as depression in chronic stress models (Zhong P. et al., Neuropsychopharmacology 2014, 39, 1763.).
- Furthermore, oligodendrocytes (OLs), the myelinating cells of the central nervous system, and their precursors (OPCs) express the cannabinoid receptor 2 (CB2) on their membrane. 2-AG is the endogenous ligand of CB1 and CB2 receptors. It has been reported that both cannabinoids and pharmacological inhibition of MAGL attenuate OLs's and OPCs's vulnerability to excitotoxic insults and therefore may be neuroprotective (Bernal-Chico, A., et al., Glia 2015, 63, 163.). Additionally, pharmacological inhibition of MAGL increases the number of myelinating OLs in the brain of mice, suggesting that MAGL inhibition may promote differentiation of OPCs in myelinating OLs in vivo (Alpar, A., et al., Nature communications 2014, 5, 4421.). Inhibition of MAGL was also shown to promote remyelination and functional recovery in a mouse model of progressive multiple sclerosis (Feliu A. et al., Journal of Neuroscience 2017, 37 (35), 8385.).
- In addition, in recent years, metabolism is talked highly important in cancer research, especially the lipid metabolism. Researchers believe that the de novo fatty acid synthesis plays an important role in tumor development. Many studies illustrated that endocannabinoids have anti-tumorigenic actions, including anti-proliferation, apoptosis induction and anti-metastatic effects. MAGL as an important decomposing enzyme for both lipid metabolism and the endocannabinoids system, additionally as a part of a gene expression signature, contributes to different aspects of tumourigenesis, including in glioblastoma (Qin, H., et al., Cell Biochem. Biophys. 2014, 70, 33; Nomura DK et al., Cell 2009, 140(1), 49-61; Nomura DK et al., Chem. Biol. 2011, 18(7), 846-856, Jinlong Yin et al, Nature Communications 2020, 11, 2978).
- The endocannabinoid system is also invlolved in many gastrointestinal physiological and physiopathological actions (Marquez L. et al., PLoS One 2009, 4(9), e6893). All these effects are driven mainly via cannabinoid receptors (CBRs), CB1 and CB2. CB1 receptors are present throughout the GI tract of animals and healthy humans, especially in the enteric nervous system (ENS) and the epithelial lining, as well as smooth muscle cells of blood vessels in the colonic wall (Wright K. et al., Gastroenterology 2005, 129(2), 437-453; Duncan, M. et al., Aliment Pharmacol Ther 2005, 22(8), 667-683). Activation of CB1 produces anti-emetic, anti-motility, and anti-inflammatory effect, and help to modulate pain (Perisetti, A. et al., Ann Gastroenterol 2020, 33(2), 134-144). CB2 receptors are expressed in immune cells such as plasma cells and macrophages, in the lamina propria of the GI tract (Wright K. et al., Gastroenterology 2005, 129(2), 437-453), and primarily on the epithelium of human colonic tissue associated with inflammatory bowel disease (IBD). Activation of CB2 exerts anti-inflammatory effect by reducing pro-inflammatory cytokines. Expression of MAGL is increased in colonic tissue in UC patients (Marquez L. et al., PLoS One 2009, 4(9), e6893) and 2-AG levels are increased in plasma of IBD patients (Grill, M. et al., Sci Rep 2019, 9(1), 2358). Several animal studies have demonstrated the potential of MAGL inhibitors for symptomatic treatment of IBD. MAGL inhibition prevents TNBS-induced mouse colitis and decreases local and circulating inflammatory markers via a CB1/CB2 MoA (Marquez L. et al., PLoS One 2009, 4(9), e6893). Furthermore, MAGL inhibition improves gut wall integrity and intestinal permeability via a CB1 driven MoA (Wang, J. et al., Biochem Biophys Res Commun 2020, 525(4), 962-967).
WO2019/115660 discloses 4H-1,4-benzoxazin-3-one compounds as MAGL inhibitors. - In conclusion, suppressing the action and/or the activation of MAGL is a promising new therapeutic strategy for the treatment or prevention of neuroinflammation, neurodegenerative diseases, pain, cancer, mental disorders, inflammatory bowel disease, abdominal pain and abdominal pain associated with irritable bowel syndrome. Furthermore, suppressing the action and/or the activation of MAGL is a promising new therapeutic strategy for providing neuroprotection and myelin regeneration. Accordingly, there is a high unmet medical need for new MAGL inhibitors.
- In a first aspect, the present invention provides a compound of formula (I)
- (a) reacting a first amine of formula 1, wherein R1 and R2 are as described herein, preferably wherein R1 and R2 are hydrogen,
- (b) transforming said compound of formula (I) to a pharmaceutically acceptable salts thereof.
- In a further aspect, the present invention provides a compound of formula (I) as described herein, for use as therapeutically active substance.
- In a further aspect, the present invention provides a pharmaceutical composition comprising a compound of formula (I) as described herein and a therapeutically inert carrier.
- In a further aspect, the present invention provides a compound of formula (I) as described herein or of a pharmaceutical composition described herein for use in inhibiting monoacylglycerol lipase (MAGL) in a mammal.
- In a further aspect, the present invention provides a compound of formula (I) as described herein or of a pharmaceutical composition described herein for use in the treatment or prophylaxis of neuroinflammation, neurodegenerative diseases, pain, cancer, mental disorders and/or inflammatory bowel disease in a mammal.
- In a further aspect, the present invention provides a compound of formula (I) as described herein or of a pharmaceutical composition described herein for use in the treatment or prophylaxis of multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colon carcinogenesis, ovarian cancer, neuropathic pain, chemotherapy induced neuropathy, acute pain, chronic pain, spasticity associated with pain, abdominal pain, abdominal pain associated with irritable bowel syndrome and/or visceral pain in a mammal.
- Features, integers, characteristics, compounds, chemical moieties or groups described in conjunction with a particular aspect, embodiment or example of the invention are to be understood to be applicable to any other aspect, embodiment or example described herein, unless incompatible therewith. All of the features disclosed in this specification (including any accompanying claims, abstract and drawings), and/or all of the steps of any method or process so disclosed, may be combined in any combination, except combinations where at least some of such features and/or steps are mutually exclusive. The invention is not restricted to the details of any foregoing embodiments. The description may encompass subject-matter extending beyond the scope of the claims. However the scope of the invention and of protection is solely defined by the appended claims and shall not extend beyond their scope.
- The term "alkyl" refers to a mono- or multivalent, e.g., a mono- or bivalent, linear or branched saturated hydrocarbon group of 1 to 6 carbon atoms ("C1-C6-alkyl"), e.g., 1, 2, 3, 4, 5, or 6 carbon atoms. In some embodiments, the alkyl group contains 1 to 3 carbon atoms, e.g., 1, 2 or 3 carbon atoms. Some non-limiting examples of alkyl include methyl, ethyl, propyl, 2-propyl (isopropyl), n-butyl, iso-butyl, sec-butyl, tert-butyl, and 2,2-dimethylpropyl. A particularly preferred, yet non-limiting example of alkyl is methyl.
- The term "alkoxy" refers to an alkyl group, as previously defined, attached to the parent molecular moiety via an oxygen atom. Unless otherwise specified, the alkoxy group contains 1 to 6 carbon atoms ("C1-C6-alkoxy"). In some preferred embodiments, the alkoxy group contains contains 1 to 4 carbon atoms. In still other embodiments, the alkoxy group contains 1 to 3 carbon atoms. Some non-limiting examples of alkoxy groups include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy and tert-butoxy. A particularly preferred, yet non-limiting example of alkoxy is methoxy.
- The term "halogen" or "halo" refers to fluoro (F), chloro (Cl), bromo (Br), or iodo (I). Preferably, the term "halogen" or "halo" refers to fluoro (F), chloro (Cl) or bromo (Br). Particularly preferred, yet non-limiting examples of "halogen" or "halo" are fluoro (F) and chloro (Cl).
- The term "bridged bicyclic heterocycle" refers to a chemical entity consisting of two heterocyclyl moieties as defined herein, or to a combination of one heterocyclyl and one cycloalkyl moiety, having two ring atoms in common, i.e., the bridge separating the two rings is either a single bond or a chain of one or two ring atoms. In some embodiments, the bridged bicyclic heterocycle is a 6-14 membered bridged bicyclic heterocycle comprising 1-3 heteroatoms selected from N, S, and O. In some preferred embodiments, the bridged bicyclic heterocycle is a 6-9 membered bridged bicyclic heterocycle comprising 1-2 heteroatoms selected from N and O. In some particularly preferred embodiments, the bridged bicyclic heterocycle is a 6-8 membered bridged bicyclic heterocycle comprising 1 nitrogen atom. Some preferred, yet non-limiting examples of bridged bicyclic heterocycles include 8-azabicyclo[3.2.1]octane-yl; 3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrolyl; 3-azabicyclo[3.1.0]hexanyl; 2-azabicyclo[2.2.1]heptane-yl; 3-azabicyclo[3.2.1]octane-yl; 2,3,3a,4,6,6a-hexahydro-1H-pyrrolo[3,4-c]pyrrolyl; 3-oxa-9-azabicyclo[3.3.1]nonane-yl; and 3-azabicyclo[3.1.1]heptane-yl.
- The term "heterocyclyl" refers to a saturated or partly unsaturated monocyclic ring system of 3 to 10 ring atoms, preferably 3 to 8 ring atoms, wherein 1, 2, or 3 of said ring atoms are heteroatoms selected from N, O and S, the remaining ring atoms being carbon. Preferably, 1 to 2 of said ring atoms are selected from N and O, the remaining ring atoms being carbon. Some non-limiting examples of heterocyclyl groups include azetidin-3-yl, azetidin-2-yl, oxetan-3-yl, oxetan-2-yl, 2-oxopyrrolidin-1-yl, 2-oxopyrrolidin-3-yl, 5-oxopyrrolidin-2-yl, 5-oxopyrrolidin-3-yl, 2-oxo-1-piperidyl, 2-oxo-3-piperidyl, 2-oxo-4-piperidyl, 6-oxo-2-piperidyl, 6-oxo-3-piperidyl, 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-piperidinyl, morpholino, morpholin-2-yl and morpholin-3-yl.
- The term "cycloalkyl" as used herein refers to a saturated or partly unsaturated monocyclic hydrocarbon group of 3 to 10 ring carbon atoms ("C3-C10-cycloalkyl"). In some preferred embodiments, the cycloalkyl group is a saturated monocyclic hydrocarbon group of 3 to 8 ring carbon atoms. Preferably, the cycloalkyl group is a saturated monocyclic hydrocarbon group of 3 to 6 ring carbon atoms, e.g., of 3, 4, 5 or 6 carbon atoms. Some non-limiting examples of cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl. A particularly preferred, yet non-limiting example of cycloalkyl is cyclopropyl.
- The term "aryl" refers to a monocyclic, bicyclic, or tricyclic carbocyclic ring system having a total of 6 to 14 ring members ("C6-C14-aryl"), preferably, 6 to 12 ring members, and more preferably 6 to 10 ring members, and wherein at least one ring in the system is aromatic. A particularly preferred, yet non-limiting example of aryl is phenyl.
- The term "heteroaryl" refers to a mono- or multivalent, monocyclic or bicyclic, preferably bicyclic ring system having a total of 5 to 14 ring members, preferably, 5 to 12 ring members, and more preferably 5 to 10 ring members, wherein at least one ring in the system is aromatic, and at least one ring in the system contains one or more heteroatoms. Preferably, "heteroaryl" refers to a 5-10 membered heteroaryl comprising 1, 2, 3 or 4 heteroatoms independently selected from O, S and N. Most preferably, "heteroaryl" refers to a 5-10 membered heteroaryl comprising 1 to 2 heteroatoms independently selected from O and N. Some non-limiting examples of heteroaryl include 2-pyridyl, 3-pyridyl, 4-pyridyl, indol-1-yl, 1H-indol-2-yl, 1H-indol-3-yl, 1H-indol-4-yl, 1H-indol-5-yl, 1H-indol-6-yl, 1H-indol-7-yl, 1,2-benzoxazol-3-yl, 1,2-benzoxazol-4-yl, 1,2-benzoxazol-5-yl, 1,2-benzoxazol-6-yl, 1,2-benzoxazol-7-yl, 1H-indazol-3-yl, 1H-indazol-4-yl, 1H-indazol-5-yl, 1H-indazol-6-yl, 1H-indazol-7-yl, pyrazol-1-yl, 1H-pyrazol-3-yl, 1H-pyrazol-4-yl, 1H-pyrazol-5-yl, imidazol-1-yl, 1H-imidazol-2-yl, 1H-imidazol-4-yl, 1H-imidazol-5-yl, oxazol-2-yl, oxazol-4-yl, oxazol-5-yl, 5,6,7,8-tetrahydroisoquinolin-1-yl, 5,6,7,8-tetrahydroisoquinolin-3-yl, 5,6,7,8-tetrahydroisoquinolin-4-yl, 5,6,7,8-tetrahydroisoquinolin-5-yl, 5,6,7,8-tetrahydroisoquinolin-6-yl, 5,6,7,8-tetrahydroisoquinolin-7-yl, and 5,6,7,8-tetrahydroisoquinolin-8-yl. Particularly preferred, yet non-limiting examples of heteroaryl are 2-pyridyl, 1H-pyrazol-3-yl, and 5,6,7,8-tetrahydroisoquinolin-3-yl.
- The term "hydroxy" refers to an -OH group.
- The term "cyano" refers to a -CN (nitrile) group.
- The term "alkylsulfonyl" refers to an alkyl group attached to the parent molecular moiety via an SO2 moiety. A particularly preferred, yet non-limiting example of alkylsulfonyl is methylsulfonyl.
- The term "haloalkyl" refers to an alkyl group, wherein at least one of the hydrogen atoms of the alkyl group has been replaced by a halogen atom, preferably fluoro. Preferably, "haloalkyl" refers to an alkyl group wherein 1, 2 or 3 hydrogen atoms of the alkyl group have been replaced by a halogen atom, most preferably fluoro. A particularly preferred, yet non-limiting example of haloalkyl is trifluoromethyl (CF3).
- The term "haloalkoxy" refers to an alkoxy group, wherein at least one of the hydrogen atoms of the alkoxy group has been replaced by a halogen atom, preferably fluoro. Preferably, "haloalkoxy" refers to an alkoxy group wherein 1, 2 or 3 hydrogen atoms of the alkoxy group have been replaced by a halogen atom, most preferably fluoro. A particularly preferred, yet non-limiting example of haloalkoxy is trifluoromethoxy (-OCF3).
- The term "pharmaceutically acceptable salt" refers to those salts which retain the biological effectiveness and properties of the free bases or free acids, which are not biologically or otherwise undesirable. The salts are formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, in particular hydrochloric acid, and organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, N-acetylcystein and the like. In addition these salts may be prepared by addition of an inorganic base or an organic base to the free acid. Salts derived from an inorganic base include, but are not limited to, the sodium, potassium, lithium, ammonium, calcium, magnesium salts and the like. Salts derived from organic bases include, but are not limited to salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, lysine, arginine, N-ethylpiperidine, piperidine, polyimine resins and the like. Particular pharmaceutically acceptable salts of compounds of formula (I) are hydrochloride salts.
- The term "protective group" (PG) denotes the group which selectively blocks a reactive site in a multifunctional compound such that a chemical reaction can be carried out selectively at another unprotected reactive site in the meaning conventionally associated with it in synthetic chemistry. Protective groups can be removed at the appropriate point. Exemplary protective groups are amino-protective groups, carboxy-protective groups or hydroxy-protective groups. Particular protective groups are the tert-butoxycarbonyl (Boc), benzyloxycarbonyl (Cbz), fluorenylmethoxycarbonyl (Fmoc) and benzyl (Bn). Further particular protective groups are the tert-butoxycarbonyl (Boc) and the fluorenylmethoxycarbonyl (Fmoc). More particular protective group is the tert-butoxycarbonyl (Boc). Exemplary protective groups and their application in organic synthesis are described, for example, in "Protective Groups in Organic Chemistry" by T. W. Greene and P. G. M. Wutts, 5th Ed., 2014, John Wiley & Sons, N.Y.
- The term "urea forming reagent" refers to a chemical compound that is able to render a first amine to a species that will react with a second amine, thereby forming an urea derivative. Non-limiting examples of urea forming reagents include bis(trichloromethyl) carbonate, phosgene, trichloromethyl chloroformate, (4-nitrophenyl)carbonate and 1,1'-carbonyldiimidazole. The urea forming reagents described in G. Sartori et al., Green Chemistry 2000, 2, 140 are incorporated herein by reference.
- The compounds of formula (I) can contain several asymmetric centers and can be present in the form of optically pure enantiomers, mixtures of enantiomers such as, for example, racemates, optically pure diastereioisomers, mixtures of diastereoisomers, diastereoisomeric racemates or mixtures of diastereoisomeric racemates. In a preferred embodiment, the compound of formula (I) according to the invention is a cis-enantiomer of formula (Ia) or (Ib), respectively, as described herein.
- According to the Cahn-Ingold-Prelog Convention, the asymmetric carbon atom can be of the "R" or "S" configuration.
- The abbreviation "MAGL" refers to the enzyme monoacylglycerol lipase. The terms "MAGL" and "monoacylglycerol lipase" are used herein interchangeably.
- The term "treatment" as used herein includes: (1) inhibiting the state, disorder or condition (e.g. arresting, reducing or delaying the development of the disease, or a relapse thereof in case of maintenance treatment, of at least one clinical or subclinical symptom thereof); and/or (2) relieving the condition (i.e., causing regression of the state, disorder or condition or at least one of its clinical or subclinical symptoms). The benefit to a patient to be treated is either statistically significant or at least perceptible to the patient or to the physician. However, it will be appreciated that when a medicament is administered to a patient to treat a disease, the outcome may not always be effective treatment.
- The term "prophylaxis" as used herein includes: preventing or delaying the appearance of clinical symptoms of the state, disorder or condition developing in a mammal and especially a human that may be afflicted with or predisposed to the state, disorder or condition but does not yet experience or display clinical or subclinical symptoms of the state, disorder or condition.
- The term "neuroinflammation" as used herein relates to acute and chronic inflammation of the nervous tissue, which is the main tissue component of the two parts of the nervous system; the brain and spinal cord of the central nervous system (CNS), and the branching peripheral nerves of the peripheral nervous system (PNS). Chronic neuroinflammation is associated with neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and multiple sclerosis. Acute neuroinflammation usually follows injury to the central nervous system immediately, e.g., as a result of traumatic brain injury (TBI).
- The term "traumatic brain injury" ("TBI", also known as "intracranial injury"), relates to damage to the brain resulting from external mechanical force, such as rapid acceleration or deceleration, impact, blast waves, or penetration by a projectile.
- The term "neurodegenerative diseases" relates to diseases that are related to the progressive loss of structure or function of neurons, including death of neurons. Examples of neurodegenerative diseases include, but are not limited to, multiple sclerosis, Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis.
- The term "mental disorders" (also called mental illnesses or psychiatric disorders) relates to behavioral or mental patterns that may cause suffering or a poor ability to function in life. Such features may be persistent, relapsing and remitting, or occur as a single episode. Examples of mental disorders include, but are not limited to, anxiety and depression.
- The term "pain" relates to an unpleasant sensory and emotional experience associated with actual or potential tissue damage. Examples of pain include, but are not limited to, nociceptive pain, chronic pain (including idiopathic pain), neuropathic pain including chemotherapy induced neuropathy, phantom pain and phsychogenic pain. A particular example of pain is neuropathic pain, which is caused by damage or disease affecting any part of the nervous system involved in bodily feelings (i.e., the somatosensory system). In one embodiment, "pain" is neuropathic pain resulting from amputation or thoracotomy. In one embodiment, "pain" is chemotherapy induced neuropathy.
- The term "neurotoxicity" relates to toxicity in the nervous system. It occurs when exposure to natural or artificial toxic substances (neurotoxins) alter the normal activity of the nervous system in such a way as to cause damage to nervous tissue. Examples of neurotoxicity include, but are not limited to, neurotoxicity resulting from exposure to substances used in chemotherapy, radiation treatment, drug therapies, drug abuse, and organ transplants, as well as exposure to heavy metals, certain foods and food additives, pesticides, industrial and/or cleaning solvents, cosmetics, and some naturally occurring substances.
- The term "cancer" refers to a disease characterized by the presence of a neoplasm or tumor resulting from abnormal uncontrolled growth of cells (such cells being "cancer cells"). As used herein, the term cancer explicitly includes, but is not limited to, hepatocellular carcinoma, colon carcinogenesis and ovarian cancer.
- The term "mammal" as used herein includes both humans and non-humans and includes but is not limited to humans, non-human primates, canines, felines, murines, bovines, equines, and porcines. In a particularly preferred embodiment, the term "mammal" refers to humans.
-
- X
- is N or C-R5;
- L
- is selected from a covalent bond, -(CH2)n-O-, -O-(CH2)p-, and -SO2-;
- n
- is an integer selected from 0, 1, 2 and 3;
- p
- is an integer selected from 1, 2 and 3;
- A
- is:
- (i) C6-14-aryl substituted with R6, R7 and R8; or
- (ii) 5-14 membered heteroaryl substituted with R9, R10 and R11; or
- B
- is a bridged bicyclic heterocycle;
- R1
- is hydrogen or C1-6-alkyl;
- R2
- is hydrogen or C1-6-alkyl;
- R3
- is hydrogen, C1-6-alkyl, halo-C1-6-alkyl, halogen or hydroxy;
- R4
- is hydrogen, C1-6-alkyl, halo-C1-6-alkyl, halogen or hydroxy;
- R5
- is hydrogen, C1-6-alkyl, halo-C1-6-alkyl, halogen or hydroxy; and
- R6, R7, R8, R9, R10, and R11
- are independently selected from hydrogen, C1-6-alkyl, halo-C1-6-alkyl, halogen, C1-6-alkoxy, halo-C1-6-alkoxy, SF5, C1-6-alkylsulfonyl, cyano, C3-10-cycloalkyl, C6-14-aryl, and 5-14 membered heteroaryl, wherein said C3-10-cycloalkyl, C6-14-aryl, and 5-14 membered heteroaryl are optionally substituted with 1-2 substituents selected from halogen, cyano, SF5 C1-6-alkyl, C1-6-alkoxy, halo-C1-6-alkyl, and halo-C1-6-alkoxy.
- Also described herein are the following enumerated Embodiments (E) of the first aspect (A1) of the invention. Only those embodiments (E) which are defined by the appended claims are included in the invention:
- E1. The compound of formula (I) according to A1, or a pharmaceutically acceptable salt thereof, wherein R1 is hydrogen.
- E2. The compound of formula (I) according to A1 or E1, or a pharmaceutically acceptable salt thereof, wherein R2 is hydrogen.
- E3. The compound of formula (I) according to any one of A1 and E1 to E2, or a pharmaceutically acceptable salt thereof, wherein R3 is hydrogen.
- E4. The compound of formula (I) according to any one of A1 and E1 to E3, or a pharmaceutically acceptable salt thereof, wherein R4 is hydrogen.
- E5. The compound of formula (I) according to any one of A1 and E1 to E4 or a pharmaceutically acceptable salt thereof, wherein R5 is hydrogen.
- E6. The compound of formula (I) according to any one of A1 and E1 to E5, or a pharmaceutically acceptable salt thereof, wherein R6 is selected from hydrogen, C1-6-alkyl, halo-C1-6-alkyl, and halogen.
- E7. The compound of formula (I) according to any one of A1 and E1 to E5, or a pharmaceutically acceptable salt thereof, wherein R6 is selected from halo-C1-6-alkyl and halogen.
- E8. The compound of formula (I) according to any one of A1 and E1 to E5, or a pharmaceutically acceptable salt thereof, wherein R6 is selected from CF3, chloro, and fluoro.
- E9. The compound of formula (I) according to any one of A1 and E1 to E8, or a pharmaceutically acceptable salt thereof, wherein R7 is selected from hydrogen and halogen.
- E10. The compound of formula (I) according to any one of A1 and E1 to E8, or a pharmaceutically acceptable salt thereof, wherein R7 is halogen.
- E11. The compound of formula (I) according to any one of A1 and E1 to E8, or a pharmaceutically acceptable salt thereof, wherein R7 is fluoro or chloro.
- E12. The compound of formula (I) according to any one of A1 and E1 to E8, or a pharmaceutically acceptable salt thereof, wherein R7 is fluoro.
- E13. The compound of formula (I) according to any one of A1 and E1 to E12, or a pharmaceutically acceptable salt thereof, wherein R8 is hydrogen.
- E14. The compound of formula (I) according to any one of A1 and E1 to E13, or a pharmaceutically acceptable salt thereof, wherein R9 is selected from hydrogen, C3-10-cycloalkyl, and C6-14-aryl, wherein said C6-14-aryl is substituted with 1-2 substituents selected from halogen and halo-C1-6-alkyl.
- E15. The compound of formula (I) according to any one of A1 and E1 to E14, or a pharmaceutically acceptable salt thereof, wherein R10 is selected from hydrogen and halogen.
- E16. The compound of formula (I) according to any one of A1 and E1 to E15, or a pharmaceutically acceptable salt thereof, wherein R11 is hydrogen.
- E17. The compound of formula (I) according to any one of A1 and E1 to E16, or a pharmaceutically acceptable salt thereof, wherein X is C-R5.
- E18. The compound of formula (I) according to any one of A1 and E1 to E17, or a pharmaceutically acceptable salt thereof, wherein L is selected from -(CH2)n-O- and -O-(CH2)p-.
- E19. The compound of formula (I) according to any one of A1 and E1 to E18, or a pharmaceutically acceptable salt thereof, wherein n is an integer selected from 0 and 1.
- E20. The compound of formula (I) according to any one of A1 and E1 to E19, or a pharmaceutically acceptable salt thereof, wherein p is 1.
- E21. The compound of formula (I) according to any one of A1 and E1 to E20, or a pharmaceutically acceptable salt thereof, wherein A is C6-14-aryl substituted with R6, R7 and R8.
- E22. The compound of formula (I) according to any one of A1 and E1 to E20, or a pharmaceutically acceptable salt thereof, wherein A is phenyl substituted with R6, R7 and R8.
- E23. The compound of formula (I) according to any one of A1 and E1 to E22, or a pharmaceutically acceptable salt thereof, wherein B is a 6-14 membered bridged bicyclic heterocycle comprising 1-3 heteroatoms selected from N, S, and O.
- E24. The compound of formula (I) according to any one of A1 and E1 to E22, or a pharmaceutically acceptable salt thereof, wherein B is a 6-9 membered bridged bicyclic heterocycle comprising 1-2 heteroatoms selected from N and O.
- E25. The compound of formula (I) according to any one of A1 and E1 to E22, or a pharmaceutically acceptable salt thereof, wherein B is a 6-8 membered bridged bicyclic heterocycle comprising 1 nitrogen atom.
- E26. The compound of formula (I) according to any one of A1 and E1 to E22, or a pharmaceutically acceptable salt thereof, wherein B is selected from 8-azabicyclo[3.2.1]octan-8-yl (a); 3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrol-2-yl (b); 3-azabicyclo[3.1.0]hexan-3-yl (c); 2-azabicyclo[2.2.1]heptan-2-yl (d); 3-azabicyclo[3.2.1]octan-3-yl (e); 2,3,3a,4,6,6a-hexahydro-1H-pyrrolo[3,4-c]pyrrol-5-yl (f); 3-oxa-9-azabicyclo[3.3.1]nonan-9-yl (g); and 3-azabicyclo[3.1.1]heptan-3-yl (h):
- E27. The compound of formula (I) according to any one of A1 and E1 to E22, or a pharmaceutically acceptable salt thereof, wherein B is selected from 8-azabicyclo[3.2.1]octan-8-yl (a); 3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrol-2-yl (b); 3-azabicyclo[3.1.0]hexan-3-yl (c); and 2-azabicyclo[2.2.1]heptan-2-yl (d):
- E28. The compound of formula (I) according to A1, or a pharmaceutically acceptable salt thereof, wherein the compound of formula (I) is a compound of formula (II):
- X
- is N or CH;
- L
- is selected from a covalent bond, -(CH2)n-O-, -OCH2-, and -SO2-;
- n
- is an integer selected from 0 and 1;
- A
- is:
- (i) C6-14-aryl substituted with R6 and R7; or
- (ii) 5-14 membered heteroaryl substituted with R9 and R10; or
- B
- is a 6-9 membered bridged bicyclic heterocycle comprising 1-2 heteroatoms selected from N and O;
- R6
- is selected from hydrogen, C1-6-alkyl, halo-C1-6-alkyl, and halogen;
- R7
- is selected from hydrogen and halogen;
- R9
- is selected from hydrogen, C3-10-cycloalkyl, and C6-14-aryl, wherein said C6-14-aryl is substituted with 1-2 substituents selected from halogen and halo-C1-6-alkyl; and
- R10
- is selected from hydrogen and halogen.
- E29. The compound of formula (I) according to A1, or a pharmaceutically acceptable salt thereof, wherein the compound of formula (I) is a compound of formula (III):
- L
- is selected from -(CH2)n-O- and -OCH2-;
- n
- is an integer selected from 0 and 1;
- A
- is C6-14-aryl substituted with R6 and R7;
- B
- is a 6-8 membered bridged bicyclic heterocycle comprising 1 nitrogen atom;
- R6
- is selected from halo-C1-6-alkyl and halogen; and
- R7
- is halogen.
- E30. The compound of formula (I) according to A1, or a pharmaceutically acceptable salt thereof, wherein the compound of formula (I) is a compound of formula (III):
- L
- is selected from -(CH2)n-O- and -OCH2-;
- n
- is an integer selected from 0 and 1;
- A
- is phenyl substituted with R6 and R7;
- B
- is selected from 8-azabicyclo[3.2.1]octan-8-yl (a); 3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrol-2-yl (b); 3-azabicyclo[3.1.0]hexan-3-yl (c); and 2-azabicyclo[2.2. 1]heptan-2-yl (d):
- R6
- is selected from CF3, chloro, and fluoro; and
- R7
- is fluoro or chloro.
- E31. The compound of formula (I) according to any one of A1 and E1 to E30, or a pharmaceutically acceptable salt thereof, wherein said compound of formula (I) is selected from the compounds disclosed in Table 1.
- E32. The compound of formula (I) according to any one of A1 and E1 to E30, or a pharmaceutically acceptable salt thereof, wherein said compound of formula (I) is selected from the group consisting of:
- (4aR,8aS)-6-[(1R,5S,6r)-6-[(2-chloro-4-fluoro-phenoxy)methyl]-3-azabicyclo[3.1.0]hexane-3-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (4aR,8aS)-6-[5-(2-chloro-4-fluoro-phenoxy)-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-2-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;
- (4aR,8aS)-6-[rel-(1R,4R,5S)-5-[[2-fluoro-4-(trifluoromethyl)phenyl]methoxy]-2-azabicyclo[2.2.1]heptane-2-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; and
- (4aR,8aS)-6-[(1S,5R)-3-[[2-fluoro-4-(trifluoromethyl)phenyl]methoxy]-8-azabicyclo[3.2.1]octane-8-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one.
- E33. The compound of formula (I) according to any one of A1 and E1 to E30, or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are both hydrogen.
- E34. The compound of formula (I) according to any one of A1 and E1 to E30, or a pharmaceutically acceptable salt thereof, wherein:
- X
- is N or CH;
- R3 and R4
- are both hydrogen; and
- B
- is a 6-9 membered bridged bicyclic heterocycle comprising 1-2 heteroatoms selected from N and O.
- E35. The compound of formula (I) according to any one of A1 and E1 to E30, or a pharmaceutically acceptable salt thereof, wherein:
- X
- is CH;
- R3 and R4
- are both hydrogen; and
- B
- is a 6-8 membered bridged bicyclic heterocycle comprising 1 nitrogen atom.
- E36. The compound of formula (I) according to any one of A1 and E1 to E30, or a pharmaceutically acceptable salt thereof, wherein:
- X
- is CH;
- R3 and R4
- are both hydrogen; and
- B
- is selected from 8-azabicyclo[3.2.1]octan-8-yl (a); 3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrol-2-yl (b); 3-azabicyclo[3.1.0]hexan-3-yl (c); and 2-azabicyclo[2.2. 1]heptan-2-yl (d):
- E37. The compound of formula (I) according to any one of A1 and E1 to E30, or a pharmaceutically acceptable salt thereof, wherein:
- L
- is selected from a covalent bond, -(CH2)n-O-, -OCH2-, and -SO2-;
- n
- is an integer selected from 0 and 1;
- A
- is:
- (i) C6-14-aryl substituted with R6 and R7; or
- (ii) 5-14 membered heteroaryl substituted with R9 and R10;
- R6
- is selected from hydrogen, C1-6-alkyl, halo-C1-6-alkyl, and halogen;
- R7
- is selected from hydrogen and halogen;
- R9
- is selected from hydrogen, C3-10-cycloalkyl, and C6-14-aryl, wherein said C6-14-aryl is substituted with 1-2 substituents selected from halogen and halo-C1-6-alkyl; and
- R10
- is selected from hydrogen and halogen.
- E38. The compound of formula (I) according to any one of A1 and E1 to E30, or a pharmaceutically acceptable salt thereof, wherein:
- L
- is selected from -(CH2)n-O- and -OCH2-;
- n
- is an integer selected from 0 and 1;
- A
- is C6-14-aryl substituted with R6 and R7;
- R6
- is selected from halo-C1-6-alkyl and halogen; and
- R7
- is halogen.
- E39. The compound of formula (I) according to any one of A1 and E1 to E30, or a pharmaceutically acceptable salt thereof, wherein:
- L
- is selected from -(CH2)n-O- and -OCH2-;
- n
- is an integer selected from 0 and 1;
- A
- is phenyl substituted with R6 and R7;
- R6
- is selected from CF3, chloro, and fluoro; and
- R7
- is fluoro or chloro.
- In a particular embodiment, the present invention provides pharmaceutically acceptable salts of the compounds according to formula (I) as described herein, especially hydrochloride salts. In a further particular embodiment, the present invention provides compounds according to formula (I) as described herein as free bases.
- In some embodiments, the compounds of formula (I) are isotopically-labeled by having one or more atoms therein replaced by an atom having a different atomic mass or mass number. Such isotopically-labeled (i.e., radiolabeled) compounds of formula (I) are considered to be within the scope of this disclosure. Examples of isotopes that can be incorporated into the compounds of formula (I) include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, sulfur, fluorine, chlorine, and iodine, such as, but not limited to, 2H, 3H, 11C, 13C, 14C, 13N, 15N, 15O, 17O, 18O, 31P, 32P, 35S, 18F, 36Cl, 123I, and 125I, respectively. Certain isotopically-labeled compounds of formula (I), for example, those incorporating a radioactive isotope, are useful in drug and/or substrate tissue distribution studies. The radioactive isotopes tritium, i.e. 3H, and carbon-14, i.e., 14C, are particularly useful for this purpose in view of their ease of incorporation and ready means of detection. For example, a compound of formula (I) can be enriched with 1, 2, 5, 10, 25, 50, 75, 90, 95, or 99 percent of a given isotope.
- Substitution with heavier isotopes such as deuterium, i.e. 2H, may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements.
- Substitution with positron emitting isotopes, such as 11C, 18F, 15O and 13N, can be useful in Positron Emission Topography (PET) studies for examining substrate receptor occupancy. Isotopically-labeled compounds of formula (I) can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the Examples as set out below using an appropriate isotopically-labeled reagent in place of the non-labeled reagent previously employed.
- The preparation of compounds of formula (I) of the present invention may be carried out in sequential or convergent synthetic routes. Syntheses of the invention are shown in the following general schemes. The skills required for carrying out the reaction and purification of the resulting products are known to those persons skilled in the art. The substituents and indices used in the following description of the processes have the significance given herein, unless indicated to the contrary.
- If one of the starting materials, intermediates or compounds of formula (I) contain one or more functional groups which are not stable or are reactive under the reaction conditions of one or more reaction steps, appropriate protective groups (as described e.g., in "Protective Groups in Organic Chemistry" by T. W. Greene and P. G. M. Wutts, 5th Ed., 2014, John Wiley & Sons, N.Y.) can be introduced before the critical step applying methods well known in the art. Such protective groups can be removed at a later stage of the synthesis using standard methods described in the literature.
- If starting materials or intermediates contain stereogenic centers, compounds of formula (I) can be obtained as mixtures of diastereomers or enantiomers, which can be separated by methods well known in the art e.g., chiral HPLC, chiral SFC or chiral crystallization. Racemic compounds can e.g., be separated into their antipodes via diastereomeric salts by crystallization with optically pure acids or by separation of the antipodes by specific chromatographic methods using either a chiral adsorbent or a chiral eluent. It is equally possible to separate starting materials and intermediates containing stereogenic centers to afford diastereomerically/enantiomerically enriched starting materials and intermediates. Using such diastereomerically/enantiomerically enriched starting materials and intermediates in the synthesis of compounds of formula (I) will typically lead to the respective diastereomerically/enantiomerically enriched compounds of formula (I).
- A person skilled in the art will acknowledge that in the synthesis of compounds of formula (I) - insofar not desired otherwise - an "orthogonal protection group strategy" will be applied, allowing the cleavage of several protective groups one at a time each without affecting other protective groups in the molecule. The principle of orthogonal protection is well known in the art and has also been described in literature (e.g. Barany and R. B. Merrifield, J. Am. Chem. Soc. 1977, 99, 7363; H. Waldmann et al., Angew. Chem. Int. Ed. Engl. 1996, 35, 2056).
- A person skilled in the art will acknowledge that the sequence of reactions may be varied depending on reactivity and nature of the intermediates.
- In more detail, the compounds of formula (I) can be manufactured by the methods given below, by the methods given in the examples or by analogous methods. Appropriate reaction conditions for the individual reaction steps are known to a person skilled in the art. Also, for reaction conditions described in literature affecting the described reactions see for example:
Comprehensive Organic Transformations: A Guide to Functional Group Preparations, 2nd Edition, Richard C. Larock. John Wiley & Sons, New York, NY. 1999 ). It was found convenient to carry out the reactions in the presence or absence of a solvent. There is no particular restriction on the nature of the solvent to be employed, provided that it has no adverse effect on the reaction or the reagents involved and that it can dissolve the reagents, at least to some extent. The described reactions can take place over a wide range of temperatures, and the precise reaction temperature is not critical to the invention. It is convenient to carry out the described reactions in a temperature range between -78 °C to reflux. The time required for the reaction may also vary widely, depending on many factors, notably the reaction temperature and the nature of the reagents. However, a period of from 0.5 hours to several days will usually suffice to yield the described intermediates and compounds. The reaction sequence is not limited to the one displayed in the schemes, however, depending on the starting materials and their respective reactivity, the sequence of reaction steps can be freely altered. - If starting materials or intermediates are not commercially available or their synthesis not described in literature, they can be prepared in analogy to existing procedures for close analogues or as outlined in the experimental section.
- The following abbreviations are used in the present text:
AcOH = acetic acid, ACN = acetonitrile , Bn = benzyl, Boc = tert-butyloxycarbonyl, CAS RN = chemical abstracts registration number, Cbz = benzyloxycarbonyl, Cs2CO3 = cesium carbonate, CO = carbon monoxide, CuCl = copper(I) chloride, CuCN = copper(I) cyanide, CuI = copper(I) iodide, DAST = (diethylamino)sulfur trifluoride, DBU = 1,8-diazabicyclo[5,4,0]undec-7-ene, DCM = dichloromethane, DEA = diethyl amine, DEAD = diethyl azodicarboxylate, DIAD = diisopropyl azodicarboxylate, DMAP = 4-dimethylaminopyridine, DME = dimethoxyethane , DMEDA = N,N'-dimethylethylenediamine, DMF = N,N-dimethylformamide, DIPEA = N,N-diisopropylethylamine, dppf = 1,1 bis(diphenyl phosphino)ferrocene, EDC.HCl = N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride, EI = electron impact, ESI = electrospray ionization, EtOAc = ethyl acetate, EtOH = ethanol, h = hour(s), FA = formic acid, H2O = water, H2SO4 = sulfuric acid, HATU = 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium-3-oxide hexafluorophosphate, HBTU = O-benzotriazole-N,N,N',N'-tetramethyl-uronium-hexafluoro-phosphate, HCl = hydrogen chloride, HOBt = 1-hydroxy-1H-benzotriazole; HPLC = high performance liquid chromatography, iPrMgCl = isopropylmagnesium chloride, I2 = iodine, IPA = 2-propanol, ISP = ion spray positive (mode), ISN = ion spray negative (mode), K2CO3 = potassium carbonate, KHCO3 = potassium bicarbonate, KI = potassium iodide, KOH = potassium hydroxide, K3PO4 = potassium phosphate tribasic, LiAlH4 or LAH = lithium aluminium hydride, LiHMDS = lithium bis(trimethylsilyl)amide, LiOH = lithium hydroxide, MgSO4 = magnesium sulfate, min = minute(s), mL = milliliter, MPLC = medium pressure liquid chromatography, MS = mass spectrum, nBuLi = n-butyllithium, NaBH3CN = sodium cyanoborohydride, NaH = sodium hydride, NaHCO3 = sodium hydrogen carbonate, NaNO2 = sodium nitrite, NaBH(OAc)3 = sodium triacetoxyborohydride, NaOH = sodium hydroxide, Na2CO3 = sodium carbonate, Na2SO4 = sodium sulfate, Na2S2O3 = sodium thiosulfate, NBS = N-bromosuccinimide, nBuLi = n-butyllithium, NEt3 = triethylamine (TEA), NH4Cl = ammonium chloride, NMP = N-methyl-2-pyrrolidone, OAc = Acetoxy, T3P = propylphosphonic anhydride, PE = petroleum ether, PG = protective group, Pd-C = palladium on activated carbon, PdCl2(dppf)-CH2Cl2 = 1,1'-bis(diphenylphosphino)ferrocene-palladium(II)dichloride dichloromethane complex, Pd2(dba)3 = tris(dibenzylideneacetone)dipalladium(0), Pd(OAc)2 = palladium(II) acetate, Pd(OH)2 = palladium hydroxide, Pd(PPh3)4 = tetrakis(triphenylphosphine)palladium(0), PTSA = p-toluenesulfonic acid, R = any group, RT = room temperature, SFC = Supercritical Fluid Chromatography, S-PHOS = 2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl, TBAI = tetra butyl ammonium iodine, TEA = triethylamine, TFA = trifluoroacetic acid, THF = tetrahydrofuran, TMEDA = N,N,N',N'-tetramethylethylenediamine, ZnCl2 = zinc chloride, Hal = halogen. -
- Accordingly, 4a,5,6,7,8,8a-hexahydro-4H-pyrido[4,3-b][1,4]oxazin-3-ones 1 are reacted with intermediates 2 in the presence of a urea forming reagent such as bis(trichloromethyl) carbonate using a suitable base and solvent such as, e.g. sodium bicarbonate in DCM, to give compounds of formula I (step a). Further urea forming reagents include but are not limited to phosgene, trichloromethyl chloroformate, (4-nitrophenyl)carbonate, 1,1'-carbonyldiimidazole or 1,1'-carbonyl-di-(1,2,4-triazole). Reactions of this type and the use of these reagents are widely described in literature (e.g. G. Sartori et al., Green Chemistry 2000, 2, 140). A person skilled in the art will acknowledge that the order of the addition of the reagents can be important in this type of reactions due to the reactivity and stability of the intermediary formed carbamoyl chlorides, as well as for avoiding formation of undesired symmetrical urea by-products.
-
- Thus, 3-aminopiperidin-4-ol derivatives 3 in which "PG" signifies a suitable protective group such as a Cbz or Boc protective group, and R2 is as defined herein can be acylated for example with acyl chlorides 4 in which R1 is as defined herein and "LG" signifies a suitable leaving group (e.g., Cl or Br), using a suitable base such as sodium or potassium carbonate, sodium hydroxide or sodium acetate in an appropriate solvent such as THF, water, acetone or mixtures thereof, to provide intermediates 5 (step a). Intermediates 4 are either commercially available or can be prepared according to literature methods in achiral (R1 = H) racemic (R1 not H) or enantiomerically pure form (R1 not H).
- Intermediates 5 can be cyclized to intermediates 6 using methods well known in the art, for example by treatment of 5 with sodium hydride in THF or potassium tert-butoxide in IPA and water (step b). Reactions of that type are described in literature (e.g. Z. Rafinski et al., J. Org. Chem. 2015, 80, 7468; S. Dugar et al., Synthesis 2015, 47(5), 712;
WO2005/066187 ). Removal of the protective group in intermediates 6, applying methods known in the art (e.g., a Boc group using TFA in DCM at temperatures between 0°C and room temperature, a Cbz group using hydrogen in the presence of a suitable catalyst such as Pd or Pd(OH)2 on charcoal in a suitable solvent such as MeOH, EtOH, EtOAc or mixtures thereof and as described for example in "Protective Groups in Organic Chemistry" by T.W. Greene and P.G.M. Wuts, 4th Ed., 2006, Wiley N.Y.), furnishes intermediates 1 (step c). - Intermediates 1 can be obtained as mixtures of diastereomers and enantiomers, respectively, or as single stereoisomers depending on whether racemic mixtures or enantiomerically pure forms of cis- or trans-3-aminopiperidin-4-ol derivatives 3 and acid chlorides 4 (when R1 is not H) are employed in their syntheses. In case racemization occurs at a stereocentre bearing R1 during the conversion of 3 to 5 (step a) and/or of 5 to 6 (step b), the resulting diastereoisomers may be separated by chromatography (e.g. HPLC, chiral HPLC) or other methods known in the art. Intermediates 3 are commercially available and their synthesis has also been described in literature (e.g.
WO2005/066187 ;WO2011/0059118 WO2016/185279 ). Optically pure cis-configured intermediates 1B and 1C can be obtained for example according to Scheme 3 by chiral separation of commercially available rac-(4aR,8aS)-4a,5,6,7,8,8a-hexahydro-4H-pyrido[4,3-b][1,4]oxazin-3-one (1A) (optionally in form of a salt such as, e.g. a hydrochloride salt) using methods known in the art, e.g. by diastereomeric salt crystallization or by chiral chromatography (step a). - In some embodiments, intermediates 2 are intermediates of type A. Intermediates of type A in which A, B, R3 and R4 are as described herein and R5 is hydrogen, C1-6-alkyl or halo-C1-6-alkyl, can be prepared by methods well known by a person skilled in the art and as exemplified by the general synthetic procedure outlined in Scheme 4.
- Bicyclic compounds 7 in which PG signifies a suitable protective group such as a Boc, Cbz or Bn protecting group (either commercially available or prepared as described in literature, e.g. in Eur. J. Org. Chem. 2017, 36, 5316; Topics in Het. Chem. 2014, 35, 189; World Journal of Pharmacy and Pharmaceutical Sciences 2014, 3(12), 536; Chem. Rev. 2014, 114(16), 8257-8322) can be subjected to a Mitsunobu reaction with alcohol derivatives 8 using an appropriate phosphine such as triphenylphosphine and a dialkyl azodicarboxylate such as DEAD or DIAD in a suitable solvent such as THF to give intermediates 9 (step a). Mitsunobu reactions of that type are broadly described in literature (e.g. Org. Chem. Front. 2015, 2, 739; Chem. Rev. 2009, 109 (6), 2551).
- Removal of the protective group from intermediates 9, applying methods known in the art, e.g., a Boc group using TFA in DCM or 4M HCl in dioxane at temperatures between 0°C and room temperature, a Bn or Cbz group using hydrogen in the presence of a suitable catalyst such as Pd or Pd(OH)2 on charcoal in a suitable solvent such as MeOH, EtOH, EtOAc or mixtures thereof and as described for example in "Protective Groups in Organic Chemistry" by T.W. Greene and P.G.M. Wuts, 4th Ed., 2006, Wiley N.Y.), furnishes intermediates A (step b).
- Intermediates 9 may alternatively be prepared by alkylation of compounds 8 with spirocyclic derivatives 10 (either commercially available or prepared by methods known in the art) in which LG signifies a suitable leaving group such as chlorine, bromine, iodine, OSO2alkyl (e.g. mesylate (methanesulfonate), OSO2fluoroalkyl (e.g. triflate (trifluoromethanesulfonate) or OSO2aryl (e.g. tosylate (p-toluenesulfonate) using a suitable base and an appropriate solvent (e.g. sodium hydride in DMF or potassium tert-butoxide in THF) at temperatures between 0°C and the boiling temperature of the solvent (step c).
- In some embodiments, intermediates 2 are intermediates of type B. Intermediates of type B in which A, B, R3 and R4 are as described herein and R5 is hydrogen; C1-6-alkyl or halo-C1-6-alkyl can be prepared by methods well known in the art and as exemplified by the general synthetic procedures outlined in Scheme 5.
- Bicyclic compounds 7 in which PG is a suitable protective group can be alkylated with compounds 13 in which LG is a suitable leaving group such as chlorine, bromine, iodine, methanesulfonate, trifluoromethanesulfonate or p-toluenesulfonate (prepared by literature methods for example from compounds 11) using using a suitable base and an appropriate solvent (e.g. sodium hydride in DMF or potassium tert-butoxide in THF) at temperatures between 0°C and the boiling temperature of the solvent (step c) to provide intermediates 12 (step a).
- Removal of the protective group from intermediates 12, applying methods known in the art and for example described under Scheme 4, step b, furnishes intermediates B (step b).
- Alternatively, intermediates 12 may be prepared from intermediates 7 and compounds 11 via Mitsunobu reaction, applying for example the conditions described under Scheme 4, step a (step c).
- Furthermore, intermediates 12 may be also prepared by alkylation of compounds 7 with compounds 10 and using for example the conditions described under Scheme 4, step c (step d). Intermediates 10 in turn may be synthesized from compounds 7 converting the hydroxy function into a suitable leaving group such as an alkyl halide (e.g. bromine by using of PBr3, chlorine through the use of SOCl2) or alkyl- or aryl-sulfonate such as methanesulfonate (using mesyl chloride) or p-toluenesulfonate (using tosyl chloride). Reactions of that type are broadly described in literature and are well known in the art.
- In some embodiments, intermediates 2 are intermediates of type C. Intermediates of type C in which A is aryl, B, R3 and R4, R12, R13 are as described herein and R5 is hydrogen; C1-6-alkyl or halo-C1-6-alkyl can be prepared by methods well known in the art and as exemplified by the general synthetic procedures outlined in Scheme 6 and described in more detail in J. Med. Chem. 2018, 61, 3008-3026.
- Also disclosed herein, but not part of the invention, is a process of manufacturing the urea compounds of formula (I) described herein, and pharmaceutically acceptable salts thereof, comprising:
- (a) reacting a first amine of formula 1, wherein R1 and R2 are as described herein, preferably wherein R1 and R2 are hydrogen,
- (b) transforming said compound of formula (I) to a pharmaceutically acceptable salts thereof.
- In one embodiment, there is provided a process according to the invention, wherein said base is sodium bicarbonate.
- In one embodiment, there is provided a process according to the invention, wherein said urea forming reagent is selected from bis(trichloromethyl) carbonate, phosgene, trichloromethyl chloroformate, (4-nitrophenyl)carbonate and 1,1'-carbonyldiimidazole, preferably wherein said urea forming reagent is bis(trichloromethyl) carbonate.
- Compounds of the present invention are MAGL inhibitors. Thus, in one aspect, the present invention provides the compounds of formula (I) as described herein for use in inhibiting
- In a further aspect, the present invention provides compounds of formula (I) as described herein for use in a method of inhibiting MAGL in a mammal.
- In a further aspect, the present invention provides the compounds of formula (I) as described herein for use in a method for inhibiting MAGL in a mammal, which method comprises administering an effective amount of a compound of formula (I) as described herein to the mammal.
- Compounds were profiled for MAGL inhibitory activity by determining the enzymatic activity by following the hydrolysis of the natural substrate 2-arachidonoylglycerol resulting in arachidonic acid, which can be followed by mass spectrometry. This assay is hereinafter abbreviated "2-AG assay".
- The 2-AG assay was carried out in 384 well assay plates (PP, Greiner Cat# 784201) in a total volume of 20 µL. Compound dilutions were made in 100% DMSO (VWR Chemicals 23500.297) in a polypropylene plate in 3-fold dilution steps to give a final concentration range in the assay from 12.5 µM to 0.8 pM. 0.25µL compound dilutions (100% DMSO) were added to 9 µL MAGL in assay buffer (50 mM TRIS (GIBCO, 15567-027), 1 mM EDTA (Fluka, 03690-100ml), 0.01% (v/v) Tween. After shaking, the plate was incubated for 15 min at RT. To start the reaction, 10 µL 2-arachidonoylglycerol in assay buffer was added. The final concentrations in the assay was 50 pM MAGL and 8 µM 2-arachidonoylglyerol. After shaking and 30 min incubation at RT, the reaction was quenched by the addition of 40µL of acetonitrile containing 4µM of d8-arachidonic acid. The amount of arachidonic acid was traced by an online SPE system (Agilent Rapidfire) coupled to a triple quadrupole mass spectrometer (Agilent 6460). A C18 SPE cartridge (G9205A) was used in an acetonitrile/water liquid setup. The mass spectrometer was operated in negative electrospray mode following the mass transitions 303.1 → 259.1 for arachidonic acid and 311.1 → 267.0 for d8-arachidonic acid. The activity of the compounds was calculated based on the ratio of intensities [arachidonic acid / d8-arachidonic acid].
Table 1 Ex. Structure IUPAC Name MAGL IC50 (nM) 1 (4aR,8aS)-6-(5-(2-chlorophenoxy)-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-2-carbonyl)-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one 8.9 2 (4aR,8aS)-6-(5-(2-methylphenoxy)-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-2-carbonyl)-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one 19.8 3 (4aR,8aS)-6-(5-(benzenesulfonyl)-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrole-2-carbonyl)-4,4a, 5,7, 8, 8a-hexahydropyrido [4,3-b][1,4]oxazin-3-one 2278.6 4 (4aR,8aS)-6-(5-[4-(trifluoromethyl)phenyl]sulfonyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrole-2-carbonyl)-4,4a, 5,7, 8, 8a-hexahydropyrido [4,3-b][1,4]oxazin-3-one 929.2 5 (4aR,8aS)-6-(5-(2-chloro-4-fluorophenyl)sulfonyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrole-2-carbonyl)-4,4a, 5,7, 8, 8a-hexahydropyrido [4,3-b][1,4]oxazin-3-one 675.6 6 (4aR,8aS)-6-[(1R,5S,6r)-6-[1-(4-fluorophenyl)pyrazol-3-yl]-3 - azabicyclo[3. 1.0]hexane-3-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido [4,3-b][1,4]oxazin-3-one 260.6 7 (4aR,8aS)-6-[(1R,5S,6r)-6-[1-[4-fluoro-3-(trifluoromethyl)phenyl]pyrazol-3 - yl]-3-azabicyclo[3.1.0]hexane-3-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido [4,3-b][1,4]oxazin-3-one 45.3 8 (4aR,8aS)-6-[(1R,5S,6r)-6-[1-(2-chloro-4-fluoro-phenyl)pyrazol-3 - yl]-3-azabicyclo[3.1.0]hexane-3-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one 111.7 9 (4aR,8aS)-6-[rel-(1R,4R,5S)-5-(5,6,7,8-tetrahydroisoquinolin-3-ylmethoxy)-2-azabicyclo[2.2.1]heptane-2-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one 76.0 10 (4aR, 8aS) -6- [rel- (lR,4R, 5 S) -5 - [(5 - chloro-4-cyclopropyl-2-pyridyl)methoxy]-2-azabicyclo[2.2.1]heptane-2-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido [4,3-b][1,4]oxazin-3-one 16.2 11 (4aR, 8aS)-6- [rel-(lR,4R,5 S)-5- [(5-chloro-4-cyclopropyl-2-pyridyl)methoxy]-2-azabicyclo[2.2.1]heptane-2-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido [4,3-b][1,4]oxazin-3-one 82.5 12 (4aR,8aS)-6-[(1R,5S,6r)-6-[(2-chloro-4-fluoro-phenoxy)methyl]-3-azabicyclo[3.1.0]hexane-3-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido [4,3-b][1,4]oxazin-3-one 6.3 13 (4aR,8aS)-6-[8-[(2-chloro-4-fluoro-phenoxy)methyl]-3-azabicyclo[3.2.1]octane-3-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one 5.1 14 (4aR,8aS)-6-[5-(2-chloro-4-fluoro-phenoxy)-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-2-carbonyl] -4,4a,5,7,8,8a-hexahydropyrido [4,3-b][1,4]oxazin-3-one 3.5 15 (4aR,8aS)-6-[5-[(2-chloro-4-fluoro-phenyl)methoxy]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta [c]pyrrole-2-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one 11.0 16 (4aR,8aS)-6-[5-[[2-fluoro-4-(trifluoromethyl)phenyl]methoxy]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta [c]pyrrole-2-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one 85.9 17 (4aR,8aS)-6-[5-[2-fluoro-4-(trifluoromethyl)phenoxy] - 3,3a,4,5,6,6a-hexahydro-1H-cyclopenta [c]pyrrole-2-carbonyl]-4,4a,5,7,8,8a-hexahydropyirido[4,3-b][1,4]oxazin-3-one 4.7 18 (4aR,8aS)-6-[rel-(1R,4S,6S)-6-[[2-fluoro-4-(trifluoromethyl)phenyl]methoxy] - 2-azabicyclo[2.2.1]heptane-2-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one 1049.4 19 (4aR,8aS)-6-[rel-(1R,4S,6R)-6-[[2-fluoro-4-(trifluoromethyl)phenyl]methoxy] - 2-azabicyclo[2.2.1]heptane-2-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one 1142.2 20 (4aR,8aS)-6-[rel-(1R,4R,5S)-5-[[2-fluoro-4-(trifluoromethyl)phenyl]methoxy] - 2-azabicyclo[2.2.1]heptane-2-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one 9.7 21 (4aR,8aS)-6-[rel-(1R,4R,5S)-5-[[2-fluoro-4-(trifluoromethyl)phenyl]methoxy] - 2-azabicyclo[2.2.1]heptane-2-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido [4,3-b][1,4]oxazin-3-one 18.6 22 (4aR,8aS)-6-[6-[[2-fluoro-4-(trifluoromethyl)phenyl]methoxy] - 3-azabicyclo[3.1.1]heptane-3-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido [4,3-b][1,4]oxazin-3-one 217.3 23 (4aR,8aS)-6-[(1S,5R)-7-[[2-fluoro-4-(trifluoromethyl)phenyl]methoxy] - 3-oxa-9-azabicyclo[3.3. 1]nonane-9-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido [4,3-b][1,4]oxazin-3-one 628.5 24 (4aR,8aS)-6-[(1S,5R)-3-[[2-fluoro-4-(trifluoromethyl)phenyl]methoxy] - 8-azabicyclo[3.2.1]octane-8-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one 1.4 25 (4aR,8aS)-6-[(1R,5S,6r)-6-[[2-fluoro-4-(trifluoromethyl)phenoxy]methyl]-3-azabicyclo[3.1.0]hexane-3-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one 32.0 26 (4aR,8aS)-6-[3-[(2-chloro-4-fluoro-phenoxy)methyl]-8-azabicyclo[3.2.1]octane-8-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido [4,3-b][1,4]oxazin-3-one 3694.0 27 (4aS,8aR)-6-[8-[(2-chloro-4-fluoro-phenoxy)methyl]-3-azabicyclo[3.2.1]octane-3-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one 669.7 28 (4aR,8aS)-6-[rel-(1R,4R,5S)-5-(5,6,7,8-tetrahydroisoquinolin-3-ylmethoxy)-2-azabicyclo[2.2.1]heptane-2-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one 54.5 - In one aspect, the present invention provides compounds of formula (I) and their pharmaceutically acceptable salts or esters as described herein, wherein said compounds of formula (I) and their pharmaceutically acceptable salts or esters have IC50's for MAGL inhibition below 25 µM, preferably below 10 µM, more preferably below 5 µM as measured in the MAGL assays described herein.
- In one embodiment, compounds of formula (I) and their pharmaceutically acceptable salts or esters as described herein have IC50 (MAGL inhibition) values between 0.000001 µM and 25 µM, particular compounds have IC50 values between 0.000005 µM and 10 µM, further particular compounds have IC50 values between 0.00005 µM and 5 µM, as measured in the MAGL assays described herein.
- In one aspect, the present invention provides compounds of formula (I) as described herein for use as therapeutically active substance.
- In one aspect, the present invention provides compounds of formula (I) as described herein for use in the treatment or prophylaxis of neuroinflammation, neurodegenerative diseases, pain, cancer, mental disorders and/or inflammatory bowel disease in a mammal.
- In one embodiment, the present invention provides compounds of formula (I) as described herein for use in the treatment or prophylaxis of neuroinflammation and/or neurodegenerative diseases in a mammal.
- In one embodiment, the present invention provides compounds of formula (I) as described herein for use in the treatment or prophylaxis of cancer in a mammal.
- In one embodiment, the present invention provides compounds of formula (I) as described herein for use in the treatment or prophylaxis of neurodegenerative diseases in a mammal.
- In one embodiment, the present invention provides compounds of formula (I) as described herein for use in the treatment or prophylaxis of inflammatory bowel disease in a mammal.
- In one embodiment, the present invention provides compounds of formula (I) as described herein for use in the treatment or prophylaxis of pain in a mammal.
- In one aspect, the present invention provides compounds of formula (I) as described herein for use in the treatment or prophylaxis of multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colon carcinogenesis, ovarian cancer, neuropathic pain, chemotherapy induced neuropathy, acute pain, chronic pain, spasticity associated with pain, abdominal pain, abdominal pain associated with irritable bowel syndrome and/or visceral pain in a mammal.
- In a preferred embodiment, the present invention provides compounds of formula (I) as described herein for use in the treatment or prophylaxis of multiple sclerosis, Alzheimer's disease and/or Parkinson's disease in a mammal.
- In a particularly preferred embodiment, the present invention provides compounds of formula (I) as described herein for use in the treatment or prophylaxis of multiple sclerosis in a mammal.
- In one aspect, the present invention provides a pharmaceutical composition comprising a compound of formula (I) as described herein and a therapeutically inert carrier.
- Exemplary, yet non-limiting examples of possible pharmaceutical compositions comprising compounds of formula (I) are described in Examples 29 and 30.
- The compounds of formula (I) and their pharmaceutically acceptable salts and esters can be used as medicaments (e.g. in the form of pharmaceutical preparations). The pharmaceutical preparations can be administered internally, such as orally (e.g. in the form of tablets, coated tablets, dragées, hard and soft gelatin capsules, solutions, emulsions or suspensions), nasally (e.g. in the form of nasal sprays) or rectally (e.g. in the form of suppositories). However, the administration can also be effected parentally, such as intramuscularly or intravenously (e.g. in the form of injection solutions).
- The compounds of formula (I) and their pharmaceutically acceptable salts and esters can be processed with pharmaceutically inert, inorganic or organic adjuvants for the production of tablets, coated tablets, dragées and hard gelatin capsules. Lactose, corn starch or derivatives thereof, talc, stearic acid or its salts etc. can be used, for example, as such adjuvants for tablets, dragées and hard gelatin capsules.
- Suitable adjuvants for soft gelatin capsules are, for example, vegetable oils, waxes, fats, semisolid substances and liquid polyols, etc.
- Suitable adjuvants for the production of solutions and syrups are, for example, water, polyols, saccharose, invert sugar, glucose, etc.
- Suitable adjuvants for injection solutions are, for example, water, alcohols, polyols, glycerol, vegetable oils, etc.
- Suitable adjuvants for suppositories are, for example, natural or hardened oils, waxes, fats, semisolid or liquid polyols, etc.
- Moreover, the pharmaceutical preparations can contain preservatives, solubilizers, viscosity-increasing substances, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents or antioxidants. They can also contain still other therapeutically valuable substances.
- The dosage can vary in wide limits and will, of course, be fitted to the individual requirements in each particular case. In general, in the case of oral administration a daily dosage of about 0.1 mg to 20 mg per kg body weight, preferably about 0.5 mg to 4 mg per kg body weight (e.g. about 300 mg per person), divided into preferably 1-3 individual doses, which can consist, for example, of the same amounts, should be appropriate. It will, however, be clear that the upper limit given herein can be exceeded when this is shown to be indicated.
- The invention will be more fully understood by reference to the following examples.
- In case the preparative examples are obtained as a mixture of enantiomers, the pure enantiomers can be separated by methods described herein or by methods known to the man skilled in the art, such as e.g., chiral chromatography (e.g., chiral SFC) or crystallization.
- All reaction examples and intermediates were prepared under an argon atmosphere if not specified otherwise.
- To an ice-cold solution of bis(trichloromethyl) carbonate (28.8 mg, 97.1 µmol) in DCM (1.83 ml) were added sodium bicarbonate (46.6 mg, 555 µmol) and (4aR,8aS)-hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one acetate (BB1, 30 mg, 139 µmol) and the mixture was stirred overnight at room temperature. To the suspension was added (3aR,6aS)-2-(phenylsulfonyl)octahydropyrrolo[3,4-c]pyrrole hydrochloride (BB5, 40.1 mg, 139 µmol) and DIPEA (71.7 mg, 96.9 µl, 555 µmol). The suspension was stirred at RT for 1.5 hours. The reaction mixture was poured on water and DCM and the layers were separated. The aqueous layer was extracted three times with DCM. The organic layers were washed twice with water, dried over MgSO4, filtered, treated with silica gel and evaporated. The compound was purified by prep HPLC (Method B3) to get the desired compound as a white solid (44 mg; 73%). LC-MS (ESI): [M+H+]+ = 435.2 m/z
- 5-(2-chlorophenoxy)octahydrocyclopenta[c]pyrrole HCl (CAS 1889054-91-4, 45 mg, 164 µmol) was dissolved in acetonitrile (0.5 ml). 4-nitrophenyl (4aR,8aS)-3-oxohexahydro-2H-pyrido[4,3-b][1,4]oxazine-6(5H)-carboxylate (BB2, 52.7 mg, 164 µmol) and DIPEA (63.6 mg, 86 µl, 492 µmol) were added at room temperature, followed by stirring at 80°C for 20h. The reaction mixture was concentrated in vacuo and purified by reverse phase HPLC (method B1). The purified product was concentrated in vacuo to afford (4aR,8aS)-6-(5-(2-chlorophenoxy)octahydrocyclopenta[c]pyrrole-2-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one (5 mg, 7.26 % yield) as a colorless solid. LC-MS (ESI): [M+H+]+ = 420.2 m/z
- A microwave vial was heat gun-dried and charged with bis(trichloromethyl) carbonate (26.6 mg, 89.6 µmol) and sodium bicarbonate (32.3 mg, 384 µmol). The flask was placed under argon and DCM (1 ml) was added to give a suspension. The suspension was cooled by an ice-bath and (1R,5S,6r)-6-((2-chloro-4-fluorophenoxy)methyl)-3-azabicyclo[3.1.0]hexane hydrochloride (BB13, 35.6 mg, 128 µmol) was added to the reaction. The mixture was stirred at 0 °C for 15 min and at room temperature overnight. The suspension turned into a clear solution overnight. The reaction mixture was then cooled down in an-ice bath and DCM (500 µl) and DIPEA (49.7 mg, 67.1 µl, 384 µmol) followed by (4aR,8aS)-hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one (BB1, 20 mg, 128 µmol) were added. The resulting off-white suspension was stirred at room temperature for 6 hours.
- The reaction mixture was poured on water and DCM and the layers were separated. The aqueous layer was extracted twice with DCM. The organic layers were dried over MgSO4, filtered and evaporated to afford an orange oil (60 mg). The crude was purified by reverse-phase HPLC (method B7) to afford 24 mg (44.2%) of (4aR,8aS)-6-[(1R,5S,6r)-6-[(2-chloro-4-fluoro-phenoxy)methyl]-3-azabicyclo[3.1.0]hexane-3-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one as a white solid after lyophilisation. LC-MS (ESI): [M+H+]+ = 424.2 m/z
- HPLC Method B1
YMC-Triart C18, 12 nm, 5 µm, 100 x 30 mm, 15 min run time, gradient 15-35-50-100% ACN in Water + 0.1% HCOOH - HPLC Method B2
YMC-Triart C18, 12 nm, 5 µm, 100 x 30 mm, 15 min run time, gradient 30-50-65-100% ACN in Water + 0.1% HCOOH - HPLC Method B3
Gemini NX, 12 nm, 5 µm, 100 x 30 mm, 15 min gradient, ACN / Water + 0.1% TEA - HPLC Method B4
YMC-Triart C18, 12 nm, 5 µm, 100 x 30 mm, 11 min run time, gradient 15-35-50-100% ACN in Water + 0.1% TEA - HPLC Method B5
YMC-Triart C18, 12 nm, 5 µm, 100 x 30 mm, 9 min run time, gradient 40-60-80-100% ACN in Water + 0.1% HCOOH - HPLC Method B6
YMC-Triart C18, 12 nm, 5 µm, 100 x 30 mm, 11 min run time, gradient 20-40-55-100% ACN in Water + 0.1% HCOOH - HPLC Method B7
Gemini NX, 12 nm, 5 µm, 100 x 30 mm, 15 min gradient, ACN / Water + 0.1% HCOOH - HPLC Method B8 (chiral)
Chiralpak AD, Normal Phase (isocratic): 65% Heptane; 35% Ethanol + NH4Oac - HPLC Method B9
Gemini NX, 12 nm, 5 µm, 100 x 30 mm, 15 min run time, gradient 30-50-65-100% ACN in Water + 0.1% HCOOH - Chiral SFC Method C1
OD-H, 12 nm, 5 µm, 250 x 4.6 mm, 30% iPrOH - Chiral SFC Method C2
AD-H, 12 nm, 5 µm, 250 x 4.6 mm, 40% MeOH - Chiral SFC Method C3
OZ-H, 12 nm, 5 µm, 250 x 4.6 mm, 35% iPrOH + 0.2% DEA - Chiral SFC Method C4
IB, 12 nm, 5 µm, 250 x 4.6 mm, 9% MeOH, 100 ml/min - Chiral SFC Method C5
IC, 12 nm, 5 µm, 250 x 4.6 mm, 30% MeOH -
- The enantiomers of rac-(4aR,8aS)-hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one dihydrochloride (BB1, CAS 1909295-00-6, 500 mg, 2.18 mmol) were separated by preparative chiral HPLC (ReprosilChiral NR column) using an isocratic mixture of EtOH (containing 0.05% of NHaOAc) : n-heptane (30 : 70).
- First eluting enantiomer: (+)-cis-4a,5,6,7,8,8a-Hexahydro-4H-pyrido[4,3-b][1,4]oxazin-3-one (BB1a). Yellow solid (0.150 g; 44.0%). MS (ESI): m/z = 157.1 [M+H]+.
- Second eluting enantiomer: (-)-cis-4a,5,6,7,8,8a-Hexahydro-4H-pyrido[4,3-b][1,4]oxazin-3-one. (BB1b). Yellow solid (0.152 g; 44.6%). MS (ESI): m/z = 157.1 [M+H]+.
-
- A suspension of rac-(4aR,8aS)-hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one dihydrochloride (BB1, 4.5 g, 19.6 mmol) in dry DCM (125 ml) was cooled down to 0°C and DIPEA (6.35 g, 8.58 ml, 49.1 mmol) was added, followed by 4-nitrophenyl carbonochloridate (4.35 g, 21.6 mmol). The reaction mixture was stirred at 0°C for 10 min and for 2 hours at room temperature. The crude reaction was diluted with dichloromethane, transfered into a separating funnel for extraction with sat. aq. Na2CO3. The organic phase was collected and the aqueous phase was back-extracted with dichloromethane. The combined organic phases were dried over sodium sulfate and evaporated down to dryness to yield 6.62 g of a crude racemic product as a yellow solid. The crude material was directly submitted for a chiral SFC separation (Method C4) to yield the two enantiomers:
First eluting enantiomer, light beige solid (3.25g), contaminated with the second enantiomer. - The fraction was submitted for another SFC chiral separation (Method C5) to yield 2.71 g of the desired enantiomer (BB2a).
-
- In a 20 ml tube under argon, tert-butyl (1R,5S,6r)-6-(1-(4-fluorophenyl)-1H-pyrazol-3-yl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (120mg, 349 µmol) was dissolved in DCM (2 ml), TFA (239 mg, 162 µl, 2.1 mmol) was added and the reaction stirred at room temperature for 16hr, and then concentrated in vacuo (azeotrop with toluene) to yield the desired product (122 mg, 98%). Used directly in next step. LC-MS (ESI): m/z = 244.2 [M+H+]+
- tert-butyl (1R,5S,6r)-6-acetyl-3-azabicyclo[3.1.0]hexane-3-carboxylate (CAS 2075712-96-6, 990 mg, 4.39 mmol) was combined with N,N-dimethylformamide dimethyl acetal (3.24 g, 3.64 ml, 26.4 mmol) and heated at 100°C over night for 15 hrs. The mixture was cooled to room temperature and directly evaporated in vacuo. The residue was extracted with ethyl acetate / water, brine, organic fractions were combined and dried over MgSO4, filtered and concentrated under reduced pressure to afford the deisred product (1.21 g, 98%) as a yellow oil, LC-MS (ESI): m/z = 281.3 [M+H+]+
- In a 20ml tube, tert-butyl (1R,5S,6r)-6-((E)-3-(dimethylamino)acryloyl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (1.21 g, 4.32 mmol) was dissolved in ethanol (6 ml) and hydrazine hydrate (302 mg, 293 µl, 6.04 mmol) was added. The reaction was stirred 1 hr at 80°C. Solvent was removed under reduced pressure, purification by preparative SFC (Princeton 2-Ethyl Pyridine column, 30x250 mm, 5% EtOH + 0.2% DEA) yielded the desired product as a yellow, viscous oil (890 mg, 83%). LC-MS (ESI): m/z = 250.1 [M+H+]+
- In a 100 ml flask under argon, tert-butyl (1R,5S,6r)-6-(1H-pyrazol-3-yl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (300mg, 1.2 mmol) was suspended in DMF (8 ml), pyridine (381 mg, 389 µl, 4.81 mmol), (4-fluorophenyl)boronic acid (219 mg, 1.56 mmol) and copper (II) acetate (328 mg, 1.8 mmol) were added. The green solution was stirred 60 hr at room temperature. Solvent was removed in vacuo, the crude was extracted with ethyl acetat / water / sat. NaCl, organic fractions were dried over MgSO4, filtered and solvent was removed. Purification by flash chromatography (SiO2, Heptane / ethyl acetate 0 to 40% in 40min) led to the desired product as a colorless, solid (317 mg, 77%). LC-MS (ESI): m/z = 288.1 [M-56+H+]+
-
- BB10 was prepared similarly as described for BB9, using tert-butyl (1R,5S,6r)-6-(1H-pyrazol-3-yl)-3-azabicyclo[3.1.0]hexane-3-carboxylate and (2-chloro-4-fluorophenyl)boronic acid in step c).
- LC-MS (ESI) for BB10: m/z = 278.2 [M+H+]+
-
- In a 20 ml tube under argon, rac-tert-butyl (1R,4R,5S)-5-((5,6,7,8-tetrahydroisoquinolin-3-yl)methoxy)-2-azabicyclo[2.2.1]heptane-2-carboxylate (40mg, 112 µmol) was dissolved in DCM (1 ml), TFA (69 µl, 0.89 mmol) was added and the reaction stirred at room temperature for 24 hr, and then concentrated in vacuo (azeotrop with toluene) to yield the desired product (60 mg, 90% pure, 99.5%) as a light yellow oil. Used directly in next step. LC-MS (ESI): m/z = 259.3 [M+H+]+
- Appel reaction: To a solution of (5,6,7,8-tetrahydroisoquinolin-3-yl)methanol (169 mg, 1.04 mmol) in dry DCM (2.91 ml) was added CBr4 (412 mg, 1.24 mmol), the mixture was cooled to 0-3°C and within 10 min triphenylphosphine (353 mg, 1.35 mmol) in 1ml dry DCM was added. Stirring continued for 1 hr at 2-4°C, then 20ml DCM and silica gel were added, the solvent was removed in vacuo and the crude was purified by flash chromatography (SiO2, heptane/ethylacetate 0 to 50% in 40min). The desired product was obtained as 190 mg (81%) of a light red solid. LC-MS (ESI): m/z = 226.1 [M+H+]+
- To a solution of rac-tert-butyl (1S,4S,5R)-5-hydroxy-2-azabicyclo[2.2.1]heptane-2-carboxylate (CAS 198835-03-9, 197 mg, 924 µmol) in dry THF (2.79 ml) was added potassium tert-butoxide 1M in THF (924 µl 924 µmol) and the turbid reaction mixture was stirred at r.t. for 30 min followed by addition of 3-(bromomethyl)-5,6,7,8-tetrahydroisoquinoline (190 mg, 840 µmol) at 0-2°C. The reaction mixture was 3 hr stirred at 3-6°C, then diluted with ethyl acetate and extracted with water, the organic phase was collected and the aqueous phase was back-extracted with ethyl acetate. The combined organic phases were dried over sodium sulfate and evaporated down to dryness. The crude material was purified by prep. HPLC (Gemini NX, 12 nm, 5 µm, 100 x 30 mm, ACN / Water+0.1% TEA) to get the desired product (40 mg, 13.3%) as a light brown solid. LC-MS (ESI): m/z = 359.3 [M+H+]+
-
- In a 20 ml tube under argon, rac-tert-butyl (1R,4R,5S)-5-((5-chloro-4-cyclopropylpyridin-2-yl)methoxy)-2-azabicyclo[2.2.1]heptane-2-carboxylate (272mg, 718 µmol) was dissolved in DCM (2 ml), TFA (332 µl, 0.4.3 mmol) was added and the reaction stirred at room temperature for 24 hr, and then concentrated in vacuo (azeotrop with toluene) to yield the desired product (381 mg, 90% pure, 94%) as a light yellow oil. Used directly in next step. LC-MS (ESI): m/z = 279.2 [M+H+]+
- Appel reaction: To a solution of (5-chloro-4-cyclopropylpyridin-2-yl)methanol (290 mg, 1.58 mmol) in dry DCM (5 ml) was added CBr4 (628 mg, 1.9 mmol), the mixture was cooled to 0-3°C and within 10 min triphenylphosphine (538 mg, 2.05 mmol) in 1ml dry DCM was added. Stirring continued for 1 hr at 2-4°C, then 20ml DCM and silica gel were added, the solvent was removed in vacuo and the crude was purified by flash chromatography (SiO2, heptane/ethylacetate 0 to 40% in 40min). The desired product was obtained as 345 mg (90% pure, 80%) of a light red semisolid. LC-MS (ESI): m/z = 248.0 [M+H+]+
- To a solution of tert-butyl 5-hydroxy-2-azabicyclo[2.2.1]heptane-2-carboxylate (CAS 198835-03-9, 324 mg, 1.52 mmol) in dry THF (5 ml) was added potassium tert-butoxide 1M in THF (1.52 ml, 1.52 mmol) and the turbid reaction mixture was stirred at r.t. for 30 min followed by addition of 2-(bromomethyl)-5-chloro-4-cyclopropylpyridine (340 mg, 1.38 mmol) at 0-2°C. The reaction mixture was 3 hr stirred at 3-6°C, then diluted with ethyl acetate and extracted with water, the organic phase was collected and the aqueous phase was back-extracted with ethyl acetate. The combined organic phases were dried over sodium sulfate and evaporated down to dryness. The crude material was purified by flash chromatography (silica gel, 0% to 50% in 40min EtOAc in heptane) to get the desired product (272 mg, 95% pure, 49.4%) as a light brown oil. LC-MS (ESI): m/z = 379.2 [M+H+]+
-
- To a solution of tert-butyl (1R,5S,6r)-6-[(2-chloro-4-fluoro-phenoxy)methyl]-3-azabicyclo[3.1.0]hexane-3-carboxylate (150.0 mg, 0.440 mmol) in EtOAc (2 mL) was added 9M HCl in EtOAc (0.4 mL, 3.6 mmol) at 0 °C. The solution was stirred at 15°C for 2.5 hrs. The solution was concentrated, then dried by lyophilization in vacuo to obtained desired product (1R,5S,6r)-6-[(2-chloro-4-fluoro-phenoxy)methyl]-3-azabicyclo[3.1.0]hexane hydrochloride (56.2 mg, 0.200 mmol, 44.94% yield as a white solid. LC-MS (ESI): m/z = 242.0 [M+H+]+
- To a solution of tert-butyl (1R,5S,6r)-6-(methylsulfonyloxymethyl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (CAS 958633-11-9, 294 mg, 1.01 mmol) in DMF (3 mL) was added cesium carbonate (493.16 mg, 1.51 mmol), 2-chloro-4-fluorophenol (0.11 mL, 1.11 mmol) at 15 °C. The mixture was heated to 85 °C and stirred for 16 hrs. The mixture was quenched with water (5 mL) at 0 °C, then extracted three times with EtOAc (5 mL) and dried over Na2SO4. The organic layers were combined and concentrated in vacuo to obtained crude product as a yellow oil. The crude product was purified by Prep-HPLC and dried by lyophilization to obtain the desired product tert-butyl (1R,5S,6r)-6-[(2-chloro-4-fluoro-phenoxy)methyl]-3-azabicyclo[3.1.0]hexane-3-carboxylate (150 mg, 0.440 mmol, 43.4% yield) as a light yellow oil. LC-MS (ESI): m/z = 286.0 [M-56+H+]+
-
- Boc-deprotection was performed as described e.g. for BB12. Crude product was obtained as a light yellow oil and was used directly for next step (Yield 99%, Purity 80%). LC-MS (ESI): m/z = 270.2 [M+H+]+
- To a solution of 2-chloro-4-fluorophenol (65.6 mg, 48.8 µl, 448 µmol), tert-butyl 8-(hydroxymethyl)-3-azabicyclo[3.2.1]octane-3-carboxylate (108 mg, 448 µmol) and triphenylphosphine (117 mg, 448 µmol) in DCM (2.24 ml) was added DIAD (99.5 mg, 95.7 µl, 492 µmol) dropwise and the reaction was stirred for 19 h at rt. The reaction mixture was quenched by addition of sat. aq. NaHCO3 solution. The phases were separated and the aq. phase was extracted with DCM three times. The combined organic layers were dried over sodium sulfate and concentrated to dryness to afford a brown oil. The crude was immobilized on Isolute and purified by column chromatography (SiO2, 0 - 30 % EtOAc in heptane) to afford tert-butyl 8-((2-chloro-4-fluorophenoxy)methyl)-3-azabicyclo[3.2.1]octane-3-carboxylate (45.9 mg, 26.3 %) as a yellow oil. LC-MS (ESI): m/z = 314.2 [M-56+H+]+
-
- Synthesis was done as described for BB14, starting from 2-chloro-4-fluorophenol (64.5 mg, 440 umol) and tert-butyl 5-hydroxyhexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate (100 mg, 440 umol. Product was obtained as a light-brown oil, yield after Boc-deprotection was 149.8 mg (purity 82%). LC-MS (ESI): m/z = 256.2 [M+H+]+
-
- BB16 was prepared similarly as described for BB11 (step b and Boc-deprotection), using tert-butyl 5-hydroxyhexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate and 1-(bromomethyl)-2-chloro-4-fluorobenzene.
- LC-MS (ESI) for BB16: m/z = 270.2 [M+H+]+
-
- BB17 was prepared similarly as described for BB11 (step b and Boc-deprotection), using tert-butyl 5-hydroxyhexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate and 1-(bromomethyl)-2-fluoro-4-(trifluoromethyl)benzene.
- LC-MS (ESI) for BB17: m/z = 304.2 [M+H+]+
-
- In a 20 ml tube under argon, tert-butyl 5-(2-fluoro-4-(trifluoromethyl)phenoxy)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate (0.290 g, 745 µmol) was dissolved in DCM (4 ml), TFA (574 µl, 7.45 mmol) was added and the reaction stirred at room temperature for 1 hr, and then concentrated in vacuo (azeotrop with toluene) to yield the desired product (321 mg, 90% pure, 96%) as a colorless oil. Used directly in next step. LC-MS (ESI): m/z = 290.2 [M+H+]+
- In a 25m1 four-necked flask under argon, tert-butyl 5-hydroxyhexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate (0.250 g, 1.1 mmol) was dissolved in THF (5 ml), and 2-fluoro-4-(trifluoromethyl)phenol (198 mg, 138 µl, 1.1 mmol) and triphenylphosphine (317 mg, 1.21 mmol) were added. The clear solution was stirred 5 min at RT, then cooled to 0-2°C and slowly DEAD (211 mg, 192 µl, 1.21 mmol) was added within 10min, stirring continued for 1 hr at 2-4°C and overnight at RT. 50ml diethylether were added to the reaction mixture, which was extracted with 2x25ml water, 2x 20ml sat NaOH and 1x 20ml brine. The organic fraction was dried over Mg2SO4, solvent was removed in vacuo. The crude material was purified by flash chromatography (silica gel, 0% to 30% EtOAc in heptane), yielding the product as a colorless oil (290 mg, 67.7%). LC-MS (ESI): m/z = 334.2 [M-56+H+]+
-
- Boc-deprotection was performed as described e.g. for BB18. Crude product was obtained as a light yellow oil and was used directly for next step (Yield 87%). LC-MS (ESI): m/z = 290.3 [M+H+]+
- To a solution of rac-tert-butyl (1R,4S,6S)-6-hydroxy-2-azabicyclo[2.2.1]heptane-2-carboxylate (Synthonix, CAS 198835-05-1; 0.300 g, 1.41 mmol) in THF (5 ml) was added potassium tert-butoxide 1M solution in THF (1.48 ml, 1.48 mmol) and the turbid reaction mixture was stirred at r.t for 15min followed by addition of 1-(bromomethyl)-2-fluoro-4-(trifluoromethyl)benzene (362 mg, 1.41 mmol). The reaction mixture was then stirred at r.t for 60 hr. The crude reaction was diluted with ethyl acetate and extracted with water, the organic phase was collected and the aqueous phase was back-extracted with ethyl acetate. The combined organic phases were dried over sodium sulfate and evaporated down to dryness. The crude material was purified by flash chromatography (silica gel, 0% to 80% EtOAc in heptane), yielding the desired product as a colorless oil (237 mg, 43%). LC-MS (ESI): m/z = 334.2 [M-56+H+]+
-
- BB20 was prepared similarly as described for BB19, using rac-tert-butyl (1R,4S,6R)-6-hydroxy-2-azabicyclo[2.2.1]heptane-2-carboxylate (Combi-Blocks QE-8592, CAS : 207405-59-2) and 1-(bromomethyl)-2-fluoro-4-(trifluoromethyl)benzene.
- LC-MS (ESI) for BB20: m/z = 290.3 [M+H+]+
-
- BB21 was prepared similarly as described for BB19, using rac-tert-butyl (1R,4R,5S)-5-hydroxy-2-azabicyclo[2.2.1]heptane-2-carboxylate (AbovChem, CAS : 198835-03-9) and 1-(bromomethyl)-2-fluoro-4-(trifluoromethyl)benzene.
- LC-MS (ESI) for BB21: m/z = 290.3 [M+H+]+
-
- BB22 was prepared similarly as described for BB19, using tert-butyl 6-hydroxy-3-azabicyclo[3.1.1]heptane-3-carboxylate (Spirochem, CAS: 1357353-36-6) and 1-(bromomethyl)-2-fluoro-4-(trifluoromethyl)benzene.
- LC-MS (ESI) for BB21: m/z = 290.2 [M+H+]+
-
- BB23 was prepared similarly as described for BB19, using tert-butyl (1R,5S,7s)-7-hydroxy-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylate (endo, Spirochem, CAS: 1148006-31-8) and 1-(bromomethyl)-2-fluoro-4-(trifluoromethyl)benzene.
- LC-MS (ESI) for BB21: m/z = 320.2 [M+H+]+
-
- BB24 was prepared similarly as described for BB19, using tert-butyl (1R,3r,5S)-3-hydroxy-8-azabicyclo[3.2.1]octane-8-carboxylate (endo, Spirochem, CAS: 143557-91-9) and 1-(bromomethyl)-2-fluoro-4-(trifluoromethyl)benzene.
- LC-MS (ESI) for BB21: m/z = 304.2 [M+H+]+
-
- BB25 was prepared similarly as described for BB18, using tert-butyl (1R,SS,6r)-6-(hydroxymethyl)-3-azabicyclo[3.1.0]hexane-3-carboxylate and 2-chloro-4-fluorophenol
- LC-MS (ESI) for BB25: m/z = 276.2 [M+H+]+
-
- BB26 was prepared similarly as described for BB13, using tert-butyl 8-(methylsulfonyloxymethyl)-3-azabicyclo[3.2.1]octane-3-carboxylate and 2-chloro-4-fluorophenol
- LC-MS (ESI) for BB26: m/z = 270. 0 [M+H+]+
- A compound of formula (I) can be used in a manner known per se as the active ingredient for the production of tablets of the following composition:
Per tablet Active ingredient 200 mg Microcrystalline cellulose 155 mg Corn starch 25 mg Talc 25 mg Hydroxypropylmethylcellulose 20 mg 425 mg - A compound of formula (I) can be used in a manner known per se as the active ingredient for the production of capsules of the following composition:
Per capsule Active ingredient 100.0 mg Corn starch 20.0 mg Lactose 95.0 mg Talc 4.5 mg Magnesium stearate 0.5 mg 220.0 mg
Ex. | Building Blocks | Synthesis and Purification Method | ESI(MS) |
1 | BB2a | A2 | m/z = 420.2[ M+H+]+ |
CAS: 1889054-91-4 | B1 | ||
2 | BB2a | A2 | m/z = 400.3 [M+H+]+ |
CAS: 1893326-25-4 | B2 | ||
3 | BB1a | A1 | m/z = 435.2 [M+H+]+ |
CAS: 1422449-96-4 | B3 | ||
4 | BB1a | A1 | m/z = 503.3 [M+H+]+ |
CAS: 1825117-24-5 | B4 | ||
5 | BB1a | A1 | m/z = 487.1 [M+H+]+ |
CAS: 1822096-52-5 | B5 | ||
6 | BB1a | A1 | m/z = 426.3 [M+H+]+ |
CAS: 2075635-92-4 | B1 | ||
7 | BB1a | A1 | m/z = 494.3 [M+H+]+ |
BB9 | B2 | ||
8 | BB1a | A1 | m/z = 460.2 [M+H+]+ |
BB10 | B6 | ||
9 | BB2a | A2 | m/z = 441.3 [M+H+]+ |
BB11 | C1 | ||
Product is the first eluting of the two diastereomers. | |||
10 | BB2a | A2 | m/z = 461.3 [M+H+]+ |
BB12 | C2 | ||
Product is the first eluting of the two diastereomers. | |||
11 | BB2a | A2 | m/z = 461.3 [M+H+]+ |
BB12 | C2 | ||
Product is the second eluting of the two diastereomers. | |||
12 | BB1a | A3 | m/z = 424.2 [M+H+]+ |
BB13 | B7 | ||
13 | BB2a | A2 | m/z = 452.2 [M+H+]+ |
BB14 | B7 | ||
14 | BB2a | A2 | m/z = 438.3 [M+H+]+ |
BB15 | B3 | ||
15 | BB1a | A1 | m/z = 452.18 [M+H+]+ |
BB16 | flash chromatography (SiO2, 0% to 10% MeOH in DCM) | ||
16 | BB1a | A1 | m/z = 486.20 [M+H+]+ |
BB17 | flash chromatography (SiO2, 0% to 10% MeOH in DCM) | ||
17 | BB1a | A1 | m/z = 472.19 [M+H+]+ |
BB18 | flash chromatography (SiO2, 0% to 10% MeOH in DCM) | ||
18 | BB1a | A1 | m/z = 472.3 [M+H+]+ |
BB19 | B8 | ||
Product is the second eluting of the two diastereomers. | |||
19 | BB1a | A1 | m/z = 472.3 [M+H+]+ |
BB20 | B8 | ||
Product is the second eluting of the two diastereomers. | |||
20 | BB1a | A1 | m/z = 472.4 [M+H+]+ |
BB21 | C3 | ||
Product is the first eluting of the two diastereomers. | |||
21 | BB1a | A1 | m/z = 472.4 [M+H+]+ |
BB21 | C3 | ||
Product is the second eluting of the two diastereomers. | |||
22 | BB1a | A1 | m/z = 472.2 [M+H+]+ |
BB22 | flash chromatography (SiO2, 0% to 10% MeOH in DCM) | ||
23 | BB1a | A1 | m/z = 502.20 [M+H+]+ |
BB23 | flash chromatography (SiO2, 0% to 10% MeOH in DCM) | ||
24 | BB1a | A1 | m/z = 486.41 [M+H+]+ |
BB24 | flash chromatography (SiO2, 0% to 10% MeOH in DCM) | ||
25 | BB1a | A1 | m/z = 458.17 [M+H+]+ |
BB25 | flash chromatography (SiO2, 0% to 10% MeOH in DCM) | ||
26 | BB2a | A2 | m/z = 452.2 [M+H+]+ |
BB26 | B9 | ||
27 | BB2b | A2 | m/z = 452.2 [M+H+]+ |
BB14 | B7 | ||
28 | BB2a | A2 | m/z = 441.3 [M+H+]+ |
BB11 | C1 | ||
Product is the second eluting of the two diastereomers. |
Claims (16)
- A compound of formula (I)X is N or C-R5;L is selected from a covalent bond, -(CH2)n-O-, -O-(CH2)p-, and -SO2-;n is an integer selected from 0, 1, 2 and 3;p is an integer selected from 1, 2 and 3;A is:(i) C6-14-aryl substituted with R6, R7 and R8; or(ii) 5-14 membered heteroaryl substituted with R9, R10 and R11; orB is a bridged bicyclic heterocycle;R1 is hydrogen or C1-6-alkyl;R2 is hydrogen or C1-6-alkyl;R3 is hydrogen, C1-6-alkyl, halo-C1-6-alkyl, halogen or hydroxy;R4 is hydrogen, C1-6-alkyl, halo-C1-6-alkyl, halogen or hydroxy;R5 is hydrogen, C1-6-alkyl, halo-C1-6-alkyl, halogen or hydroxy; andR6, R7, R8, R9, R10, and R11 are independently selected from hydrogen, C1-6-alkyl, halo-C1-6-alkyl, halogen, C1-6-alkoxy, halo-C1-6-alkoxy, SF5, C1-6-alkylsulfonyl, cyano, C3-10-cycloalkyl, C6-14-aryl, and 5-14 membered heteroaryl, wherein said C3-10-cycloalkyl, C6-14-aryl, and 5-14 membered heteroaryl are optionally substituted with 1-2 substituents selected from halogen, cyano, SF5 C1-6-alkyl, C1-6-alkoxy, halo-C1-6-alkyl, and halo-C1-6-alkoxy.
- The compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are both hydrogen.
- The compound of formula (I) according to any one of claims 1 to 2, or a pharmaceutically acceptable salt thereof, wherein R3 and R4 are both hydrogen.
- The compound of formula (I) according to any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, whereinR9 is selected from hydrogen, C3-10-cycloalkyl, and C6-14-aryl, wherein said C6-14-aryl is substituted with 1-2 substituents selected from halogen and halo-C1-6-alkyl;R10 is selected from hydrogen and halogen; andR11 is hydrogen.
- The compound of formula (I) according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein X is C-R5 and R5 is hydrogen.
- The compound of formula (I) according to any one of claims 1 to 5, or a pharmaceutically acceptable salt thereof, whereinL is selected from -(CH2)n-O- and -O-(CH2)p-;n is an integer selected from 0 and 1; andp is 1.
- The compound of formula (I) according to any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, whereinA is C6-14-aryl substituted with R6, R7 and R8;R6 is selected from halo-C1-6-alkyl and halogen;R7 is halogen; andR8 is hydrogen.
- The compound of formula (I) according to claim 7, or a pharmaceutically acceptable salt thereof, whereinA is C6-14-aryl substituted with R6, R7 and R8;R6 is selected from hydrogen, C1-6-alkyl, halo-C1-6-alkyl, and halogen;R7 is selected from hydrogen and halogen; andR8 is hydrogen.
- The compound of formula (I) according to claim 8, or a pharmaceutically acceptable salt thereof, whereinA is phenyl substituted with R6, R7 and R8;R6 is selected from CF3, chloro, and fluoro;R7 is fluoro or chloro; andR8 is hydrogen.
- The compound of formula (I) according to any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, wherein B is a 6-14 membered bridged bicyclic heterocycle comprising 1-3 heteroatoms selected from N, S, and O.
- The compound of formula (I) according to claim 10, or a pharmaceutically acceptable salt thereof, wherein B is a 6-8 membered bridged bicyclic heterocycle comprising 1 nitrogen atom.
- The compound of formula (I) according to claim 11, or a pharmaceutically acceptable salt thereof, wherein B is selected from 8-azabicyclo[3.2.1]octan-8-yl (a); 3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrol-2-yl (b); 3-azabicyclo[3.1.0]hexan-3-yl (c); and 2-azabicyclo[2.2.1]heptan-2-yl (d):
- A compound selected from:(4aR,8aS)-6-(5-(2-chlorophenoxy)-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-2-carbonyl)-4,4a,5,7,8,8a-hexahydropyrido[4,3-b] [1,4]oxazin-3-one;(4aR,8aS)-6-(5-(2-methylphenoxy)-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-2-carbonyl)-4,4a,5,7,8,8a-hexahydropyrido[4,3-b] [1,4]oxazin-3-one;(4aR,8aS)-6-(5-(benzenesulfonyl)-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrole-2-carbonyl)-4,4a,5,7,8,8a-hexahydropyrido[4,3-b] [1,4]oxazin-3-one;(4aR,8aS)-6-(5-[4-(trifluoromethyl)phenyl]sulfonyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrole-2-carbonyl)-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;(4aR, 8aS)-6-(5-(2-chloro-4-fluoro-phenyl)sulfonyl-1,3 ,3 a,4,6,6a-hexahydropyrrolo [3,4-c]pyrrole-2-carbonyl)-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;(4aR,8aS)-6-[(1R,5S,6r)-6-[1-(4-fluorophenyl)pyrazol-3-yl]-3-azabicyclo[3.1.0]hexane-3-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b] [1,4]oxazin-3-one;(4aR,8aS)-6-[(1R,5S,6r)-6-[1-[4-fluoro-3-(trifluoromethyl)phenyl]pyrazol-3-yl]-3-azabicyclo[3.1.0]hexane-3-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3 -one;(4aR,8aS)-6-[(1R,5S,6r)-6-[1-(2-chloro-4-fluoro-phenyl)pyrazol-3-yl]-3-azabicyclo[3.1.0]hexane-3-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3 -one;(4aR,8aS)-6-[rel-(1R,4R, 5 S)-5 -(5, 6,7, 8-tetrahydroisoquinolin-3 -ylmethoxy)-2-azabicyclo[2.2.1]heptane-2-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3 -one;(4aR,8aS)-6-[rel-(1R,4R,5S)-5-[(5-chloro-4-cyclopropyl-2-pyridyl)methoxy]-2-azabicyclo[2.2.1]heptane-2-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;(4aR,8aS)-6-[rel-(1R,4R,5S)-5-[(5-chloro-4-cyclopropyl-2-pyridyl)methoxy]-2-azabicyclo[2.2.1]heptane-2-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3 -one;(4aR,8aS)-6-[(1R,5S,6r)-6-[(2-chloro-4-fluoro-phenoxy)methyl]-3-azabicyclo[3.1.0]hexane-3-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3 -one;(4aR,8aS)-6-[8-[(2-chloro-4-fluoro-phenoxy)methyl]-3-azabicyclo[3.2.1]octane-3-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b] [1,4]oxazin-3-one;(4aR,8aS)-6-[5-(2-chloro-4-fluoro-phenoxy)-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-2-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;(4aR,8aS)-6-[5-[(2-chloro-4-fluoro-phenyl)methoxy]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-2-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;(4aR, 8aS)-6-[5- [[2-fluoro-4-(trifluoromethyl)phenyl]methoxy] -3,3 a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-2-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3 -one;(4aR,8aS)-6-[5-[2-fluoro-4-(trifluoromethyl)phenoxy]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-2-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;(4aR,8aS)-6-[rel-(1R,4S,6S)-6-[[2-fluoro-4-(trifluoromethyl)phenyl]methoxy]-2-azabicyclo[2.2.1]heptane-2-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;(4aR,8aS)-6-[rel-(1R,4S,6R)-6-[[2-fluoro-4-(trifluoromethyl)phenyl]methoxy]-2-azabicyclo[2.2.1]heptane-2-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;(4aR,8aS)-6-[rel-(1R,4R,5S)-5-[[2-fluoro-4-(trifluoromethyl)phenyl]methoxy]-2-azabicyclo[2.2.1]heptane-2-carbonyl]-4,4a, 5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;(4aR,8aS)-6-[rel-(1R,4R,5S)-5-[[2-fluoro-4-(trifluoromethyl)phenyl]methoxy]-2-azabicyclo[2.2.1]heptane-2-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;(4aR,8aS)-6-[6-[[2-fluoro-4-(trifluoromethyl)phenyl]methoxy]-3-azabicyclo[3.1.1]heptane-3-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b] [1,4]oxazin-3-one;(4aR,8aS)-6-[(1S,5R)-7-[[2-fluoro-4-(trifluoromethyl)phenyl]methoxy]-3-oxa-9-azabicyclo[3.3.1]nonane-9-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;(4aR,8aS)-6-[(1S,5R)-3-[[2-fluoro-4-(trifluoromethyl)phenyl]methoxy]-8-azabicyclo[3.2.1]octane-8-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;(4aR,8aS)-6-[(1R,5S,6r)-6-[[2-fluoro-4-(trifluoromethyl)phenoxy]methyl]-3-azabicyclo[3.1.0]hexane-3-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;(4aR,8aS)-6-[3-[(2-chloro-4-fluoro-phenoxy)methyl]-8-azabicyclo[3.2.1]octane-8-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b] [1,4]oxazin-3-one;(4aS,8aR)-6-[8-[(2-chloro-4-fluoro-phenoxy)methyl]-3-azabicyclo[3.2.1]octane-3-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; and(4aR,8aS)-6-[rel-(1R,4R,5S)-5-(5,6,7,8-tetrahydroisoquinolin-3-ylmethoxy)-2-azabicyclo[2.2.1]heptane-2-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one.
- A compound of formula (I) according to any one of claims 1 to 12 or a compound of claim 13 for use as therapeutically active substance.
- A pharmaceutical composition comprising a compound of formula (I) according to any one of claims 1 to 12 or a compound of claim 13 and a therapeutically inert carrier.
- A compound of formula (I) according to any one of claims 1 to 12 or a compound of claim 13, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 15 for use in the treatment or prophylaxis of neuroinflammation, neurodegenerative diseases, pain, cancer, mental disorders and/or inflammatory bowel disease in a mammal, in particular for use in the treatment or prophylaxis of multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colon carcinogenesis, ovarian cancer, neuropathic pain, chemotherapy induced neuropathy, acute pain, chronic pain, spasticity associated with pain, abdominal pain, abdominal pain associated with irritable bowel syndrome and/or visceral pain in a mammal.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19196089 | 2019-09-09 | ||
PCT/EP2020/074897 WO2021048036A1 (en) | 2019-09-09 | 2020-09-07 | 4,4a,5,7,8,8a-hexapyrido[4,3-b][1,4]oxazin-3-one compounds as magl inhibitors |
Publications (3)
Publication Number | Publication Date |
---|---|
EP4028401A1 EP4028401A1 (en) | 2022-07-20 |
EP4028401B1 true EP4028401B1 (en) | 2023-11-22 |
EP4028401C0 EP4028401C0 (en) | 2023-11-22 |
Family
ID=67902336
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP20772007.9A Active EP4028401B1 (en) | 2019-09-09 | 2020-09-07 | 4,4a,5,7,8,8a-hexapyrido[4,3-b][1,4]oxazin-3-one compounds as magl inhibitors |
Country Status (17)
Country | Link |
---|---|
US (2) | US20210094971A1 (en) |
EP (1) | EP4028401B1 (en) |
JP (1) | JP2022546853A (en) |
KR (1) | KR20220061119A (en) |
CN (1) | CN114364682A (en) |
AR (1) | AR119910A1 (en) |
AU (1) | AU2020344921A1 (en) |
BR (1) | BR112022003704A2 (en) |
CA (1) | CA3151218A1 (en) |
CL (1) | CL2022000551A1 (en) |
CO (1) | CO2022002339A2 (en) |
CR (1) | CR20220091A (en) |
IL (1) | IL289233A (en) |
MX (1) | MX2022002554A (en) |
PE (1) | PE20220904A1 (en) |
TW (1) | TW202124392A (en) |
WO (1) | WO2021048036A1 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR114136A1 (en) | 2017-10-10 | 2020-07-29 | Hoffmann La Roche | HETEROCYCLIC COMPOUNDS |
WO2019105915A1 (en) | 2017-11-28 | 2019-06-06 | F. Hoffmann-La Roche Ag | New heterocyclic compounds |
TW201938164A (en) | 2018-01-08 | 2019-10-01 | 瑞士商赫孚孟拉羅股份公司 | New heterocyclic compounds |
PE20211089A1 (en) | 2018-08-13 | 2021-06-14 | Hoffmann La Roche | NEW HETEROCYCLIC COMPOUNDS AS INHIBITORS OF MONACILGLICEROL LIPASE |
BR112022002375A2 (en) | 2019-09-12 | 2022-07-19 | Hoffmann La Roche | 4,4A,5,7,8,8A-HEXAPYRIDO[4,3-B][1,4]OXAZIN-3-ONA COMPOUNDS AS MAGL INHIBITORS |
MX2023002224A (en) | 2020-09-03 | 2023-03-15 | Hoffmann La Roche | Heterocyclic compounds. |
WO2024071398A1 (en) * | 2022-09-30 | 2024-04-04 | 小野薬品工業株式会社 | Abhd6 antagonist |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7579495B2 (en) | 2003-12-19 | 2009-08-25 | Momentive Performance Materials Inc. | Active-releasing cyclic siloxanes |
WO2011059118A1 (en) | 2009-11-10 | 2011-05-19 | Kim Hyun Jeen | System for testing olfactory perception |
US10407407B2 (en) | 2015-05-21 | 2019-09-10 | Glaxosmithkline Intellectual Property Development Limited | Benzoimidazole derivatives as PAD4 inhibitors |
WO2017087858A1 (en) * | 2015-11-20 | 2017-05-26 | Abide Therapeutics, Inc. | Pyrazole compounds and methods of making and using same |
WO2017087863A1 (en) * | 2015-11-20 | 2017-05-26 | Abide Therapeutics, Inc. | Pyrazole compounds and methods of making and using same |
TW201930300A (en) * | 2017-12-15 | 2019-08-01 | 瑞士商赫孚孟拉羅股份公司 | New heterocyclic compounds |
TW201938164A (en) * | 2018-01-08 | 2019-10-01 | 瑞士商赫孚孟拉羅股份公司 | New heterocyclic compounds |
SI3768684T1 (en) * | 2018-03-22 | 2023-06-30 | F. Hoffmann - La Roche Ag | Oxazine monoacylglycerol lipase (magl) inhibitors |
PE20211380A1 (en) * | 2018-08-13 | 2021-07-27 | Hoffmann La Roche | NEW HETEROCYCLIC COMPOUNDS AS MONOACYLGLICEROL LIPASE INHIBITORS |
PE20211089A1 (en) * | 2018-08-13 | 2021-06-14 | Hoffmann La Roche | NEW HETEROCYCLIC COMPOUNDS AS INHIBITORS OF MONACILGLICEROL LIPASE |
PL3883936T3 (en) * | 2018-11-22 | 2023-11-20 | F. Hoffmann-La Roche Ag | New heterocyclic compounds |
-
2020
- 2020-09-04 US US17/012,589 patent/US20210094971A1/en not_active Abandoned
- 2020-09-07 EP EP20772007.9A patent/EP4028401B1/en active Active
- 2020-09-07 JP JP2022515504A patent/JP2022546853A/en active Pending
- 2020-09-07 KR KR1020227007722A patent/KR20220061119A/en unknown
- 2020-09-07 WO PCT/EP2020/074897 patent/WO2021048036A1/en active Application Filing
- 2020-09-07 AR ARP200102489A patent/AR119910A1/en unknown
- 2020-09-07 AU AU2020344921A patent/AU2020344921A1/en active Pending
- 2020-09-07 PE PE2022000300A patent/PE20220904A1/en unknown
- 2020-09-07 CN CN202080062559.0A patent/CN114364682A/en active Pending
- 2020-09-07 MX MX2022002554A patent/MX2022002554A/en unknown
- 2020-09-07 CR CR20220091A patent/CR20220091A/en unknown
- 2020-09-07 BR BR112022003704A patent/BR112022003704A2/en unknown
- 2020-09-07 CA CA3151218A patent/CA3151218A1/en active Pending
- 2020-09-08 TW TW109130703A patent/TW202124392A/en unknown
-
2021
- 2021-12-21 IL IL289233A patent/IL289233A/en unknown
-
2022
- 2022-02-28 CO CONC2022/0002339A patent/CO2022002339A2/en unknown
- 2022-03-04 CL CL2022000551A patent/CL2022000551A1/en unknown
- 2022-05-05 US US17/737,656 patent/US20220275005A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CO2022002339A2 (en) | 2022-03-08 |
CA3151218A1 (en) | 2021-03-18 |
KR20220061119A (en) | 2022-05-12 |
CL2022000551A1 (en) | 2022-11-18 |
BR112022003704A2 (en) | 2022-05-24 |
TW202124392A (en) | 2021-07-01 |
US20210094971A1 (en) | 2021-04-01 |
MX2022002554A (en) | 2022-03-22 |
CR20220091A (en) | 2022-04-01 |
EP4028401C0 (en) | 2023-11-22 |
WO2021048036A1 (en) | 2021-03-18 |
CN114364682A (en) | 2022-04-15 |
AU2020344921A1 (en) | 2022-02-17 |
IL289233A (en) | 2022-02-01 |
JP2022546853A (en) | 2022-11-09 |
EP4028401A1 (en) | 2022-07-20 |
US20220275005A1 (en) | 2022-09-01 |
AR119910A1 (en) | 2022-01-19 |
PE20220904A1 (en) | 2022-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP4028401B1 (en) | 4,4a,5,7,8,8a-hexapyrido[4,3-b][1,4]oxazin-3-one compounds as magl inhibitors | |
EP3883936B1 (en) | New heterocyclic compounds | |
EP4028403B1 (en) | 4,4a,5,7,8,8a-hexapyrido[4,3-b][1,4]oxazin-3-one compounds as magl inhibitors | |
KR20210044217A (en) | Novel heterocyclic compounds as monoacylglycerol lipase inhibitors | |
TW202003525A (en) | New heterocyclic compounds | |
AU2020354414A1 (en) | New heterocyclic monoacylglycerol lipase (MAGL) inhibitors | |
US20210094972A1 (en) | Heterocyclic compounds | |
AU2020355507A1 (en) | Heterocyclic compounds | |
RU2809257C2 (en) | Heterocyclic compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20220411 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
RAV | Requested validation state of the european patent: fee paid |
Extension state: MA Effective date: 20220411 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20230612 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602020021566 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
U01 | Request for unitary effect filed |
Effective date: 20231122 |
|
U07 | Unitary effect registered |
Designated state(s): AT BE BG DE DK EE FI FR IT LT LU LV MT NL PT SE SI Effective date: 20231206 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240223 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240322 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231122 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240322 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240223 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231122 |